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ABSTRACT

Human Cytomegalovirus (HCMV) is the leading cause of both non-hereditary mental retardation
and hearing loss, and CMV infection/reactivation causes serious complications in transplant and
immune compromised patients. Due to these issues, development of a CMV vaccine and/or
therapeutics is required. To achieve this goal, it is necessary to gain a better understanding of
CMV pathogenesis. Because of its coevolution with humans, HCMV has evolved genes with
homology to human immune modulatory genes. Several of these genes help CMV establish a
successful and lifelong infection within the host. An example is the viral CXC chemokine
homolog UL146 gene (vCXCL-1). UL146 varies between clinical isolates and has been
associated with clinical outcomes of HCMV infection. In this dissertation we characterized the
vCXCL-1 protein from different clinical isolates in vitro (Chapter 1). We hypothesized that,
variability in vCXCL-1 leads to differential activation of neutrophils, which in turn leads to
the observed differences in HCMV pathogenesis. In this study we identified the similarities and
differences in the functional activity of vCXCL-1s from different HCMV isolates and suggest
how the variability can affect neutrophil function and CMV pathogenesis. In order to understand
the contribution of vCXCL-1 in the pathogenesis of CMV infection in vivo (Chapter 2), we
tested the hypothesis that vCXCL-1 from chimpanzee CMV (vCXCL-1CCMV) is a functional
CXC chemokine and contributes to viral dissemination, similar to the MCMV CC
chemokine.

However, contrary to this hypothesis, we found that overexpression of the

chemokine is detrimental to the dissemination of MCMV by recruiting more inflammatory
monocytes and NK cells to the site of infection. In an effort to develop a novel anti-CMV
treatment, we tested the hypothesis that heparan sulfate binding peptides can act as potential
antivirals (Chapter 3). Peptides of different lengths and net charge were generated and tested
for their ability to prevent MCMV infections.

Of those tested, the cationic peptides reduced

MCMV infection in vitro by ~ 90%. In summary my research suggests that over expression of
chemokines can attenuate CMV dissemination making it a potential vaccine candidate and that a
peptide that binds to heparan sulfate can be a potential CMV therapeutic.
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INTRODUCTION
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PART I: What We Have Learned From Animal Models of HCMV
This part (Part I) is a publication by the same title published in the book titled Human
Cytomegaloviruses: Methods and Protocols in 2014 authored by Pranay Dogra and Tim E.
Sparer and has been reproduced here with permission from the publisher (Appendix 5)

Dogra P, Sparer T. What We Have Learned from Animal Models of HCMV. In: Yurochko AD,
Miller WE, editors. Human Cytomegaloviruses. Methods in Molecular Biology. 1119: Humana
Press; 2014. p. 267-88.

My primary contributions to this paper include (1) researching the topic and, (2) writing of this
review article.

1. Abstract

Although human cytomegalovirus (HCMV) primary infection is generally asymptomatic, in
immune-compromised patients HCMV increases morbidity and mortality. As a member of the
betaherpesvirus family, in vivo studies of HCMV are limited due to its species specificity. CMVs
from other species are often used as surrogates to express HCMV genes/proteins or used as
models for inferring HCMV protein function in humans. Using innovative experiments, these
animal models have answered important questions about CMV's life cycle, dissemination,
pathogenesis, immune evasion, and host immune response. This chapter provides CMV
biologists with an overview of the insights gained using these animal models. Subsequent
chapters will provide details of the specifics of the experimental methods developed for each of
the animal models discussed here.

2. Introduction
One of the hallmarks of β herpesviruses is their species specificity. This means that human
CMV (HCMV) does not productively infect mouse cells and vice versa. The species barrier is
not due to attachment or entry, but a combination of factors including blocks in immediate early
gene expression and specificity of anti-apoptotic proteins (3-8). Without the ability to use
2

HCMV in animal models, it necessitates the development and utilization of animal models of
HCMV infection. Despite these limitations, animal models have been useful for studying
pathogenesis, immune control, immune evasion, dissemination within the host, latency and
reactivation, and vaccine/drug development (9-14). In this chapter we will discuss the four main
animal models used to study HCMV. After a discussion of the advantages and disadvantages of
each model, the proceeding sections will focus on the characteristics of HCMV infection that
have been investigated in the different animal models. The main animal models are:

1. The mouse CMV (MCMV) model.
2. The rat CMV (RCMV) model.
3. The guinea pig CMV (GPCMV) model.
4. The rhesus CMV (RhCMV) model.

3. Advantages and Disadvantages of the Animal Models
The complexity of host-viral interaction makes an exact mimic of HCMV infection of humans
difficult. Nonetheless we have gained tremendous insight into the pathogenesis of HCMV with
these animal models. However it must be kept in mind that these models have their limitations
for studying HCMV pathogenesis. Below are some of the major advantages and disadvantages of
the different animal models discussed in this chapter.

3.1. Mouse model
Advantages


Characteristics of MCMV infection in mice are similar to that of HCMV infection in
humans (15-18).



MCMV contains homologues and/or at least functional homologues of many HCMV
genes and gene products. The MCMV genome can be easily manipulated to either delete
or exchange genes between HCMV and MCMV (19, 20).
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The mouse has a well-characterized immune system, short gestational periods, and large
litter sizes. There are numerous immunologic reagents available including transgenic and
knockout mice (20, 21).

Disadvantages


A major disadvantage of the mouse model is that the placental barrier is refractory to
CMV transmission (22), except in a severe combined immune deficient (SCID) mice
(23). This is most likely is due to the three-cell-thick trophoblast layer that separates
maternal and fetal circulations (20).

3.2. Rat model
Advantages


Similarity between HCMV and RCMV pathogenesis (14)



HCMV genetic counterparts in the RCMV genome and the availability of viral mutants
(20, 24)



Availability of immunologic reagents and transgenic animals (20).



Larger size makes it better suited to surgical manipulation

Disadvantages


No clear disease phenotype in pups for modeling congenital infection.



Congenital and placental infections have only recently been described (20).

3.3. Guinea pig model (Reviewed in (9, 25)
Advantage


GPCMV can cross the guinea pig placenta, causing infection in utero. This is probably
due to single trophoblast layer separating maternal and fetal circulations. This makes the
guinea pig well suited for the study of vaccines designed to interrupt transplacental
transmission of infection (10, 20).



The presence of HCMV counterpart genes in the GPCMV genome (26).

Disadvantage


The lack of immunologic reagents for guinea pig studies.



Lengthy guinea pig gestational periods with relatively small litter size slows down animal
studies (20).

4

3.4. Rhesus model (Reviewed in (11))
Advantage


High similarity between the pathogenesis of infection of HCMV and RhCMV (11, 27,
28).



Relatedness of the genomes of RhCMV and HCMV and the availability of viral mutants
(20, 29).

Disadvantage


The high cost of the animal maintenance.



The paucity of RhCMV-seronegative animals because RhCMV infection is ubiquitous in
most colonies (20).

4. Pathogenesis
Before discussing the animal models used for studying HCMV pathogenesis, it is important to
discuss what is known about HCMV disease in humans. HCMV infection causes severe disease
in immunocompromised patients including individuals with AIDS, organ transplant patients,
cancer (30) and newborns (31). Infection in these patients can sometimes cause clinical disease
including mononucleosis-like syndrome, interstitial pneumonia, gastroenteritis, retinitis, or
transplant rejection. Acute rejection and cardiac allograft vascular disease is reduced with
suppression of subclinical cytomegalovirus infection (32-34). HCMV is the leading viral cause
of congenital birth defects following infection in utero. Worldwide between 0.5 to 2% of
newborns are infected. The majority of newborns are asymptomatic at birth but some exhibit
outward signs of infection including microcephaly, jaundice, and hepatosplenomegaly (35, 36).
About 10% of the asymptomatic newborns develop neurological dysfunction, most prominently
sensorineural hearing loss (SNHL) that appears when they are older (20, 37, 38).

Animal

models provide some insights into these different aspects of HCMV disease.
In immunocompetent individuals HCMV infection is generally asymptomatic. However
clinical studies point to HCMV’s contribution to cardiovascular (39-42) and inflammatory bowel
diseases (43-45). HCMV infection is associated with many types of cancers (46-50), however
there is no strong evidence of transformation of normal human cells after HCMV infection (48,
49). In cardiovascular disease there is an association between HCMV infection and the
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thickening of the arteriole walls during heart transplantation rejection (51), vasculopathy (52),
and arteriolar dysfunction (53).
Some aspects of these HCMV-related diseases can be recapitulated in different animal
models. This, in turn, allows the assessment of CMV’s contribution to the disease and
exploration of potential treatment. Although not all aspects parallel human infection and disease,
these animal models are an excellent resource for dissecting particular CMV disease models.
Discussed below are the main observations gleaned from animal models of HCMV pathogenesis.

4.1 Congenital infection
Animal model systems that mimic HCMV-induced developmental abnormalities have been used
to study the pathological outcomes of CMV congenital disease (9-11, 54-57). GPCMV and
RhCMV, due to their natural ability to cross the placental barrier and cause in utero infection
have been the models of choice for congenital infections (10, 57-60). Although MCMV and
RCMV are very inefficient at crossing the placenta due to the unique features of the
trophoblastic layer, MCMV in the SCID model and a new strain of RCMV are capable of
crossing the placenta and cause symptoms similar to HCMV congenital disease (12, 23).
Because this is an inefficient process, direct injection of the virus into the central nervous system
(CNS) of the fetus, uterus, placenta, brain or peritoneum of neonatal animals is most commonly
used to recapitulate HCMV induced congenital disease (21, 54-57, 61-65).

One of the

drawbacks of these models is assessing whether the infection has led to SNHL or other
developmental defects.
Discoveries using these models have led to a better understanding of how HCMV infection
leads to developmental defects. Mouse studies have shown that the susceptibility to CMV
infection is dependent on gestational age/developmental stage of the embryo. Although
embryonic stem cells are resistant to CMV infection initially, as they differentiate they become
permissive to MCMV replication (61, 66). Once the pup is born there is a reduction in the
susceptibility of the brain during development from neonate to adult. This may be due to a
decrease in the number of susceptible cells in the developing brain (67) or increased immune
responses, providing protection against infection (68). CMV targets neural stem cells and the
auditory nerve spiral ganglion in the developing brain (28, 57, 69-71). Several factors that
contribute to the development of SNHL have been identified using the murine model of CMV
6

congenital infection, including ultrastructural lesions of the neurons, reduction in the number of
spiral ganglion neurons (21) and cytopathic effects of viral replication in the inner ear (cochlea)
(20, 28, 57, 70, 72). The virus spreads to the inner ear most likely via the perilymphal routes (20)
where the inflammation induced by CMV viral chemokines may contribute towards pathogenesis
(72, 73).
Similarly, the intrauterine model of rhesus CMV infection identified that CMV infection of
neuronal stem/progenitor cells before neuronal migration, differentiation, and organization,
results in more severe outcomes (57). Infection after these developmental processes are
completed results in less severe disease suggesting the timing of CMV infection during fetal
development is one factor determining disease severity. CMV infection is not limited to the
developing CNS. Systemic CMV infection can cause non-CNS diseases like intra uterine growth
restriction, renal and hepatic damage to the fetus (28, 57).
Animal models of neonatal CMV infection have provided tremendous insight into CMV
neuropathogenesis and the role of immune responses in controlling infection (66, 71, 74-76). The
neonatal mouse model of CMV infection in the presence of maternal antibodies has contributed
to current vaccination strategies. The fact that experimental intrauterine infection of rhesus
monkeys does not always lead to adverse outcomes implies that other factors limit CMV disease
(57).

4.2 Vasculopathy and Graft Rejection
The rat and mouse models have been used to investigate the role of CMV infection in
cardiovascular disease (CVD). In humans, circumstantial evidence points to the contribution of
HCMV infection to the development of arterial restenosis following angioplasty, atherosclerosis,
and solid organ transplant vascular sclerosis (TVS) (77, 78). In the mouse model, MCMV
infection accelerates atherosclerosis development in mice with high cholesterol (79-83). CMV
infection has a proinflammatory influence on the microvasculature that increases its
susceptibility

to

both

proinflammatory

and

thrombogenic

responses

caused

by

hypercholesterolemia (84). MCMV and RCMV chemokine receptors M33 and R33 respectively,
which are functional homologs of HCMV US28, are required for smooth muscle cell migration
to the site of vascular injury. Their accumulation in the vessel intima leads to vessel narrowing
and development of CVD (85, 86).
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In rat organ transplantation models of chronic rejection (CR), active CMV replication
(87, 88), contributes to accelerated graft rejection and increased vasculopathy in allograft vessels
(89-93). Several tissue specific RCMV genes involved in host modification of inflammatory and
tissue repair processes are upregulated in allograft recipients and may contribute to CR (94).
RCMV chemokine receptor R33 also plays an important role in acceleration of CR (86).
Although prophylactic treatment with ganciclovir in humans delays the time to allograft rejection
(95, 96), the rat model shows that recipients of latently infected donor hearts treated with
ganciclovir does not prevent CR or TVS. One explanation for this discrepancy is that RCMVinduces tertiary lymphoid structure formation and alteration of donor tissue T cell profiles prior
to transplantation (97). Both the mouse and rat models provide unique tools to dissecting the
role that CMV plays in CVD and graft rejection.

4.3 Retinitis
The mouse model of CMV retinitis is a common model for HCMV retinitis. MCMV readily
infects ocular tissue (98-101) and establishes latency in the eye (102). During the acute phase of
the response to CMV infection, there is a rapid expansion and infiltration of CD8+ T cells into
the infected retina. This is followed by a contraction phase where viral antigen presentation and
CD8+ T cell activation occurs in the spleen and the draining lymph nodes but not in the retina or
iris (103). Using this model, TNFα was shown to induce apoptosis of retinal neurons and that
bystander cells contribute to the pathogenesis of CMV retinitis (104, 105), while not being T-cell
dependent (105). The mouse model also highlights the protective role of CD8+ T cells (106, 107)
and NK cells (108) against MCMV-induced necrotizing retinitis. The mouse model, although
not perfect, provides a system for exploring not only the mechanism of CMV retinitis but also
potential treatment options.

4.4 CMV Infection of an Immunodeficient Host
HCMV is one of the opportunistic infections in late-stage AIDS patients, leading to pneumonitis,
gastroenteritis and/or retinitis. The animal models that best recapitulate this scenario are mouse
retrovirus-induced immunodeficiency syndrome (MAIDS), and either spontaneous simian AIDS
(SAIDS) or experimental infection rhesus monkeys with SIV (109, 110). In the rhesus model,
CMV infection is similar to human infections of the gastrointestinal tract, hepatobiliary system,
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lungs, and testicles (111, 112). Much like in humans, reactivation of CMV and the development
of disseminated CMV disease are the result of diminished CMV-specific CD4+ T cell and CD8+
T cell immune responses (113, 114). Interestingly in this model, RhCMV and SIV co-infection
suggested that concurrent primary infection with CMV could augment the development of AIDS
(11, 115). In the mouse model, although T cell subsets play role in MAIDS/MCMV pathology,
Dix and colleagues suggested that the type of T cell response (i.e., perforin-mediated
cytotoxicity) contributes to the severity of MCMV-retinitis (116).
Without an HIV equivalent in the guinea pig model, cyclophosphamide treatment is used as
an immune suppressant. The suppression of T and B cell immunity following CMV infection
leads to lethal CMV infection in these animals (117). This once again illustrates the importance
of these immune cells for maintaining control of CMV infection.

5. Immune Control
In the mouse and rhesus models of CMV infection CD8+ T cells, CD4+ T cells, and NK
cells are the major cell types responsible for immune control of replication, latency and
reactivation (113, 118-120).

In the rhesus model, the target antigens for cytotoxic T

lymphocytes (CTL) responses are the immediate-early proteins 1 and 2, and pp65-2, the
homolog of HCMV pp65 (121, 122). With the identification of the major target antigens, it is
now possible to explore vaccination strategies using the major CTL target as antigens.
Using these animal models, virus-specific antibodies have also been shown to play a
crucial role in preventing CMV induced pathology (123, 124). The neutralizing antibodies target
mainly glycoprotein B (gB). However in the recently completed human vaccine trials, gB
vaccination generated a strong antibody response and with a vaccine efficacy that exceeded
predictions albeit with less than 50% efficacy (125). In order to test whether inclusion of
additional antigens could increase vaccine efficacy, a DNA vaccination/vaccinia virus primeboost regimen was used to vaccinate rhesus monkeys. They were subsequently challenged with
RhCMV and the amount of viral shedding was measured. Even with these additional antigens,
the monkeys were not protected completely from infection and still shed virus (126). It will be
interesting to see if this level of protection is sufficient to protect the developing fetus in RhCMV
(57).
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For understanding immune control the mouse model has allowed an in depth analysis of
the immune responses for controlling MCMV infection (127-130). Besides showing that CTLs
and NK cells are important in controlling MCMV infection (131-133), this model system also
showed that different immune cells control MCMV infection in different organs. For example,
CD4+ T cells expressing IFN control MCMV in the liver and IL10 expressing CD4+ T cells are
important for clearance in the salivary gland (134-136).

6. Immune Evasion
The previous section discussed how animal hosts control CMV infection, but CMV has evolved
mechanisms for evading many of these responses. Using animal models of CMV infection,
many factors involved in virus immune evasion and their role in CMV survival and damage in
their host have been identified. These CMV proteins not only allow the virus to avoid the
immune system, but can also activate it to the virus’ advantage (reviewed in (137, 138)). In the
mouse model the MCMV chemokine homolog MCK-2 (m131-m129) has a potent pro
inflammatory property and plays a crucial role in dissemination and immune evasion (139-141).
The function of the HCMV viral chemokines, vCXCL-1 and vCXCL-2, in vivo has been inferred
from this data, even though they are from a different subclass of chemokines (142, 143). The
constitutively active CMV chemokine receptors utilize the signaling from the chemokine
receptors for its advantage. In HCMV there are four chemokine-like receptors: US27, US28
UL33, UL78 (reviewed in (144)). The rodent homologues, M33 and M78 in MCMV and R33 in
RCMV, are the counterparts of HCMV UL33 and have a crucial role in immune evasion and/or
dissemination (145-147). Recently the mouse model was used as a surrogate for replacing the
function of M33 with the HCMV G-Protein coupled receptor (GPCR) homologues US28 and
UL33 (148). The RhCMV genome also encodes six CXC chemokines and five viral GPCRs (29,
149-152), and although they are dispensable for virus growth in vitro, the function of most of
these proteins in vivo is unknown (153).
HCMV also encodes proteins with cytokine homology. HCMV encodes a homolog to
host IL10 (154-159). Endogenous IL10 is an immune suppressive cytokine that down regulates
T cell activation. RhCMV also encodes a homolog of rhesus IL-10, which possesses potent antiinflammatory activity that weakens the antibody and cellular immune responses in vivo (160,
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161). MCMV lacks an equivalent IL10 homologue, which reduces its usefulness as a model of
HCMV IL10 in vivo.
The MHC class I homologs MCMV M144 and RCMV R144 are the counterparts of
UL18 in HCMV. Because of their MHC class I homology, it was speculated that UL18 and its
counterparts would therefore be important for preventing NK cell lysis. Using knockout viruses
in their respective models, these proteins contribute to virus survival and dissemination (162,
163) (reviewed in (164)). In vivo, the MCMV protein m04/gp34, which escort class I proteins to
the cell surface, was shown to prevent NK cell activation (165). Taken together the mouse
system has been valuable for mapping which immune evasion proteins are important for
resistance to NK cell lysis.
In human, mouse, and rhesus CMVs, there are several proteins that alter class I
expression/antigen processing and presentation in vitro.

These proteins are “functional”

homologues of proteins in HCMV (i.e., limited sequence homology but similar functions). The
HCMV encoded proteins, gpUS2, gpUS3, gpUS6, and gpUS11, interfere with MHC class I
surface expression and antigen presentation (146, 166). The RhCMV homologues of HCMV
gpUS2 and gpUS11 are the functionally related gpRh182 and gpRh189 proteins, while gpRh185
also has many of the functional features of gpUS2, gpUS3, and gpUS11 (167). It was initially
hypothesized that these proteins would diminish CD8+ T cell detection but in vivo evidence
following infection with recombinant viruses lacking some or all of these proteins leads to a
similar immune response and equivalent viral titers. Recent evidence from animal models points
to a role for these MHC homologs in superinfection (168). Superinfection not only explains how
humans can be infected multiple times with the same strain of CMV but also presents a problem
for vaccinologists. The data from the rhesus experiment points to the difficulties of effective
vaccine development, which will require more than this partially protective CD8+ T cell response
(169). Paradoxically, the MCMV equivalents of the class I immune modulating proteins
(m152/gp40, m04/gp34, and m06/gp48) contribute to an increase in processed and presented
antigens leading to a greater CD8+ T cell response. This casts into doubt the working hypotheses
about these proteins dampening CD8+ T cell responses (170). Perhaps this is the host’s
countermeasure for the viral counter measure!
CMV infection also induces inflammatory mediators, which seem to have an important
role in viral replication. Cyclooxygenase-2 (COX-2), for example, is an enzyme that leads to the
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generation of inflammatory lipid-derived compounds such as prostaglandin E(2). Although
HCMV does not have a COX-2 homolog, it up regulates cellular COX-2 protein expression upon
infection. COX-2 and the production of prostaglandin E(2) are necessary for HCMV infection.
In fact, COX-2 inhibitors prevent normal HCMV replication (171). Unlike HCMV, RhCMV
encodes a COX-2 homolog, which is critical for viral growth in endothelial cells (172). Thus,
controlling inflammation is not only important for immune responses but also contributes to
efficient viral replication. The role of the CMV induced or encoded inflammatory mediators in
vivo have yet to be determined.
HCMV inhibits apoptotic cellular defenses (Reviewed in (173)). Using knockout mice
and viral deletion mutants, Upton et al showed the importance of the viral inhibitor of RIP
(vIRA), encoded from the M45 locus of MCMV (174). vIRA inhibits RIP3 activation of
necrosis (174). Although there is no equivalent gene in HCMV, it encodes other inhibitors of
apoptosis, which may serve a similar function (175, 176). Perhaps HCMV must only counteract
apoptotic pathways instead of RIP3/necrosis pathways (reviewed in (177, 178))

7. Dissemination within the Host
Clinical studies have revealed the routes of HCMV person to person spread. Vertical
transmission of HCMV occurs via transplacental transfer of virus (179-181), intrapartum
transmission (182) and via breastfeeding from infected mother to child (183-187). Horizontal
transmission includes organ transplantation from an infected donor, exposure to infected
secretions (i.e., saliva), contact with infected urine during childhood (188), and sexual activity in
adulthood (189). Inside the host the infection spreads mainly via leukocytes (190).
MCMV is an excellent experimental model for studying the interaction of CMV with
different tissues and cells following infection (191-195). CMVs can productively infect many
different cell types. These include epithelial cells of the salivary glands, kidneys, lung, liver, and
intestines (196). MCMV can infect endothelial cells lining the spleen (197), myocytes, brown
fat adipocytes, connective tissue fibrocytes, bone marrow stromal cells, dendritic cells,
monocytes and tissue macrophages, but the B- and T-cell compartments of lymphoid organs,
including the thymus are not infected (198). The mouse model has demonstrated that circulating
leukocytes, predominantly mononuclear cells, disseminate MCMV and that cell-associated
viremia is biphasic.

First, primary dissemination of MCMV leads to infection of
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reticuloendothelial organs the liver and spleen. This is followed by viral amplification and a
more intense secondary viremia to organs such as the salivary gland (199). This system also
allowed the identification of the genes that are necessary for virus replication in the different
tissues (200). Recently an MCMV conditional gene expression system was used to quantify
viral productivity in specific cell types and determine the role that each one plays in viral
dissemination in vivo (201, 202). Viral factors including chemokines, GPCRs, anti-apoptotic
genes, and tegument proteins play a role in viral dissemination and full pathogenicity in the
mouse (139-141, 146-148, 175, 176, 203).

8. Latency and Reactivation
In humans HCMV remains latent in endothelial cells and cells of the myeloid lineage (reviewed
in (204)). Animal models of latency and reactivation have played a role in our somewhat limited
understanding of the maintenance of CMV latency and the signals necessary for reactivation
(reviewed in (198, 205)). Studies with mouse and guinea pig models of CMV confirmed the role
of myeloid lineage cells in virus persistence and the specificity of the CD8+ T cell responses
during latent infection (102, 206-210). Viral and host factors, including novel “unfit” NK cells,
have been identified that contribute to persistence and latency in different organs (145, 175, 176,
211). Also in the murine system, the helper function of CD4+ T cells (212) and antigen
presentation on non-hematopoietic and hematopoietic cells (213) play important roles in memory
inflation in latently infected hosts.
CMV reactivation in the mouse model includes a kidney transplantation model (214).
Several factors inducing reactivation have been identified (198, 215, 216). However immune
suppression and cytokine mediated activation of the productive viral cycle appears to be the most
common inducers of recurrence (118, 198, 217). Transcription of IE1 and the differentiation state
of the cell may not be sufficient for virus reactivation (218, 219). However allogeneic organ
transplantation, tissue implantation, or cell transfer (220) are important factors for inducing the
reactivation of MCMV and RCMV (219, 221, 222). The mouse system was also used to
understand the source of the reactivated virus in models of organ transplantation. Using a kidney
transplantation model in the mouse, Klotman et al. showed that the source of reactivated MCMV
in an uninfected recipient comes from the transplanted organ, but if the recipient is latently
infected, the majority of the time the reactivated virus comes from the recipient (223). The
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rodent models have been very useful for modeling transplantation reactivation and for dissecting
mechanisms of reactivation.

9. Vaccine and Drug Development and Testing
The animal models for CMV infection have been used to test new candidate vaccines and the
potency of existing ones. The gB vaccine that has shown some promise in clinical trials was
initially tested in animal models of both congenital infection and immunosuppression. (123-125).
All of the models except for the rat have provided some clues to vaccine design. In the guinea
pig model, systemic immunity to GPCMV has been shown to protect against hearing loss
following congenital infection (76, 224) (reviewed in (25)). Antibodies against gB have been
shown to be protective against congenital disease, which provided hope that this would also
work in humans (225, 226). Vaccination with gB DNA subunit has shown some capacity to
provide protection against congenital CMV infection (227, 228).

More recent vaccination

studies with GPCMV matrix protein GP83, a homolog of HCMV pp65, generated protective T
cell-mediated immune responses against congenital GPCMV infection and disease (229). This
highlights other possible avenues for protective vaccination.

In the rhesus model, DNA

vaccination with plasmids encoding gB, pp65-2 and IE-1 has shown promise. The gB-pp65
combined vaccine significantly reduces RhCMV copy numbers in plasma and oral shedding of
the virus and has proven to be much better than vaccines directed against only gB (126, 230).
Because of its affordability and the availability of reagents for dissecting the immune
response, the mouse has been particularly useful for testing potential vaccine strains such as
attenuated viruses or viruses that overexpress potential immune stimulators (i.e., for NK cells)
(231-236). Although these animal models of vaccination have not yielded an efficacious vaccine
in humans, they have provided the foundational baseline of which proteins, routes, and
attenuation genes to target.
The susceptibility of animal CMVs to various antiviral drugs makes them ideal for the
identification of potential antiviral compounds (reviewed in (237)). MCMV is susceptible to
ganciclovir (GCV) (238). More recently, a number of nucleoside analogues with Z- or Emethylenecyclopropane structures have been evaluated in the mouse model and possess better
activity than GCV (239, 240). GPCMV is resistant to GCV (241). However, it is susceptible to
cidofovir and cyclic cidofovir (242). The guinea pig model has been used to demonstrate the
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efficacy and safety of cidofovir and cyclic cidofovir (243, 244). The administration of these
drugs during pregnancy prevents GPCMV mortality in pups (245). Other novel non-nucleoside
analogues have also been tested in guinea pigs using the immunosuppressive model of CMV
infection (246).
RhCMV has comparable susceptibility to GCV, foscarnet, and benzimidazole
nucleosides (247). The highly conserved sequence of the drug target proteins in HCMV and
RhCMV make this model ideal for testing the efficacy and safety of novel anti-HCMV drugs
both in immunocompetent and immunocompromised animals. (29, 149, 247)

10. Animal Models for HCMV Studies in vivo
True animal models of HCMV infection are extremely difficult to develop due to its strict
species-specificity. However, several attempts have been made to develop models of HCMV
infection in animals that recapitulate one or more phases of the viral replication cycle. Human
cells/tissue fragments implanted into mouse (248) and rats (249) have been shown to support
viral infection in vivo, but only within the implanted cells.
In SCID mice human fetal thymus and liver implants were placed under the kidney
capsule (SCID-hu mice) (250) or fragments of human fetal retina were placed in the anterior
chamber of the eye and supported HCMV growth (240, 251-254). Using the SCID-hu mouse
model Wang et al demonstrated that the ULb’ region, encoding 19 open reading frames, present
in all virulent strains but deleted from attenuated strains is essential for HCMV replication in
vivo (255). An in vivo model of HCMV retinal infection in athymic rats has also been developed
using the same approach (256).
SCID-hu mice do not support systemic infection nor do these mice develop viral latency
(250, 254). In order to study systemic and latent HCMV infection, reactivation, and viral spread
within myeloid progenitors, monocytes, and macrophages, a model system in which huCD34+
hematopoietic stem cells (HSCs) are engrafted into NOD/SCID mice has been developed. In this
model, granulocyte-colony stimulating factor (G-CSF) leads to reactivation of latent HCMV in
monocytes/macrophages that have migrated into organ tissues. The results from this study also
suggest that G-CSF mobilized blood products from seropositive donors pose an elevated risk for
HCMV transmission to recipients (257).

These implant-based animal models for HCMV
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infection have also proved to be valuable for drug testing and vaccine development against
HCMV (237).

11. Summary
This chapter has provided an overview of CMV infections in the different animal models. Each
one has provided important insights into the lifecycle of HCMV and each has its promoters and
detractors as models for HCMV infection. In the following chapters, experts in the field will
provide details of how to use both animal and cellular systems to address important questions in
CMV biology. Importantly, the animal models described in this chapter will ultimately provide
the conduit by which discoveries in fundamental virological processes can be examined and
extended to an in vivo setting.

PART II: Literature Review

1. Chemokines

Chemokines are important in the regulation of a number of biological processes.. They are small
proteins (approximately 9-30 amino acids or 8-12 kDa in size) produced by leukocytes that
mediate their signaling through G-protein coupled receptors (258-260). Chemokine gradients
provide directed movement of cells through blood or tissues. They are classified based on the
number and spacing of the two cysteine residues on the N-terminus of the chemokine. Following
this criteria, chemokines are classified as C, CC, CXC, and CX3C chemokines. For example, the
CXC chemokine (α subfamily) chemokines have two cysteines separated by an amino acid
residue while the CC chemokines (β subfamily) have two juxtaposed cysteine residues. The C
chemokines (γ subfamily) have only one cysteine, and the CX3C chemokines (δ subfamily) have
two cysteines separated by three amino acids (261).
CXC chemokines are further subdivided into ELR or non-ELR CXC chemokines
depending on the presence of a glutamate-leucine-arginine (ELR) motif directly preceding the
CXC motif of the chemokine (262). The ELR CXC chemokines bind to CXCR1 and/or CXCR2
and are responsible for the activation and migration of neutrophils (262, 263). Single amino acid
substitutions in the ELR motif showed all three residues, especially arginine, are sensitive to
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modification and are critically important for CXCL8 (IL-8) function (264, 265). The non ELR
chemokines attract cells other than neutrophils (e.g., CXCL10 (IP-10) attracts monocytes, T
lymphocytes, and natural killer (NK) cells (266, 267), CXCL9 (MIG) attracts tumor-infiltrating
T lymphocytes (268), CXCL12 (SDF-1) stimulates the proliferation of B cells (269)). The ELR
motif is critical to the specificity of chemokine function as illustrated by the experiments wherein
the addition of ELR to the N-terminal domain of the non-ELR CXC chemokine, CXCL4 (PF4),
transforms it into a neutrophil chemoattractant (264). This addition, however, was not sufficient
for IP-10, which also requires additional Gly31 and Pro32 changes to become a fully functional
on human neutrophils (270).

ELR CXC chemokines have also been shown to possess

angiogenic properties. For example, CXCL8 (IL-8), CXCL7 (NAP-2), CXCL1 (GRO-α),
CXCL2 (GRO-β), CXCL3 (GRO-γ), and CXCL5 (ENA-78) have proangiogenic properties
because of their ability to recruit endothelial cells (271, 272). ELR CXC chemokines like
CXCL1 (GRO-α), CXCL2 (GRO-β), and CXCL3 (GRO-γ) have also been reported to possess
angiostatic properties at higher concentrations (>~1000 fold higher) (273-275). Unlike the ELR
CXC chemokines, many non-ELR CXC chemokines only have angiostatic properties (262, 274).
The CC chemokines form the largest family of chemokines with 28 members and attract
a variety of cell types including monocytes, basophils, eosinophils, and dendritic cells (DCs)
(262, 276). The first CC chemokine to be characterized, CCL2 (monocyte chemotactic protein1: MCP-1), attracts monocytes but not neutrophils (277). MCPs not only attract monocytes
(277-280), but also CD4+ and CD8+ T lymphocytes (281-283) and basophils (284-287). CCL4
(macrophage inflammatory protein-1β: MIP-1β), which is produced mainly by macrophages, has
been shown to attract NK cells and monocytes (288). The CCL5 (RANTES) (289) and CCL11
(eotaxin) (290) have also been shown to be potent eosinophils attractants.
CX3CL1 (fractalkine) is the only member of the CX3C chemokine family. Fractalkine is
produced as a long protein (373 amino acids) with an extended mucin-like stalk and a chemokine
domain on top (291). CX3CL1 is expressed on neurons, lung epithelial cells, kidney, and in the
intestine (292-294). CX3CL1 binds to CX3CR1 on cells and to induce chemotaxis, cellular
adhesion and increases cell survival during hemostasis and inflammation (292). The mucin-like
stalk anchors CX3CL1 to the surface of endothelial cells and promotes strong adhesion of
leukocytes to the endothelium (295, 296) and may play a role in promoting atherosclerosis (297).
The membrane-bound form can also be enzymatically cleaved to become a soluble chemokine
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(85 or 95 kDa) that can potentially attract monocytes and T lymphocytes (291, 295, 296).
CX3CL1 has been speculated to be involved with low-grade inflammation in adipose tissue and
function as an adipokine positively upregulated in obesity and diabetes (298, 299). Recent
studies show that CX3CL1 plays a direct role in type 2 diabetes by controlling insulin production
(300) and enhancing pancreatic β cells survival (301).
The members of the C chemokine family lack two of the four cysteine residues that are
characteristic of chemokines (302). This family is represented by two chemokines, XCL1
(lymphotactin α) and XCL2 (lymphotactin β) (302-305). Lymphotactin (Lptn) has also been
reported to be chemotactic for B lymphocytes, T lymphocytes and neutrophils through CXCR1
receptor (306). Therefore, Lptn could potentially play an important role in the regulating T and
B lymphocyte and neutrophil trafficking during inflammatory and immunological responses
(306).
Secreted chemokines, being cationic, can bind negatively charged glycosaminoglycans
(GAGs) such as heparan sulfate (HS) on the surface of cells or within the extracellular matrix
(259, 307, 308). The GAGs provide a solid support for gradient formation allowing for the
directed movement of cells under conditions of blood flow at the endothelial surface as well as
receptor interactions (259, 307, 309, 310). For example CXCL8 (IL-8) binds to GAG through its
C-terminal α-helix and shows enhanced chemotactic activity towards neutrophils when bound to
HS (311). In studies using extracellular matrix (ECM)-coated culture dishes, CCL4 (MIP-1β)
and CCL5 (RANTES) mediated leukocyte adhesion and chemotaxis that was GAG-dependent
(312). Proudfoot et al. demonstrated the importance of chemokine-GAG interactions in vivo
using mutated chemokines that do not bind GAGs efficiently and showed that these chemokines
induced chemotaxis in vitro but were severely limited in the recruitment of cells compared to
wild type chemokines when injected into the peritoneum of mice (313).
Microbial products and inflammatory cytokines like TNF induce the expression of
chemokines and their receptors to initiate the inflammatory response (314). For example, MIP-1
produced by macrophages in response to bacterial endotoxins leads to the activation and influx
of neutrophils to the site of infection (308, 315). Chemokines are also necessary for efficient
homing of leukocytes during homeostasis. For example, CCL19 and CCL21 induce the
migration of T cells and CXCL12 the migration of B cells into secondary lymphoid tissues (316).
Chemokines also control tissue retention by controlling lymphocyte egress via the afferent
lymph. For example, CCR7 expression on CD4+ and CD8+ T cells is essential for the egress of
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these cells from the lung during an inflammatory response (317-319). Chemokines induce
chemotaxis by regulating the expression of leukocyte adhesion molecules such CD11a, b, and c.
These adhesion molecules are the α component of the β2-integrin heterodimeric receptor. For
example, CXCL8 upregulates the expression of β2-integrins on neutrophils (320).
Conformational changes to the β2-integrins in response to chemokine leads to a strong adhesion
and arrest of the leukocytes to the endothelium facilitating their transmigration into tissues (321,
322).
In addition to chemotaxis, chemokines also participate in inducing effector functions of
immune cells. Activation of granulocytes in response to chemokines leads to their degranulation
contributing to the inflammatory response (323). For example, neutrophils activated in response
to chemokines release antimicrobial proteins such as defensins and lysozyme as well as proteases
capable of degrading proteins of the extracellular matrix and basement membrane (324).
Chemokines are also capable of triggering respiratory burst in immune cells leading to the
formation of reactive oxygen species, oxygen metabolites with potent antimicrobial activities
(325). Chemokines can also provide important survival signals for CD4+ T cells in peripheral
tissue. For example, CX3CR1 was found to be important for the development of allergic airway
inflammation in mice (326). Chemokines also play a critical role in the development of memory
cell populations by determining their migration and surveillance properties (327).
2. Chemokine Receptors
2.1 Structure, Ligand Binding, and Activation
Chemokine signaling is mediated through their cognate G protein coupled receptors (GPCRs).
GPCR activation requires interaction between specific domains of the receptor and several
motifs on the chemokine. Approximately 20 signaling chemokine receptors have been reported
as well as three non-signaling scavenger receptors that dampen the immune response by binding,
internalizing, and degrading chemokines (328-330). Chemokine receptors are GPCR seventransmembrane (7TM) helical regions connected by extra-cellular loops (ECLs) (Figure I1.1A).
Until 2007, none of chemokine receptors had been crystallized. The models were based on
bovine rhodopsin, the only 7TM receptor for which three-dimensional structures had been solved
at the time (331-334). From this structure, the N terminus and three of ECLs are extracellular,
whereas the C terminus and three intracellular loops (ICLs) face the cytoplasm.
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A.
ECL2
ECL1

ECL3

B.
ICL1

ICL2
ICL3

ECL = Extracellular Loop
TM = Transmembrane
ICL = Intracellular Loop

Figure I1.1. Receptor structure and receptor-ligand interaction. (A) Structure of
CXCR1 showing the 7TM regions, ECL and ICLs. The two disulphide bonds are shown
as dotted lines. (B) Hypothetical model of the interaction of a chemokine (pink) with its
receptor (blue). The model illustrates the interaction between the N-terminal domain of
the ligand with the receptor helical bundle, and the interaction of the core domain of the
ligand with the ECLs of the receptor (as observed for CXCR4-vMIPII, CCR1-CCL3).
Figures adapted from Park et.al, 2012, Nature (336) and Allen et al., 2007, Annu. Rev.
Immunol (340).
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The structures of CXCR1 (335) and CXCR4 (336) have recently been described and
show significant similarities. Both the structures show a kink that changes the direction of TM
helix TM2 (335, 336). The extracellular portion of TM7, just after ECL3, is tilted towards the
central axis of the receptor in CXCR1 (335). The TM7 helix is also about one turn longer in
CXCR1 at the intracellular end compared to CXCR4. The H8 helix present in CXCR1
immediately preceding the mobile C terminus and absent in CXCR4, has a distinctly
amphipathic amino acid sequence that interacts with the phospholipid bilayer to stabilize the
conformation of CXCR1 (335).
Two disulphide bonds, one connecting the N terminus to the extracellular part of TM7
and the other connecting the extracellular end of TM3 to ECL2 have been identified in the
structures of the chemokine receptors (335, 336).

These Cys pairs are conserved in the

sequences of other chemokine receptors as well. They play an important role in shaping the
extracellular structure of the receptor, ligand binding, and provide restraints for receptor structure
determination (335). Charged residues are located near the membrane-water interface in both
CXCR1 and CXCR4, where they interact with basic residues on the ligand (337). In addition,
four charged residues, contributed by helices TM2, TM3 and TM7, form a polar cluster in the
core of the helical bundle of CXCR1, and may be involved in ligand binding and signal
transduction (335). Residues in the ICL2 (i.e., the aspartic acid, arginine, tyrosine (DRY) motif
(338)) and in the ICL3 between Thr 228 to Gln 236 connecting helices TM5 and TM6 are
important for CXCR1 coupling to G proteins. These residues are critical for the ability of the
chemokine receptor to induce calcium mobilization, chemokine mediated migration, and cell
adhesion (335, 336, 338). The importance of these residues in chemokine receptor signaling is
apparent in scavenger receptors that lack the DRY motif, and thus are unable to induce a
downstream signal (339).
The use of chimeric proteins and mutagenesis studies identified the N terminus of several
receptors (CCR2, CCR3, CCR5, and CXCR1) as important for ligand binding (337, 340, 341).
For example, it has been shown that the chemokine interacts via its globular core with the
receptor N terminus chemokine recognition site 1 (CRS1) and via its N terminus with the CRS2
(Figure I1.1B) (337, 339, 342). Blanpain et al. (343) showed that the globular body of the
chemokine contacts the ECL2 in addition to the N terminus orienting the chemokine as
suggested by Skelton et al (337). By generating chemokine receptor elements on a soluble
scaffold (i.e., CROSSes), Stone et al. also demonstrated that the N termini and ECL3 were
needed for proper binding of the ligand to CCR3 and CCL11 (344, 345). Many of the
chemokine receptors (CCR2, CCR5, CCR8, CXCR4, CX3CR1) are also glycosylated and/or
tyrosine sulfated on their N termini (346-352). The tyrosine sulfation increases the affinity of the
receptors for their ligands, but the function, if any, of glycosylation is unknown.
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GPCRs are thought to exist as homo or hetero dimers and/or higher-order oligomers
(353-361), with hetero- and homodimers activating distinct signaling pathways (357).
Dimerization might influence receptor function by regulating the trafficking of receptors to the
cell surface and other locations within the cell (356), receptor specificity, and signaling (357,
362). Residues in TM1 and TM4 (Ile52 and Val150) have been shown to be involved in the
ligand dependent dimerization of CCR5 (363). Dimerization of CXCR2 occurs shortly after
synthesis and is therefore likely to be ligand-independent (360). However, other reports describe
agonist-dependent oligomerization that could lead to complex signaling (364). Receptors can
also undergo heteromerization (e.g., CCR2 can heteromerize with CCR5 when co-expressed in a
cell. In this case, ligands of CCR5 can block signaling through CCR2 and vice versa (365). The
activation of the receptors will also depend on the ligands. Chemokines can bind to the receptor
dimer as a monomer (366) or dimer (357, 361). Thus, receptor and chemokine dimerization
contributes to the complexity of chemokine responses including ligand recognition, signaling
specificity and receptor trafficking.
Amino acid residues at the N-terminus of both CC and CXC chemokines preceding the
first cysteine are considered critical for receptor binding, activation, and specificity (259, 367371). In studies with N-terminus truncation mutants of CXCL12 (SDF-1), the residues 1-8
preceding first cysteine in are essential for receptor binding (372). Additionally the deletion of
the first two residues generates a receptor antagonist (372). For CCL2 (MCP-1), all of the 10
amino acid residues preceding the first cysteine are required for full activity (367, 368). Altering
even a single amino acid residue at the N-terminus of CCL7 (MCP-3) and CCL5 (RANTES)
produces potent antagonists (370, 371). In addition to that, the ELR CXC chemokines require
the ELR motif and the N-loop region following the second cysteine for receptor recognition,
activation, and specificity (259, 265, 270, 337, 369, 373, 374). Skelton et al. showed that the
CXCR1 N-terminus fragment interacts along the ELR and N-loop motifs of CXCL8 (IL-8)
(337). Moreover, swapping the N loops of CXCL8 and CXCL1 caused an interchange in their
receptor binding and specificity (369). Synthetic peptides comprising the N-terminus and the Nloop have reduced activities compared to the full-length chemokines suggesting that the other
regions within the chemokine also contribute to receptor interactions and activation (262).
With a better understanding of the structure-function relationship of chemokines and their
receptors we can now begin to understand how differences in the sequence and structure of the
virally encoded chemokines and receptors (as discussed in section 3 below) can induce different
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signaling cascades that benefit the virus. This difference in signaling of the viral chemokines
may play a role in viral pathogenesis by inducing differential migration and effector functions of
immune cells leading to increased dissemination, inflammation, or increased viral replication.

2.2 Signaling
The G proteins that interact with the GPCRs are heterotrimeric and composed of α, β, and γ
subunits (375, 376). To date, 17 Gα, 5 Gβ, and 12 Gγ proteins have been described (376-378).
The binding of a chemokine to the GPCR induces conformational changes in the receptor, which
activates its guanine-nucleotide exchange factor (GEF) function.

The activated GPCR

exchanges GDP for GTP on the Gα subunit that causes the dissociation of the Gα subunit from
the Gβγ dimer. Both the dissociated Gα and Gβγ subunits in turn activate several downstream
effectors (379-381).

The Gα subunit remains in the activated GTP-bound state until the

hydrolysis of GTP to GDP, which leads to re-association of the heterotrimer and termination of
the signal by the regulator of G-protein signaling protein signaling protein (382)
There are four subfamilies of the α subunit of the G proteins: Gαs, Gαi/o, Gαq/11, and
Gα12/13 and each of the Gα protein signals several downstream effectors. Signaling via Gαs
activates adenylyl cyclase (AC), which increases the levels of cyclic AMP (cAMP) subsequently
activating mitogen-activated protein kinases (MAPK) and protein kinase A signaling cascades
(383). On the other hand, signaling via Gαi/o inhibits AC, reducing the levels of cAMP, which
in turn activates the G-protein-coupled potassium channels leading to the hyperpolarization of
the cell membrane (384). Gαq/11 protein activates phospholipase Cβ (PLCβ), and Gα12/13
subunit activates Rho guanine nucleotide exchange factors (385). 8 of the 17 Gα proteins are
widely distributed, but the remaining 9 are expressed in selective cell types (377), which leads to
the specific type of signaling pathway induced in response to receptor engagement in a particular
cell type (377).
The dissociated Gβγ subunits also regulate signaling pathways leading to the
phosphorylation of PLCβ (386, 387). Activated PLCβ cleaves phosphatidylinositol 4,5bisphosphate to inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 in turn elicits calcium
mobilization from the endoplasmic reticulum into the cytoplasm while DAG activates protein
kinase C (PKC) (388). PKC activation is required to upregulate β2 integrins, such as
CD11b/CD18, on neutrophils and eosinophils (389, 390). In addition, Gβγ also stimulates
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serine-threonine kinase, Akt, through phosphatidylinositol 3- kinase (PI3K) (378).

Akt

activation, as well as ERK pathway, is responsible for chemotaxis of HL60 cells or CXCR2
transfected HEK293 cells (391, 392). The diversity of the subunits that make up G proteins and
overlapping signaling cascades through Gα and Gβγ is responsible for the complex and multiple
downstream signaling events in response to the activation of GPCRs.
After initial signaling, the G protein receptor kinases (GRKs) and β-arrestins shut off
signaling through GPCRs (393). GRKs phosphorylate serine and threonine residues at the Cterminus of the GPCR, providing a binding site for β-arrestin. β-arrestin binding to the GPCR
stearically interferes with the association of the G protein with the GPCR leading to the
desensitization of the receptor (394). The GRK-β-arrestin system also induces clathrin-mediated
internalization of the inactivated GPCR into the endosomal compartments for receptor recycling
(395, 396). β-arrestins can also act as adaptors to mediate signaling through GPCRs
independently of G proteins leading to the activation of MAPK, SRC, nuclear factor-κB (NF-κB)
and phosphoinositide 3-kinase (394, 397, 398). To conclude, the coupling of a GPCR with
multiple combinations of G proteins and β-arrestins can generate numerous complex signaling
pathways and cellular effects even from similar ligands.

3. Cytomegalovirus Encoded Homologs of Chemokines, Cytokines, and their Receptors

In vitro experiments have shown that only 41 CMV ORFs are part of the core set of genes
essential for HCMV replication in culture (399). There are about 88 genes that are non-essential
for replication of the virus in vitro but may play a role in the survival/replication of the virus in
vivo (399). Some of these genes encode immune modulatory chemokine (400) and cytokine
(161, 401) homologs and receptors (402, 403). The following section discusses the details about
the diversity and function of these CMV proteins.

3.1 CXC Chemokine Homologs in CMV
The HCMV genome carries two open reading frames (ORFs), UL146 and UL147, that encode
CXC chemokine homologs: viral CXCL-1 and 2 (vCXCL-1 and vCXCL-2) respectively (400).
Similar to HCMV, chimpanzee CMV (CCMV) also encodes homologs of UL146 and UL147 in
addition to UL146-related genes UL146a and UL157 that are not present in other CMVs (404).
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The rhesus CMV (RhCMV) also carries a homolog of the HCMV UL147, rh158 (29). The
virulent HCMV Toledo strain contains at least 19 ORFs in the 15 kb UL/b’ region including the
viral chemokine genes (UL146 and UL147) which are missing in the lab adapted and attenuated
AD169 strain (400). The absence of these genes does not affect the growth of AD169 in vitro,
leading to the speculation that these genes may have a role in HCMV pathogenesis (400, 405,
406). The UL146-encoded protein, vCXCL-1, is a functional CXC chemokine (407).

It can

bind both hCXCR2 and hCXCR1 (407, 408) and is capable of inducing chemotaxis and calcium
flux in isolated human neutrophils similar to CXCL8 (407, 409). The evidence for the role of
viral CXC chemokines in HCMV dissemination comes from experiments with HCMV UL146UL147 deletion recombinants. In these experiments, viral passage to neutrophils was impaired
while retaining its tropism for other cell types (410). No formal proof exists for the secretion of
vCXCL-2 and there is no functional data for vCXCL-2 (138, 411). All data to date focuses on
vCXCL-1 and not vCXCL-2.
Data from sequencing studies shows that the UL146 gene is one of the most variable
genes in the entire HCMV genome (405, 406, 412-418). UL146 from clinical isolates shows 4%
identity (5 residues) and 5% similarity (6 residues) to each other (416). It has been hypothesized
that this variability may correlate to the severity of CMV disease (414, 415, 419). A recent study
conducted by Paradowska et al. provided for evidence in support of this hypothesis by
concluding that there is a correlation between HCMV vCXCL genotypes and the clinical sequela
observed (405). However, other similar studies could not find such a correlation between the
UL146 genotype and CMV pathogenesis, which was attributed to the small sample size in these
studies (412, 413, 415).

3.2 CC Chemokine Homologs in CMV
The HCMV UL128 ORF encodes a protein with limited homology to CC chemokines (420).
The encoded protein promotes the migration of human peripheral blood mononuclear cells
(PBMC) and induces expression of pro-inflammatory cytokines TNF-α and IL-6 similar to that
reported for MIP-1α (421, 422). The HCMV UL128 protein however, is non-functional in
clinical HCMV strains (i.e., Toledo and Merlin) due to a partial inversion or frame shift mutation
(420). CCMV and RhCMV also have a UL128 ORF homolog (143, 149). The HCMV UL130
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ORF encodes a protein containing a putative C chemokine fold (423), although functional data is
lacking.
In addition to being a potent chemokine, the UL128 locus (UL128, UL130 and UL131A)
of HCMV are essential for growth in endothelial cells, DC, epithelial cells, and for transmission
to leukocytes (410, 424, 425). The UL128/130/131 proteins form a complex with glycoprotein
H and L (gH/gL) on the virion surface to form the pentameric complex (426). The pentameric
complex mediates entry of HCMV into endothelial and epithelial cells whereas the gH/gL/gO
complexes mediate virus entry into fibroblasts (425, 426). Therefore, the genes at the UL128
locus play a dual role, as a potent chemokine and tropism determinant.
Splicing of the m131 and m129 genes of murine CMV (MCMV) produces a CC
chemokine homolog MCK-2 (427, 428). Initially, the protein product of m131 (MCK-1) alone
was characterized as a functional chemokine (429). However, MCK-1 is a portion of a CC
chemokine including a long carboxy-terminal domain, which includes the entire m129 ORF
Together, MCK-1 with this carboxy domain form MCK-2 (427, 428). In vivo studies using
MCMV recombinants deleted in MCK-2 demonstrated the role of MCK-2 in viral dissemination
in vivo (139, 140). The recombinants are defective in their dissemination to the salivary gland
and demonstrate lesser inflammation at the site of inoculation in the foot pad (139, 140). MCK-2
has been shown to recruit myeloid progenitor cells (141, 430) and monocytes (429). These cell
types participate in the viral dissemination to the salivary gland (141, 430) and also provide a
reservoir for establishing latency (206, 431-433). MCK-2 can also attract cells similar to the
myeloid-derived suppressor cells (MDSCs) to the site of infection and impair proliferation and
the differentiation of CMV-specific CD8+ T cells (434). Wagner et al. recently showed that the
complex formed between MCK-2 and gH is incorporated into the virion envelope and plays a
role in promoting MCMV infection monocytes/macrophages in vitro and in vivo (435).
Therefore like the HCMV CC chemokine homolog, MCK2 also has dual role as a chemokine as
a determinant of MCMV cell tropism.
Rat CMV (RCMV) genes r129 and r131 have limited homology to MCMV genes m129
and m131genes (24). Deleting the r131 ORF was shown to encode a functional CC chemokine
that is a functional homolog of the MCMV MCK-2 protein. The r131 deleted recombinants
develop less swelling at the site of infection in the paw and demonstrate impaired viral
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dissemination to the salivary gland as well as lower viral titers in the salivary gland compared to
wild type virus (436) paralleling the MCK-2 phenotype.
Guinea pig CMV (GPCMV) encodes a CC chemokine with homology to CCL3 (MIP-1α)
and CCL14 (hemofiltrate CC-chemokine 1, HCC-1) not encoded by other animal CMVs (437,
438). GPCMV-MIP signals via hCCR1 and induces Ca+2 flux similar to CCL3 (438, 439). Both
CCL3 and CCL14 are known to enhance the proliferation of myeloid progenitor cells. As such,
GPCMV-MIP production aids in viral dissemination and latency in vivo (440). Intracochlear
inoculation of guinea pigs with the GPCMV-MIP deletion viruses resulted in reduced hearing
loss compared to wild type virus, demonstrating its role in CMV pathogenesis (441).

3.3 Chemokine Receptor Homologs in CMV
The HCMV genome encodes for four chemokine receptors: US27, US28, UL33 and UL78 (402,
403). US28 has pleiotropic roles as an immune modulator and oncogene (144, 442, 443). US28
displays 30% homology with the β-chemokine receptor CCR1 and to lesser extent to CCR2 and
CCR5 (444). The protein, pUS28, is the only viral chemokine receptor shown to bind CC as
well CX3C chemokines (444-446). pUS28 is expressed on infected cells and can signal upon
ligand binding to induce cellular responses similar to host β-chemokine receptors (444, 447-450).
pUS28 also displays constitutive signaling activity, which leads to the activation of
phospholipase C causing the accumulation of IP3 and DAG, as well as promoting NF-κB
activation (451-455). Signaling through these pathways induces smooth muscle cell migration
(SMC)(448), which may contribute to the development of HCMV associated atherosclerosis
(456). Using integrated analysis of sequence, structure, and simulations of pUS28, Burg et al.
discovered that pUS28 has a distinctive structure near the cytoplasmic end of TM3. This results
in a destabilization of the receptor’s inactive state and is responsible for the observed ligandindependent constitutive activity (457). US28 is also transcribed during HCMV latency (437,
458, 459). However, its role in this setting is yet to be determined.
The ability of pUS28 to bind, sequester, and internalize chemokines allows it to act as an
immune modulator by disrupting the chemokine gradient (460, 461). Experiments with HCMV
US28 deletion mutants demonstrated that the chemotaxis of monocytes towards CCL5 and
CCL2, which are expressed in response to infection, could be inhibited (462). pUS28, by virtue
of its constitutive signaling activity, can also promote tumorigenesis by up-regulating signaling
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via the STAT3/IL-6 axis to induce the proliferation of cells (463-465). Transgenic mice
expressing pUS28 under the control of the villin promoter developed intestinal neoplasia that
could be further enhanced by co-expression of the US28 ligand CCL2 (466). Transcripts of
US28 and pUS28 have also been detected in primary cultures of glioblastomas and paraffin
embedded glioblastoma tissue samples in nearly 60% of cases analyzed (465, 467), suggesting
the involvement for pUS28 in tumorigenesis in humans.
Very little is known about the functions of other members of the HCMV chemokine
receptor family. They are considered orphan receptors with no known ligands. pUS27 does not
possess constitutive signaling activity (468). The protein localizes mainly to intracellular
multivesicular bodies, but can also be detected at the cell surface and is incorporated into the
virion envelope. The envelope-localized pUS27 appears to play a role in the extracellular spread
of the virus in both fibroblasts and endothelial cells (468-470). pUS27 can colocalize and
heteromerize with pUS28 without inhibiting its constitutive signaling activity (471). The role of
this complex in CMV pathogenesis, however, is unknown.
The UL33 gene is conserved in all β-herpesviruses, including HCMV (UL33), RCMV
(R33), and MCMV (M33). The UL33 protein and its rodent homologs also show constitutive
activity, although they differentially activate specific signaling pathways (452, 455, 472, 473).
The pR33 and pM33 are not essential for viral replication in vitro, nor does pM33 play a role in
hematogenous dissemination in vivo (474). However, these proteins are important for viral
replication and cell to cell spread in the salivary gland (147, 474-476) and reactivation from
spleen and lung explants (148, 475). The constitutive activity of pM33 is required for efficient
dissemination and replication MCMV in vivo (477). pM33 can be activated upon binding CCL5
and both pM33 and pR33 induce SMC migration similar to pUS28 (85, 86).

Moreover,

replacing M33 with US28 from HCMV, partially complements the activity of MCMV M33
deletion recombinant (148). This data suggests that pM33 is a functional homolog of the HCMV
US28 (85) and that GPCRs of the UL33 family might modulate cellular trafficking contributing
to viral pathogenesis.
UL78 is the newest member of the HCMV chemokine receptor family and is not required
for the replication of the virus in vitro (478). The genomic location of both UL33 and UL78 is
conserved among all known β-herpesviruses, suggesting a role for these proteins in the viral life
cycle in vivo (479). A recent study has shown that pUL33 and pUL78 can form a complex with
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pUS28 without affecting its constitutive activity. However, this might interfere with the ability
of pUS28 to induce NF-κB activation, suggesting a potential regulatory role for this complex in
infected cells (471, 480). Both pUL78 and pUL33 can also heteromerize with the host
chemokine receptors CCR5 and CXCR4 in THP-1 cells. This interaction inhibits HIV-1
infection of infected cells (481) and may function to modulate the host immune response to
chemokines that bind to CCR5 and CXCR4 (481).

3.4 Cytokine Homologs in CMV
During productive infection the HCMV gene UL111A encodes a homolog of human IL-10 (hIL10) called cmvIL-10 (161, 401). Alternative splicing of the UL111A gene leads to the expression
of another viral IL-10 homolog during latency termed latency associated cmvIL-10 (LAcmvIL10)(482). The cmvIL-10 transcript encodes a 175 amino acid protein, whereas LAcmvIL-10 has
139 amino acid residues. Both cmvIL-10 and LAcmvIL-10 share 27% amino acid identity with
hIL-10. Deletion of the UL111A gene from HCMV neither affects virus replication (483) nor the
establishment and maintenance of HCMV latency in vitro (484). Although divergent in its
sequence from hIL-10, cmvIL-10 can still bind and signal through the hIL-10 receptor (161, 401,
485) and has immunomodulatory functions similar to those of hIL-10. For example, similar to
hIL-10, cmvIL-10 can inhibit the production of pro-inflammatory cytokines TNF-α, IL-1β, and
IL-6 from lipopolysaccharide (LPS) stimulated PBMCs and monocytes. They also decrease the
monocytic expression of major histocompatibility complex (MHC) class I and MHC class II
(159, 486, 487) and inhibit the maturation and effector function of monocyte derived DCs (156,
157, 488), plasmacytoid DCs (154) and microglial macrophage, which results in a limited
chemotaxis of activated T lymphocytes towards these cells (489). cmvIL-10 can also stimulate
proliferation and differentiation of B lymphocytes (158) and monocyte differentiation towards a
more macrophage like phenotype rather than a dendritic cell phenotype. This allows the virus to
replicate in these cells and not be presented to T cells in the lymph node (490). During latency,
viral IL-10 down-regulates the cytokines associated with DC differentiation (491) and the
surface expression of MHC class II on latently infected cells leading to an impaired CD4+ T cell
recognition of latently infected cells in vitro (484).
While both cmvIL-10 and LAcmvIL-10 can suppress MHC class II on primary human
myeloid progenitor cells and monocytes (159, 492), LAcmvIL-10 does not impair DC
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maturation, nor does it inhibit the expression of proinflammatory cytokines and costimulatory
molecules CD40, CD80, and CD86 expressed on stimulated DCs, which cmvIL-10 and hIL-10
do (492). Furthermore, it also lacks the ability to stimulate B cells and phagocytic macrophages
(158, 490). Structural differences between cmvIL-10 and LAcmvIL-10 might account for this
difference in the function range of cmv IL-10 and LAcmvIL-10. Studies using hIL-10 receptor
blocking antibodies have shown that LAcmvIL-10 may either not bind and signal through the
hIL-10 receptor or it may do so differently than cmvIL-10 and hIL-10 (492), which might result
in a restricted range of functions.
RhCMV encodes a functional IL-10 homolog (RhcmvIL-10) and has been used to
evaluate the role of cmvIL-10 in vivo (160, 161, 493). In studies using RhcmvIL-10 deleted
mutants, rhesus macaques infected with the mutants displayed enhanced inflammatory response
and diminished macrophage infiltration (160). At the same time, these infected macaques
demonstrated a significantly higher DC numbers, a stronger CD4+ T cell proliferative response
and higher IgG titers (160).

cmvIL-10 can also enhance congenital

HCMV

disease by

impairing cytotrophoblast remodeling of the uterine vasculature to limit fetal growth (494). The
combination of cmvIL-10’s ability to suppress pro-inflammatory mediators accompanied by
stimulation of B cells, works to skew the host immune response such that it is less than effective
at controlling virus replication. In addition the ability of viral IL-10 to alter the differentiation of
latently infected myeloid progenitors, inhibition of the formation of mature DCs could be another
mechanism by which HCMV restricts immune clearance of latently infected cells. It has also
been hypothesized that viral IL-10 expressed during HCMV infection induces an antiinflammatory macrophage phenotype (M2 macrophage) to enhance virus pathogenesis in vivo.

3.5 Cytokine Receptor Homologs in CMV
The UL144 gene of HCMV encodes a type I transmembrane glycoprotein homologous to tumor
necrosis factor receptor (TNFR) superfamily members (495). UL144 is also one of the most
variable genes in the HCMV genome (416, 419, 496). The protein, pUL144, however, does not
function through binding of TNF ligand family members (495, 497). A pUL144 fusion protein
was shown to bind to B- and T-lymphocyte attenuator (BTLA), an inhibitory receptor found on
T-cells (498, 499). This binding inhibits the proliferation of CD4+ T cells induced by anti-CD3
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and anti-CD28 stimulation (498). HCMV might employ a similar strategy to attenuate the antiviral T-cell response in vivo.
pUL144 also interacts with TNFR associated factor (TRAF6) and the cellular tripartite
motif 23 protein (TRIM23) as a co-factor to activate NF-κB signaling (497, 500). This signaling
induces the chemokine CCL22 (497, 501), which attracts regulatory T-cells (502) suggesting the
role of pUL144 as an immunoevasin for HCMV (497).

3.6 Secreted Chemokine Binding Protein Homologs in CMV
pUL21.5 is a small secreted chemokine binding glycoprotein (CBP) encoded by HCMV.
The CBP shows no homology to known proteins and is not conserved across viruses (503).
pUL21.5 is capable of binding CCL5 (RANTES) but not CCL3, CCL2 or CXCL8 (504). This
suggests that it can act as a sink to sequester free CCL5 to compete for CCL5 binding to its
receptor (504). The mRNA for UL21.5 is incorporated into the mature virion and is available for
translation immediately following infection (505). CCL5 is a potent chemoattractant of immune
effector cells such as monocytes, T-cells, macrophages, and dendritic cells (506). HCMV has
multiple strategies to modulate CCL5 expression and function, suggesting an important role of
CCL5 in the anti-HCMV immune response. However, there is currently no data evaluating the
function of p21.5 to interfere with CCL5 function and its effect on viral survival in vivo.

4. Current status of vaccines and anti-virals against HCMV

4.1 Current status of CMV vaccines
As discussed in chapter 1, animal models have been used to evaluate strategies to develop
a CMV vaccine. Some of these products are currently in human clinical trials (507). Initial
studies in renal transplant recipients using the Towne vaccine provided evidence of reduced
severity of end organ disease (EOD) (508). Several chimeric live virus vaccines, including ones
with a Towne backbone and segments of the attenuated Toledo and others have also been
evaluated in phase I trials (509-511). Sanofi Pasteur is testing a subunit vaccine containing the
soluble glycoprotein B (gB) in phase II double-blind randomized placebo-controlled trials (125,
512). In this study, the vaccine protected ~ 50% of seronegative women from acquiring primary
infection and reduced viral load parameters post kidney or liver (125, 512). GlaxoSmithKline
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has also evaluated a gB subunit vaccine in a phase I clinical trial (513, 514). Astellas is currently
using a DNA vaccine expressing gB and pp65, in which they noted reduced reactivation of CMV
in hematopoietic stem cell recipients (515, 516). Currently, Novartis is currently exploring a
novel alphavirus recombinant vaccine expressing gB, pp65, and the major immediate-early
antigen (517). Recently it has been shown that entry into epithelial and endothelial cells is
prevented by antibodies to gB or the pentameric complex (426, 518). Newer targets of cytotoxic
T-lymphocytes have also been identified and are currently under investigation (519). Although it
has been demonstrated that vaccination can boost immune responses in seropositive women
(520), it is currently unknown if this is sufficient to prevent congenital infection.

4.2 Current status of CMV anti-virals
In the absence of any licensed CMV vaccine, antiviral therapy has been critical. The
current clinical protocol results in dramatically improved outcomes for immunocompromised
patients. Currently licensed drugs for the treatment of CMV infections include the nucleoside
analogs ganciclovir (GCV), valganciclovir (VGCV), foscarnet (FOS), and cidofovir (CDV)
(521-523).

These nucleoside analogs have been highly successful due to the potential for

chemical diversity within the class and the differentiation of target viral DNA polymerases from
host enzymes (521).

Ganciclovir has become the gold standard for management of CMV

diseases in the majority of patient settings (521). These drugs have been used to prevent CMV
infection and disease, primarily in solid organ and hematopoietic stem cell transplants (521-523).
The anti-sense RNA, fomivirsen is licensed for intravitreal administration to treat CMV retinitis
and EOD in AIDS patients (521-524). The potential use of these drugs is being explored for the
treatment of congenital CMV infection (525, 526). Continuous efforts in the industry and
academia have led to the development of newer candidates with enhanced antiviral efficacy and
apparently minimal side effects (e.g. Maribavir, Cidofovir ester, etc.) (521, 523). Recently, the
phospholipid specific antibody bavituximab, that targets phosphatidylserine in the outer leaflet of
the virion envelope has been shown to be effective against MCMV by preventing cellular
attachment and entry (527).

These compounds are still in the early stages of clinical

development and have yet to be approved.
At the same time, the clinical utility of most of these agents is limited by poor oral
bioavailability, associated toxicities, and the potential for development of resistance with
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extended use (521-524). Therefore, novel therapeutic agents with a different mechanism of
action than the currently used drugs and low toxicity are needed to address these limitations.

4.3 Challenges in developing an effective CMV vaccine
Natural immunity against CMV is imperfect, in part due to the ability of CMV to evade
the host immune response (138, 411). Vaccines could improve upon natural immunity by
stimulating a protective immune response. However, a major barrier in the development of a
CMV vaccine is the ability of CMV to co-infect, re-infect and reactivate even in the face of a
strong immune response. Recent studies have shown that high titers of anti-CMV antibodies are
unable to prevent congenital infection (528). Moreover, immune competent individuals generate
a very strong immune response against CMV, with up to 10% of CD4 and CD8+ T cells being
CMV specific and yet still unable to prevent CMV re-infection (411, 519). These observations
suggest that there are still gaps in our knowledge regarding CMV transmission and epidemiology
that need to be closed in order to develop a successful CMV vaccine.

5. Conclusion and Statement of Research Aims

Due

to

high

morbidity

and

mortality

in

HCMV

infected

newborns

and

immunocompromised individuals, the development of an HCMV vaccine or other effective
therapeutic treatment is necessary. However, as discussed above, no vaccine against CMV is
currently available despite over three decades of research. This in part, is due to the limited
understanding of HCMV pathogenesis including viral dissemination.
As described above CMV encodes homologs of several host proteins with the ability to
exploit existing cellular signaling pathways and evade the anti-viral immune response. These
proteins facilitate viral infection, dissemination, and survival and complicate the understanding
of the virus even further. CMV disseminates within the host via cell-associated viremia in cells
of hematopoietic origin including monocytes and neutrophils. Although the virally encoded
homologs share some activities with their host counterparts, they also demonstrate specific
differences in function (e.g., constitutive signaling of chemokine receptor homologs, which is
attributed to specific structural aspects of the viral receptor not found in the human receptor).
The CMV-encoded chemokine homologs can alter the response of leukocytes during viral
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infection and could have an effect on viral pathogenesis. For example, the CC chemokine of
MCMV and RCMV, MCK2 and pR131 respectively, induce inflammatory responses that
enhance virus dissemination to the salivary gland in vivo, while GPCMV-MIP induces an
inflammatory response leading to hearing loss. HCMV encoded vCXCL-1 demonstrates
hypervariability and the vCXCL-1 genotype could be a determinant of HCMV pathogenesis.
Further study is required to characterize the vCXCL-1 gene from different HCMV isolates in
vitro and evaluate to its role in the context of viral infection in an appropriate animal model in
vivo.
Although effective, the current antivirals have several shortcomings including toxic side
effects and the emergence of drug resistant CMV strains. Therefore, research that would
contribute to closing these gaps in our knowledge or that lead to the development of new
therapeutics is needed.

We address these issues using recombinant proteins, viral recombinants, and synthetic cationic
peptides and in the mouse model of CMV to test the following hypotheses in this dissertation:

1. Polymorphisms in vCXCL-1, lead to differences in cellular activation that contribute to
HCMV pathogenesis.
2. vCXCL-1 is a functional CXC chemokine that contributes to viral dissemination.
3. Heparan sulfate binding peptides prevent CMV infection of the cells.

We hope that these studies will broaden our understanding of HCMV immune evasion strategies
and provide evidence to support the development of novel HCMV vaccines/therapeutics.
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CHAPTER 1: NOVEL HUMAN CYTOMEGALOVIRUS VIRAL CHEMOKINES,
vCXCLl-1s, DISPLAY FUNCTIONAL SELECTIVITY FOR NEUTROPHIL
SIGNALING AND FUNCTION
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This chapter is a publication by the same title published in the Journal of Immunology in 2015
by Jinho Heo, Pranay Dogra, Tom J. Masi, Elisabeth A. Pitt, Petra de Kruijf, Martine J. Smit,
Tim E. Sparer and has been reproduced here with permission from the journal (appendix 6).
Copyright 2015, The American Association of Immunologists Inc.

Heo J, Dogra P, Masi TJ, Pitt EA, de Kruijf P, Smit MJ, et al. Novel Human Cytomegalovirus
Viral Chemokines, vCXCL-1s, Display Functional Selectivity for Neutrophil Signaling and
Function. J Immunol. 2015. Epub 2015/05/20. doi: 10.4049/jimmunol.1400291. PubMed PMID:
25987741.

My use of “we” in this chapter refers to my coauthors and myself. My primary contributions to
this paper include (1) researching the topic, (2) generating and purifying the chemokines (used to
generate figures 1.2 and 1.5) (3) performing experiments to generate data for figure 1.2 and for
the rebuttal letter from the reviewers, (4) writing up the results and discussion of the figures
generated for the main manuscript and rebuttal letter.
1. Abstract

Human cytomegalovirus (HCMV) uses members of the hematopoietic system including
neutrophils for dissemination throughout the body. HCMV encodes a viral chemokine, vCXCL1, that is postulated to attract neutrophils for dissemination within the host. The gene encoding
vCXCL-1, UL146, is one of the most variable genes in the HCMV genome. Why HCMV has
evolved this hypervariability and how this affects the virus’ dissemination/pathogenesis is
unknown. Because the vCXCL-1 hypervariability maps to important binding and activation
domains, we hypothesized that vCXCL-1s differentially activate neutrophils, which could
contribute to HCMV dissemination and/or pathogenesis. In order to test whether these viral
chemokines affect neutrophil function, we generated vCXCL-1 proteins from 11 different clades
from clinical isolates from HCMV-congenitally infected infants. All vCXCL-1s were able to
induce calcium flux at a concentration of 100 nM and integrin expression on human peripheral
blood neutrophils (PBNs) in spite of differences in affinity for the CXCR1 and CXCR2
receptors. In fact their affinity for CXCR1 or CXCR2 did not directly correlate with chemotaxis,
G protein-dependent and independent (β-arrestin2) activation, or secondary chemokine (CCL22)
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expression. Our data suggest that vCXCL-1 polymorphisms impact the binding affinity, receptor
usage, and differential PBN activation that could contribute to HCMV dissemination and/or
pathogenesis.

2. Introduction

Human cytomegaloviruses (HCMVs) are ubiquitous pathogens that are well adapted to modulate
host immune responses (138, 529). HCMV contains genes for immune evasion that function to
increase viral survival, dissemination, and may contribute to pathogenesis (411). There are a
large number of open reading frames (~82) in HCMV that are non-essential for virus replication
in vitro but may have a role in immune evasion in vivo (168, 400). In one of these regions, the
UL/b’ region, the open reading frames (ORFs), UL146 and UL147, have limited homology to
host CXC chemokines (400). Yet, the UL146 protein from the Toledo strain of HCMV, vCXCL1Toledo, acts as a functional CXC chemokine (407) that binds to CXCR1 and CXCR2, induces
neutrophil chemotaxis and calcium mobilization (408). This gene is one of the most variable in
the entire HCMV genome (412, 413, 415, 417, 418). This variability is localized throughout the
entire chemokine including the N-terminus and N-loop region, which are important for
chemokine receptor binding and activation (259, 369). Some strains even alter the Glu-Leu-Arg
(ELR) prior to the CXC motif, which is a critical for receptor recognition and activation (373,
374).

We hypothesized that hypervariable vCXCL-1s produced from HCMV-infected

endothelial cells recruit neutrophils with alterations in binding, activation, and neutrophil
functions that contribute to viral dissemination and possibly its pathogenesis.
Eleven distinct vCXCL-1 clades were previously found in clinical isolates from
congenitally infected infants (416). In these groups the N-loop region was highly variable. In
addition one isolate, vCXCL-1TX15, encoded a non-ELR CXC chemokine. Although the genetic
variability of vCXCL-1 does not definitively correlate with congenital outcomes, the
hypervariablilty within the N-loop region suggests that the vCXCL-1s may have different
interactions with the chemokine receptors CXCR1 and CXCR2. In order to address functional
variability of the vCXCL-1s, recombinant vCXCL-1s from each clade were generated.
Competition binding, signaling, and neutrophil activation assays were utilized to assess the effect
of vCXCL1 variability on chemokine function.
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3. Materials and Methods

Materials
Dulbecco’s modified Eagle’s medium (DMEM), penicillin and streptomycin were obtained from
Hyclone Laboratories (Logan, Utah).
(Manassas, Virginia).

Fetal bovine serum was purchased from Mediatech

DMEM containing 25 mM HEPES and L-glutamine, OPTI-MEM,

Hygromycin-B and Geneticin were obtained from Invitrogen (Paisley, United Kingdom).
Bovine Serum Albumin Fraction V (BSA) was purchased from Roche (Mannheim, Germany).
Polyethylenimine (PEI) was obtained from Polysciences (Warrington, PA, USA).
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I-CXCL8

and 35S-GTPS was obtained from PerkinElmer Life Sciences (Boston, MA, USA).
Clinical isolates used for cloning of the vCXCL-1 open reading frames were provided by
Dr. James Bale (University of Utah School of Medicine), Dr. Sunwen Chou, (Oregon Health and
Science University), and Dr. Gail J. Demmler (Texas Children's Hospital) as described in (416).

Cell culture and CXCR2 transfection
Insect cells, serum-free adapted SF9 cells (Invitrogen, Carlsbad, USA), were grown at 28°C in
serum-free Sf-900 II SFM medium (Invitrogen, Carlsbad, USA). Hi5 cells (Invitrogen, USA)
were grown in suspension at 28°C in serum-free Insect-XPRESS medium (Lonza, Switzerland).
Both cells were grown in non-humidified, ambient air-regulated incubator.
PathHunterTM HEK293-CXCR2 cells (DiscoveRx, Fremont, USA), were grown at 5%
CO2 and 37°C in DMEM with 25 mM HEPES and L-glutamine supplemented with 10% (v/v)
heat-inactivated fetal bovine serum, 50 IU/ml penicillin, 50 g/ml streptomycin, 800 g/ml
Geneticin and 200 g/ml Hygromycin-B.
HL-60 T2 cell transfectants over-expressing CXCR2 (a kind gift from Dr. Ann
Richmond, Vanderbilt University, USA) were grown at 5% CO2 and 37°C in RPMI-1640
Hyclone Laboratories (Logan, Utah) supplemented with 10% (v/v) fetal bovine serum, 50 IU/ml
penicillin, 50 g/ml streptomycin, 400 g/ml G418 (Mediatech, Manassas, USA).
For
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S-GTPγS experiments, HEK293T cells were grown at 5% CO2 and 37°C in

Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) fetal bovine serum, 50
IU/ml penicillin and 50 g/ml streptomycin. HEK293T were transiently transfected (per 10 cm
dish) with 2.5 ug of cDNA encoding human CXCR2 supplemented with 2.5 ug of pcDEF3 by
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using linear polyethyleneimine (PEI) with a molecular weight of 25 kDa as previously described
(530).

Neutrophil isolation
PBNs were isolated from EDTA-treated blood from healthy human volunteers using dextran
sedimentation and density gradient centrifugation as previously described (531). Erythrocytes
were lysed with hypotonic lysis in 0.2% NaCl. Neutrophils were resuspended in the buffers for
the individual assays. Viable neutrophils were quantified with trypan blue exclusion using a
hemacytometer. The use of human subjects has been approved by the University of Tennessee
Institutional Review Board (IRB# 6476B).

Production of recombinant vCXCL-1 proteins
The vCXCL-1 gene, UL146, was PCR amplified from HCMV DNA from each of the 11 clades.
Amplicons were cloned into the baculovirus transfer plasmid 1392 (Invitrogen, Carlsbad, USA),
which contains homologous regions for recombination into the baculovirus genome.

PCR

primers were designed to include the open reading frame (ORF) and with an additional 2-4
glycines and six histidines on the carboxyl terminus of the proteins for purification.

For

generation of baculoviruses, SF9 cells were transfected with the 1392/UL146 ORF plasmid
construct and linearized AcNPV DNA (Sapphire Baculovirus DNA) (Orbigen USA) using
transfection reagent Cellfectin (Invitrogen, Carlsbad, USA).

Recombinant baculoviruses

containing the UL146 gene were titered and used to infect Hi5 cells for optimum protein
expression. 48 hrs after infection, cells and supernatants were harvested. Recombinant protein
was isolated from the supernatants using Ni-NTA agarose beads (Qiagen, San Diego, USA) and
resuspended in PBS. Protein concentration was quantified using silver staining of SDS-PAGE
gel using lysozyme as a standard and analyzed using Quantity One software (Bio-Rad, Hercules,
USA). MALDI-TOF was used to confirmed protein purity and the correct m.w.

Intracellular calcium mobilization assays
Release of calcium from intracellular stores was determined on freshly isolated PBNs
resuspended in Minimal Essential Medium (MEM). PBNs at 5 x 106 cells/ml were loaded with 4
μM Fluo-4, AM (Molecular Probes from Invitrogen, Carlsbad, USA) for 60 min at 37 °C. Cells
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were then washed once with MEM and incubated for another 30 min for completion of the
esterification process. Finally the cells were diluted to 1 x 106 cells/ml in MEM and for the
calcium flux assay. Chemokines were added to 2 ml of cells at a final concentration of 100, 10
and 1 nM.

Calcium flux was measured using a Photon Technology International

Spectrophotometer (Birmingham, NJ, USA) at an excitation of 494nm nm and emission of
516nm, FeliX32 software for analysis. Relative intracellular calcium levels post stimulation were
expressed as change in fluorescence = fluorescence after stimulation – background fluorescence
(Δ Fluorescence) for each of the chemokines tested.
β2 integrin staining
1×106 cells PBNs were resuspended in RPMI-1640 with 1% FBS and exposed to 100 nM of
chemokines for 2 h at 37 °C. Cells were washed with PBS and blocked with 1% goat serum.
PBNs were incubated with fluorescently conjugated CD11a, CD11b, and CD11c antibodies
(Caltag Invitrogen, Carlsbad, USA) on ice for 30 min. and fixed with 4% paraformaldehyde.
Cells were analyzed with flow cytometry (FacsCalibur, BD Bioscience).

Human PBN chemotaxis assays
Chemotaxis assays were performed on freshly isolated PBNs resuspended in HBSS with 0.1%
BSA and 10 mM HEPES. Assays were performed in triplicate in 96-well chemotaxis plates. 30
μl of chemokines were loaded at varying concentrations (100 and 500nM) into the lower well of
the modified Boyden chamber (Neuroprobe, Gaithersburg, USA) and fitted with a 5 μm filter.
PBNs were labeled with 1:1000 CalceinAM (Invitrogen, Carlsbad, CA) for 1hr. on a rotating
wheel at 37°C.

Cells were washed with PBS and resuspended to 5×106 cells/ml. 20 μl were

added to the upper well. The PBNs were allowed to migrate for 2-3 hr. at 37°C. The number of
PBNs that migrated to the chemokines was measured on a fluorescent plate reader (Synergy 2,
Biotek, USA) minus the fluorescence from the buffer only control wells.

Receptor binding analysis
The ability of vCXCL-1s to compete for binding to either CXCR1 or CXCR2 was evaluated as
previously described (407).

Briefly, 1×105 - 3×105 HEK293 cells stably over-expressing

CXCR1 or CXCR2 were incubated with 100pM
40
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I-labeled CXCL8 (MP Biomedical) and

increasing concentrations of unlabeled chemokines for 1 hour at room temperature. Cells were
collected on glass filters, washed twice, and bound radioactivity was measured with liquid
scintillation counting. The graph was plotted and competition constants (IC50) were analyzed
using GraphPad Prism 5 for Windows.
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S-GTPS binding assay

Two days after transfection with CXCR2 expression constructs, HEK293T cells were detached
from the plastic surface using ice-cold phosphate-buffered saline (PBS) and centrifuged at 1500g
for 10 min at 4°C. The pellet was resuspended in ice-cold PBS and centrifuged. Cells were
resuspended in ice-cold membrane buffer (15 mM Tris, 1 mM EGTA, 0.3 mM EDTA, and 2 mM
MgCl2 , pH 7.5), followed by homogenization using a Teflon-glass homogenizer and rotor. The
membranes were subjected to two freeze-thaw cycles using liquid nitrogen, followed by
centrifugation at 40,000g for 25 min at 4°C. The pellet was rinsed once with ice-cold Trissucrose buffer (20 mM Tris and 250 mM sucrose, pH 7.4) and subsequently resuspended in the
same buffer and stored (-80°C). Protein concentration was determined using a BCA-protein
assay (Thermo Scientific, Rockford, USA).
Membranes (2.5 µg/well) were incubated in 96-well plates in assay buffer (50 mM
Hepes, 10 mM MgCl2, 100 mM NaCl, pH 7.2 with 5 µg saponin/well, 3 µM GDP and
approximately 500 pM of
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S-GTPS added) and the indicated concentrations of CXCL8 or

vCXCL-1 to a final volume of 100 l. The reaction mixtures were incubated for 1 hour at room
temperature, harvested with rapid filtration through Unifilter GF/B 96-well filterplates
(PerkinElmer, USA) and washed three times with ice-cold wash buffer (50 mM Tris-HCl and 5
mM MgCl2, pH 7.4).
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S-GTPS incorporation was determined using a Microbeta scintillation

counter (PerkinElmer, USA). Functional data were evaluated by a non-linear curve fitting using
GraphPad Prism 4.0 (GraphPad Software, inc., San Diego, CA).
-arrestin recruitment assay
PathHunterTM HEK293-CXCR2 cells were plated out overnight at 1x104 cells/well (384-wells
format) in 20 l OPTI-MEM. A pre-incubation with vehicle (PBS + 0.1 % BSA) of 30 min at
37°C and 5% CO2, was followed by 90 min with CXCL8 or vCXCL-1 stimulation at 37°C and
5% CO2. 12 l PathHunter Detection Reagents (DiscoveRx, Fremont, USA) was added. After
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60 min. incubation at room temperature, -galactosidase, as an indicator of -arrestin-CXCR2
interaction, was measured for 0.3 sec in a Victor2 1420 Multilabel Reader. Functional data were
evaluated using a non-linear curve fitting using GraphPad Prism 4.0 (GraphPad Software, inc.,
San Diego, CA).

Quantitative real-time PCR of CCL22 expression
HL-60 T2 cell transfectants over-expressing CXCR2 were differentiated for 7 days with 1.3%
DMSO prior to chemokine treatment. Medium was exchanged with HBSS and incubated with
viral chemokines at a final concentration of 100 nM for 4 h at 37 °C. Total RNA was isolated
with Tri-Reagent (Sigma, St. Louis, USA) and reverse transcribed using ProtoScript M-MuLV
first strand cDNA synthesis kit (NEB, Ipswich, USA). Real-time PCR was performed using iQ5
Real-Time PCR Detection System (Bio-Rad, Hercules, USA) with a reaction mixture volume of
25 µl containing SYBR green (NEB DyNAmo SYBR green qPCR kit), 300 nM of each primer,
and ~25ng of cDNA.

Primers for CCL22 were purchased from SABiosciences (Cat #

PPH00697E). The reaction conditions were 95°C for 10 min, followed by 40 cycles of 95°C for
15 sec. and 60°C for 60 sec. The results were analyzed with the iQ5 Optical System Software
(Bio-Rad, Hercules, USA). The relative gene expression levels were calculated as the fold
change using the formula: Ratio = 2−ΔΔCT, where ΔCTtarget or reference = threshold cycle (CT) of
the control gene (ACT1) − CT of the target gene (CCL22), and ΔΔCT = ΔCTreference − ΔCTtarget
(532). The housekeeping gene encoding actin (ACT1) was used as a reference control. Primers
for

ACT1

were

5’-TGAGATGCATTGTTACAGGA-3’

(forward)

and

5’-

CACGAAAGCAATGCTATCAC-3’ (reverse) generating a 120-bp product.

4. Results

Amino acid sequences alignment
Previously, we sequenced the UL146 gene from 51 clinical isolates and showed that it comprised
11 genetic clades (416). Representative isolates from the 11 clades were aligned with vCXCL-1
from the Toledo strain (vCXCL-1Toledo) (Figure 1.1). The percent identities of the mature forms
of the vCXCL-1s, without the signal sequences, vary between 23.7% - 61.2% compared to
vCXCL-1Toledo.

The vCXCL-1s contain ~20 additional residues on the carboxyl terminus
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compared to host chemokines CXCL1 and CXCL8, but the function of these extra residues is
unknown.

Alignment of the vCXCL-1s and the host chemokines show seven conserved

residues, including the arginine (R) in the ELR motif, two cysteines (C) in the N-terminus (part
of the CXC motif), a proline (P) at position 32, cysteines at position 35 and 55, and a leucine (L)
at position 56. Furthermore, all vCXCL-1s contain a glycine (G), valine (V), histidine (H),
tryptophan (W) and proline (P) at position 21, 54, 60, 65 and 87, respectively, which are lacking
in the host chemokines. The ELR motif was conserved in all except vCXCL-1TX15. The
variability in the N-loop region (270), C-terminus (533, 534), and even in the ELR motif (506),
led us to evaluate differences in chemokine receptor binding and functional responses (535).

vCXCL-1 production using the baculovirus expression system
In order to address functional differences between the vCXCL-1s, we generated recombinant
vCXCL-1s using the baculovirus protein expression system. Unlike protein production from
prokaryotes, baculovirus expression provides mammalian signal-sequence cleavage, eukaryotic
glycosylation patterns and protein folding. Because some vCXCL-1s contain multiple predicted
signal cleavage (407) and glycosylation sites, and differences in recombinant protein refolding
conditions, we chose to express and purify them using the baculovirus system. All vCXCL-1s
were 6 His-tagged and purified using Ni-NTA agarose beads. Purity was confirmed with matrixassisted laser desorption/ionization-time of flight (MALDI-TOF) and resulted in the predicted
molecular weights (11-15 kDa).

vCXCL-1s stimulate calcium release in PBNs
Release of intracellular calcium is a common indicator of chemokine activation of PBNs (143,
407). CXCL8 and CXCL1 were shown to induce calcium flux at similar concentrations via
CXCR2 (536). To investigate vCXCL-1’s activation of PBNs, vCXCL-1s from the different
strains were added to freshly isolated PBNs.

All vCXCL-1s induced calcium flux at a

concentration of 100 nM including 100751, which is not shown in Figure 1.2. However they
differ in their ability to induce a calcium flux at other concentrations tested (Figure 1.2). This
demonstrates that even though the viral chemokines can induce calcium mobilization in PBNs,
the different vCXCL-1s have differing sensitivities for calcium signaling that may induce
differential downstream activation of PBNs.
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Figure 1.1 Amino-acid alignment of the mature forms of recombinant vCXCL-1s and
the host chemokines CXCL1 and CXCL8 with vCXCL-1Toledo. Seven amino acid
residues that are 100% conserved are indicated with an *. The important ELR, N-loop
region, and 30s and 40s loops are indicated at the top.
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Figure 1.2 CXCL8, CXCL1, and the different vCXCL-1s induce intracellular
calcium mobilization on human PBNs. Changes in fluorescence were measured over
time after exposure to different concentrations of chemokines (after 20 seconds at
baseline as indicated with an arrow). Data shown are representative figures of three
independent experiments.
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vCXCL-1s upregulate CD11b and CD11c
β2 integrins are receptors that form heterodimers composed of an α component, such as CD11a,
CD11b, and CD11c, and a β component, CD18. They are present on circulating leukocytes and,
once the cell is activated, initiate adhesion to endothelial cells and subsequent transmigration
across the endothelium (537).

Host chemokine, CXCL8, upregulates CD11b and CD11c

expression (538, 539). Moreover, vCXCL-1Toledo and the vCXCL-1 from chimpanzee CMV also
increases integrins on PBNs (143). In this study, we tested the ability of vCXCL-1s to alter the
surface expression of these receptors on PBNs (Figure 1.3). Exposure to the vCXCL-1s or host
chemokines, CXCL1 and CXCL8, does not change cell surface expression levels of CD11a.
However, CD11b and CD11c levels are increased upon exposure to either the vCXCL-1s or host
chemokines. The percent change in the mean fluorescent intensity of CD11b was 57-91% for the
viral chemokines, which similar to CXCL1 upregulation (82%) but less than CXCL8 (143%).
Likewise, the percent change of CD11c varied from 35-55% for the vCXCLs, which is similar to
CXCL1 (43%) but lower than CXCL8 (80.3%). These results demonstrate that the viral
chemokines selectively induce β2 integrins (CD11b and CD11c) upregulation but without
significant differences between them at 100nM.

Differential migration of human PBNs
Both CXCL8 and vCXCL-1Toledo are potent chemoattractants for PBNs (373, 407). Even though
there were no differences in calcium flux and integrin expression, these readouts could have a
lower threshold for activation compared to a more complex PBN function like migration. We
quantified the PBNs that chemotaxed to different vCXCL-1 concentrations and found differences
in their migratory ability (Figure 1.4). All vCXCL-1s except vCXCL-1TX24 and vCXCL-1TX15
induce migration at 500nM while at 100nM only vCXCL-1C952, vCXCL-1E760, vCXCL-1Toledo,
vCXCL-1100751, and vCXCL-1C956 could stimulate migration. This is the first time that
differences between the different vCXCL-1s were observed in a functional assay.
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Figure 1.3 vCXCL-1s elicit changes in surface expression of CD11a and CD11b.
PBNs were incubated with 100 nM viral or host chemokine for 2 hours. The shaded
curve represents expression levels of integrins on unstimulated PBNs. Table below
lists the percentage change in mean fluorescence intensity (chemokine stimulated mean
fluorescence intensity/unstimulated mean fluorescence intensity x 100). Graphs are
representative of three independent experiments.

47

Figure 1.4 Differential chemotaxis of PBNs to vCXCL-1s partially correlates with
affinity. Chemotactic response of human PBNs to 500 nM and 100nM of CXCL8,
CXCL1, or vCXCL-1s.

The chemotactic response was measured as fluorescence

intensity of migrated PBN labeled with CalceinAM. Background chemotaxis was
subtracted from all samples. Data shown are representative data of three independent
experiments performed in triplicate.
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Affinities for CXCR1 and CXCR2
Because some CXC chemokines such as CXCL8 bind to both CXCR1 and CXCR2 and these
receptors are important for chemotaxis (540-542), we investigated receptor usage and affinity of
the different chemokines for CXCR1 and CXCR2.
vCXCL-1s to displace
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Competition binding assays using the

I-CXCL8 on HEK293 cells expressing either CXCR1 or CXCR2

(Figure 1.5) showed IC50 concentrations that ranged from 2.6 - 148.7 nM for CXCR2 and 3.3 nM
to > 1,000 nM (i.e. no competition) for CXCR1. Using cluster analysis of the averages of the
different IC50’s we divided the chemokines into high, medium-high, medium-low, and low
affinity binders for CXCR2 (Figure 1.5A). The group of high affinity binders (2.6 - 3.6 nM)
along with CXCL8, are vCXCL-1Toledo and vCXCL-1C952. Medium-high affinity binders (11.3 18.6 nM) are vCXCL-1Tx11, vCXCL-1E760, vCXCL-1C956, vCXCL-1100751 and medium-low
members are vCXCL-1102410, vCXCL-1Tx24, vCXCL-1C954 (32.7 - 55.5 nM). The low affinity
group (> 141 nM) contains only two members, vCXCL-1Towne and vCXCL-1Tx15. Interestingly,
the viral chemokines with high affinity for CXCR2 (vCXCL-1Toledo and vCXCL-1C952) have weak
binding to CXCR1 compared to the host chemokines. Generally the higher the affinity for
CXCR2 the more likely the viral chemokines will bind to CXCR1 (Figure 1.5B). The mediumhigh CXCR2 binders generally do not bind to CXCR1 except for vCXCL-1E760. These data
indicate that the viral chemokines bind with differing affinities for CXCR2 with weak to no
binding to CXCR1. All vCXCL-1s regardless of their affinity for CXCR1 or CXCR2 (except
vCXCL-1TX24 and vCXCL-1TX15) induce migration above the limit of detection at 500nM. At
the lower concentration (100 nM) only the high affinity or the select medium-high affinity
binders (i.e., vCXCL-1E760, vCXCL-1100751 and vCXCL-1C956) could induce migration (Figure
1.4).
This data implies that affinity for CXCR2 (i.e., high affinity equals high migration)
and/or CXCR1 usage are potential factors in PBN migration (541, 542). Because it is not strictly
correlated with affinity, differential agonist activation signals could also contribute to PBN
migration as well.
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Figure 1.5 vCXCL-1s have different binding affinities for human CXCR1 or
CXCR2. Displacement of
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I-CXCL8 binding to HEK293 cells stably expressing

human CXCR2 (A) or CXCR1 (B). Cells were incubated with indicated concentration
of vCXCL-1s and 200 pM
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I-CXCL8 for one hour at room temperature.

For

simplicity, curves for TX11, C956, 102410, and C954 are not shown. (C) The average
IC50 +/- standard error for all vCXCL-1s for either CXCR2 or CXCR1 (n=3-12).
Those with incomplete competition curves are indicated with a > of a predicted IC50.
Those chemokines with no competition at all concentrations tested are listed as >1000
IC50.
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vCXCL-1s induce differential 35S-GTPγS binding and β-arrestin2 recruitment
Chemotactic responses can be mediated via G-protein dependent and/or G-protein independent
signaling. Berger et al (539) demonstrated that CXCL8-induced β2 integrin CD11b upregulation
and migration of neutrophils is Gαi dependent. Chemokine-induced calcium flux involves Gαi
proteins as well (543, 544). Based on these studies and observation of differences in migration
and binding, we investigated whether vCXCL-1s display differences in G-protein dependent and
independent signaling that could explain the differences in migration.
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S-GTPγS binding

experiments were performed on HEK293T membranes expressing human CXCR2 (Figure 1.6AB). The pEC50 value of CXCL8 in this assay is 6.9. Only CXCL1 and vCXCL-1Toledo are able to
reach a maximal response equivalent to 1 µM CXCL8. vCXCL-1Toledo is a high affinity CXCR2
agonist capable of inducing migration (Figure 1.6) and uses G proteins (Figure 1.6A).
Surprisingly, vCXCL-1C952, another high affinity binder of CXCR2 that induces PBN migration
does not induce a G protein response. All those with medium-affinity for CXCR2, except for
vCXCL-1TX11, have medium potency for G protein binding, regardless of their ability to induce
migration. vCXCL-1TX11 has a medium-high affinity for CXCR2 and induces PBN migration
but does not use G proteins for inducing this response. As expected, those with low affinity for
CXCR2 had no GTP binding (vCXCL-1Towne and vCXCL-1TX15). Based on the dose response
curves, we propose a potency order of the chemokines for CXCR2: CXCL8 ~ CXCL1 ~
vCXCL-1Toledo ≥ Intermediate: vCXCL-1E760, vCXCL-1100751, vCXCL-1C956, vCXCL-1102410,
vCXCL-1TX24, vCXCL-1C954 > vCXCL-1C952. No response: vCXCL-1Towne, vCXCL-1TX11,
vCXCL-1TX15. These results illustrate that the different vCXCLs use G protein dependent
mechanisms that correlate with affinity for CXCR2 except in two cases (vCXCL-1C952 and
vCXCL-1TX11).
Traditionally, β-arrestin proteins were thought to function only to desensitize activated
GPCRs. However, in the last decade β-arrestins were shown to induce intracellular signaling as
well (394, 545). The involvement of β-arrestins in chemokine-induced chemotaxis was first
described for the CXCR4/CXCL12 axis (546) and involves the p38 MAPK pathway (547).
Following from these studies, a role for β-arrestin2 in CXCR2 directed chemotaxis was shown
(534, 548, 549). β-arrestin2 induced chemotaxis could explain the differences seen with the
different chemokines (Figure 1.6). To measure chemokine-induced β-arrestin2 recruitment, we
used the PathHunter-HEK293-CXCR2 indicator cell line, which produces a functional βgalactosidase in response to β-arrestin2 (550). The pEC50 value of CXCL8 in this assay is 9.1.
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Figure 1.6 G protein activation and β-arrestin2 signaling correlates with CXCR2
affinity. vCXCL-1 chemokine induction of
membranes expressing CXCR2 (A-B).
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S-GTPγS binding to HEK293T

Data are corrected for basal
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S-GTPyS

binding (n=3-4). vCXCL-1 β-arrestin2 recruitment in PathHunterTM indicator cells (CD). Data are expressed as percentage of β-galactosidase activity, in which the response
to 1 µM CXCL8 is set to 100% (n=3-4).
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Figure 1.6C-D shows that CXCL8, CXCL1, vCXCL-1Toledo, vCXCL-1C952 and vCXCL-1E760
make full dose-response curves, whereas the other viral chemokines display incomplete curves
or no β-arrestin2 signalling. Based on these data the potency order of the vCXCL-1s for βarrestin2 activation is: CXCL8 (pEC50 = 9.1 nM) [high affinity for CXCR2] ≥ CXCL1 (pEC50 =
8.3 nM) [high affinity for CXCR2] ~ Toledo (pEC50 = 8.4 nM) [high affinity for CXCR2] ~
E760 (pEC50 = 8.1 nM) [med-high affinity for CXCR2] ≥ C952 (7.5 nM) [high affinity for
CXCR2] ≥ C956 [med-high affinity for CXCR2] ~ 102410 [med-low affinity for CXCR2] ~
100751 [med-high affinity for CXCR2] ~ C954 [med-low affinity for CXCR2] ~ TX24 [medlow affinity for CXCR2] ≥ C952 [med-low affinity for CXCR2] ≥ TX15 [low affinity for
CXCR2] ~ TX11 [med-high affinity for CXCR2] ~ Towne [low affinity for CXCR2]. For the
most part, high affinity for CXCR2 or CXCR1 tracks with β-arrestin2 activation. There are a
few exceptions. A medium-high affinity binder, vCXCL-1C956, did not induce β-arrestin2 while
the low affinity, vCXCL-1Towne, did signal. These data point to differential signalling or “biased
agonism” that leads to differential G protein activation and β-arrestin2 potencies not directly
correlated with receptor affinity (551).

vCXCL-1s differentially induce secondary chemokine production (CCL22)
We have observed differences in migratory ability, G protein activation, and β-arrestin2
recruitment, but how could these phenotypes affect HCMV dissemination or pathogenesis?
HCMV productively infects macrophages and dendritic cells and may have evolved vCXCL-1s
to increase the recruitment of these cell types via neutrophil activation. Macrophage derived
chemokine (MDC), CCL22, recruits multiple immune cells, such as monocytes, dendritic cells,
NK cells, and the Th2 subset of T cells (552). The induction of CCL22 could have profound
effects on the recruited cell types as well as the immune response to CMV. Not only could these
cells increase dissemination and/or CMV replication, CCL22 could also lead to an increase in the
Th2 response and a down-regulation of Th1 responses (553, 554). In fact, another UL/b’ protein,
UL144, upregulates CCL22 and has been implicated in immune modulation (i.e., recruitment and
activation of Th2 and Treg) (497). In order to address whether the vCXCL-1s induce CCL22, we
performed quantitative real-time PCR for CCL22 expression on a neutrophil-like cell line that
over expresses CXCR2 (Figure 1.7). vCXCL-1Toledo, vCXCL-1E760, and vCXCL-1C952, had the
highest induction of CCL22, which is similar to CXCL1. vCXCL-1Toledo and vCXCL-1C952 are
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high-affinity CXCR2 binders while vCXCL-1E760 belongs to the medium-high group. Others, in
the medium-high binding group, except vCXCL-1100751, induce CCL22. In contrast, all the
members in the medium-low (i.e., vCXCL-1102410 and vCXCL-1C954) or low affinity group (i.e.,
vCXCL-1Tx15 and vCXCL-1Towne) except for vCXCL-1Tx24 do not induce CCL22. As seen in
with PBN migration, G protein and β-arrestin2 usage, high affinity binders activate downstream
signaling and functional outcomes while the medium binders are variable and low affinity
binders do not except for calcium flux and integrin upregulation.

5. Discussion

Our findings contribute to our understanding of the functions of the HCMV viral chemokines
and their agonist activation of CXCR2. In trials where different HCMVs were inoculated into
volunteers, role of the viral chemokines was suggested in human disease. For example, the
Towne strain of HCMV was less virulent than the Toledo virus in humans. Towne differs from
the Toledo strain in the ULb’ region which contains the UL146 and UL147 viral chemokine
genes (555-557). Here we have shown that Towne produces a vCXCL-1 with a low affinity for
CXCR2, induces a lower calcium flux (with no induction at 1nm), minimal ability for
chemotaxis, and no signaling compared with the more virulent Toledo strain vCXCL-1 (Table
1.1). Although this is only circumstantial evidence and one of several differences between the
Toledo and Towne strains, vCXCL-1 differences in PBN activation are potentially contributing
factors to the HCMV virulence observed in these studies. Other animal models of HCMV
pathogenesis provide a more direct link between viral chemokines and pathogenesis. The guinea
pig CMV (GPCMV) chemokine homolog functionally signals through the CCR1 receptor and
plays a role in viral dissemination in vivo (437, 438, 558). Furthermore, this virally induced
inflammation contributes to cytomegalovirus-related inner ear injury (i.e., auditory pathology)
(441).

Whether the differences in the vCXCL-1s contribute to HCMV virulence and/or

dissemination in a similar manner to this animal model remains to be tested. The role of
vCXCL-1s in human pathogenesis is especially difficult without knowing the concentrations of
these chemokines during an active HCMV infection in vivo.
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Figure 1.7 vCXCL-1s differentially induce CCL22 expression via CXCR2.
Neutrophil-like HL60 T2 cells were incubated in the presence of 100 nM of the
indicated vCXCL-1s or host chemokine. Each bar represents the average from three
separate experiments of the fold change in CCL22 mRNA expression levels
(stimulated /unstimulated cells +/- SEM). All data are normalized to -actin mRNA
expression levels. A ratio of 1, indicated with a gray line, represents no change in
expression compared to unstimulated cells.

55

We propose two non-exclusive models for how HCMV vCXCL-1s could function in
vivo. One model for HCMV dissemination is the “neutrophil shuttle model”. In this model the
neutrophil functions as a vehicle for HCMV dissemination (559). PBNs pick up HCMV during
neutrophil transendothelial migration and subsequently transmit infectious virus to fibroblasts
(560, 561). We analyzed PBN induction of calcium flux and adhesion molecules upon vCXCL-1
treatment as indicators of neutrophil activation (Figure 1.2, 1.3), which could affect subsequent
cell-mediated viral dissemination (562). vCXCL-1 activated PBNs could transport virus and
allow it to infect surrounding tissues or different cells. Ideally we would address this shuttling
effect directly with an antigenemia assay where vCXCL-1-treated neutrophils are assayed for
their ability to “take up” HCMVs after migration through an infected monolayer (563).
Unfortunately, potential differences in migration were masked by the large amount of the
host chemokines that are secreted following HCMV infection of the fibroblast monolayer (data
not shown). These “background” host chemokines conceal the effects of the vCXCL1s in this in
vitro model system. In the present study, although the binding affinities to CXCR2 and/or
CXCR1 were variable (Figure 1.5), all vCXCL-1s induce intracellular calcium mobilization in
PBNs, albeit to different degrees at the concentrations tested (Figure 1.2) and upregulate β2
integrins on the surface of PBNs (Figure 1.3) similar to levels induced with human CXCL1 or
CXCL8. We speculate that vCXCL1-s from all the clades activate PBNs to increase contact with
the endothelium. After activation/adhesion neutrophils could be induced to migrate to the site of
HCMV infection. To further investigate this possibility, we measured vCXCL-1-induced
migration. The resulting chemotaxis profile did not directly correlate with receptor affinity
(Figure 1.5C). Although the majority medium affinity vCXCL-1s had migration only at 500nM,
others had none at all (vCXCL-1TX24) or at lower concentrations (100nM) (vCXCL-1100751). This
leads us to conclude that CXCR2 binding affinities do not directly correlate with subsequent
PBN activation, integrin upregulation or chemotaxis patterns. This may not be too surprising as
others have observed decreases in CXCR2 affinity while still inducing a calcium flux (265, 564)
and elastase production (270). Others have observed a complex relationship between binding and
activation similar to our observations with our medium affinity vCXCL-1s (565). These data
illustrate the complexity of the CXCR2 response to agonist stimulation and its relationship with
affinity.
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A complementary/alternate model to explain the relationship between the vCXCL-1s,
PBNs, and HCMV is the “neutrophil amplifier model”. This model focuses on vCXCL-1
induction of exocytosis of neutrophilic granules or secretion of specific cytokines/chemokines.
These inflammatory mediators could increase inflammatory responses that subsequently recruit
other immune cells (566). These infiltrating immune cells would provide a better vehicle for
HCMV spread. Macrophages and dendritic cells are better targets for HCMV infection because
HCMV can productively infect them (567-570) while PBN infections are nonproductive (561).
The attraction/differentiation of myeloid cells could provide a means to infect a cell type that
allows for more efficient virus production and/or dissemination within the host (568). The
vCXCL-1s induce differential CCL22 production that could have effects on myeloid cell
chemotaxis. In our studies, the upregulation of CCL22 correlates with the vCXCL1s’ affinity for
CXCR2 (Figure 1.7). 57% of medium-affinity vCXCL-1s induce CCL22 expression (vCXCL1TX11, vCXCL-1E760, vCXCL-1C956, and vCXCL-1TX24) while others did not (vCXCL-11000751,
vCXCL-1102410, and vCXCL-1C954). The neutrophil amplifier model would predict that those
viruses that do not induce CCL22 in PBNs would be less pathogenic, but we have no in vivo data
for this. Comparisons of the sequelae from HCMV congenitally infected infants, the vCXCL-1’s
that induce CCL22 do not correlate with clinical outcomes (416). Our interpretation of this data
cannot completely exclude the shuttle model our study only measured a single inflammatory
chemokine and others chemokines/cytokines such as CCL2, CCL3, and CCL7 that were not
measured could have a role in congenital sequelae.
This study is the first to examine how the natural variation in the vCXCL-1s affects
binding and PBN function. These variants provide an opportunity to assess how changes within
CXC chemokines affect signaling as a “biased agonist.” Biased agonists stimulate GPCRs with
differential signaling and functional outcomes (551). The activation of CXCR2 initially appears
to be redundant. Host CXCL1, CXCL2, CXCL3, CXCL6 and CXCL8 all bind and activate
CXCR2. Recently Rajagopal et al (571) measured β-arrestin2 recruitment, cAMP signaling, and
internalization with the different ligands on CXCR2. These related chemokines displayed a
biased agonism for cAMP and β-arrestin2 activation. Our study found that high affinity for
CXCR2 leads to activation of G protein dependent and independent signaling (Figure 1.6). As
expected, those vCXCL-1s with low affinity for CXCR2 do not initiate detectable signaling. The
chemokines with medium range affinity are more complex. Some have moderate G protein
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signaling without β-arrestin2 (vCXCL-1C956) or no G protein activation with only β-arrestin2
signaling (vCXCL-1TX11). Our data suggest a complex robustness to the viral chemokine
response that only partially correlates with affinity.
In conclusion our data suggest that polymorphisms in the vCXCL-1s elicit differential
affinity to CXC chemokine receptors, which generates varying cellular responses or differential
activation and triggering of diverse downstream signals. High affinity for CXCR2 leads to
activation of G protein dependent and independent signaling with full activation of calcium flux,
integrin expression, and CCL22 transcription (Table 1.1). Those with low affinity for CXCR2
still induce calcium flux and integrin expression while not initiating detectable signaling or
CCL22 expression and modest PBN migration. These data point to different thresholds for the
different neutrophil functions. Calcium flux and integrin expression have low thresholds where
any degree of stimulation will activate them (572). Other functional outcomes (i.e., migration,
signaling, or CCL22 expression) are more complex. Generally the extremes in affinity (i.e., high
or low) correlate with signaling, migration, and CCL22 production. Those with medium range
affinity are more complex and result in varying degrees of activation (573). This nuanced
response points to the biased agonism of these novel vCXCL-1s that could affect neutrophils and
we speculate an effect on subsequent HCMV dissemination or virulence.
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Table 1.1 Summary of vCXCL-1 functional outcomes
Key: +++ highest activation; ++ high activation; + activation; +/- weak activation; - no
activation
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CCL22

CHAPTER 2: A LITTLE COOPERATION HELPS MCMV GO A LONG WAY – THE
INTERACTION BETWEEN DIFFERENT MCMVs RESCUES A DISSEMINATION
DEFECT WITHIN HOST
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Abstract

Evaluation of the role of vCXCL-1 in the context of HCMV infection is limited to in vitro and in
silico analysis due to the species specificity of the CMV. In this study, we used the murine CMV
(MCMV) mouse model to evaluate the function of this chemokine in vivo. The primary
dissemination to the popliteal lymph node, spleen, and lung of the recombinant MCMVs
expressing vCXCL-1CCMV and mCXCL1 was similar to the parental MCMV, which does not
express any chemokine (RM4511). However, neither of the recombinants was recovered from
the salivary gland (SG) at any time point. The absence of the recombinants from the SG of
SCID mice suggested that the adaptive immune system is not responsible for viral clearance of
the recombinants.

Neutrophil depletion was unable to rescue the dissemination of the

recombinants to the SG, even though the recombinants overexpess proteins that attract
neutrophils. The dissemination was restored upon immune ablation using cyclophosphamide and
in NSG mice, which lack T, B lymphocytes, and NK cells. These results suggest that the
aberrant expression of the chemokine induces cells of the innate immune system to curtail the
dissemination of the recombinants to the SG. To better understand the mechanism of this
dissemination defect, a series of co-infections between parental and recombinant MCMVs were
carried out to address whether dissemination defect was dominant. Similar to the experiments
with immune ablation, dissemination of the recombinants to SG was restored in immune
sufficient mice during co-infection of parental and overexpressing recombinants. We show that
co-infection of the same cells was necessary in order to overcome the dissemination defect. We
also found that co-infection in vitro reduced chemokine levels, without affecting the virus titers.
During the co-infection in vivo, we measured reduced numbers of NK cells and inflammatory
61

monocytes recruited to the site of infection, compared to a recombinant alone infection during
co-infection. Therefore, from this study we concluded that vCXCL-1 is a functional chemokine
in vivo. However, continuous expression of the chemokine is detrimental to the dissemination of
MCMV by recruiting more inflammatory monocytes and NK cells to the site of infection. These
cells types are absent or reduced in NSG mice, cyclophosphamide treated animals, and during
co-infection. During the co-infection, there is a intracellular resource competition that reduces
the chemokine levels produced from the recombinants that also reduces the inflammatory cells
(i.e., NK and inflammatory monocytes) recruited to the site of infection, restoring the
dissemination of the recombinants to the SG.

Introduction
Human cytomegalovirus (HCMV) is a ubiquitous -herpesvirus that is an important pathogen in
immune compromised individuals and newborns (509, 574). It infects between 50% and 90% of
the population resulting in largely asymptomatic infections (574). However, HCMV can cause
serious complications in immunocompromised individuals and newborns (574, 575). Primary or
reactivated HCMV is a frequent cause of retinitis in AIDS patients (576) and increases the
incidence of organ rejection and graft versus host disease in transplant recipients (577, 578).
Central nervous system damage due to congenital HCMV infection affects between 5000 and
8000 newborns in the U.S. each year (579). As a result, HCMV is the leading cause of infectious
hearing loss and non-hereditary mental retardation (574). Understanding HCMV pathogenesis is
important for the development of an effective vaccine or potential therapeutics. Due to the longterm morbidity associated with CMV congenital infections, the Institute of Medicine lists the
development of a CMV vaccine as a top priority (509).
CMVs encode numerous proteins that modulate the host immune system. CMVs can
inhibit apoptosis of infected cells, impair antigen processing, and alter the inflammatory response
including the chemokine network (580). Chemokines are small, chemotactic cytokines that are
important for leukocyte trafficking and activation. Chemokines are divided into four groups (CC,
CXC, CX3C, C) based on the spacing of their amino-terminal cysteines (261). Most chemokines
are members of either the CC or CXC class. These chemokines attract and activate a variety of
immune cells responsible for the viral clearance and contribute to CMV pathogenesis (581, 582).
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HMCV infection alters the expression of host chemokines (583) and many CMVs also
encode viral homologs of chemokines and their receptors (138, 411, 584, 585). The virulent lab
strain of HCMV, Toledo (557), produces a functional CXC chemokine, vCXCL-1Tol, which
binds the chemokine receptors CXCR1 and CXCR2 inducing chemotaxis and calcium flux in
freshly isolated human peripheral blood neutrophils (PBNs) (407, 408). In our previous studies,
we have shown that the viral chemokine from chimpanzee cytomegalovirus (vCXCL-1CCMV) is a
homolog of vCXCL-1Tol, and triggers calcium release and chemotaxis of PBNs (143). Both viral
chemokines were also shown to upregulate the expression of adhesion molecule on PBNs and
downregulated neutrophil apoptosis, albeit with different potencies (143). These findings provide
circumstantial evidence for a role of vCXCL-1 in activating and recruiting neutrophils for CMV
dissemination. Clinical evidence, including the recovery of HCMV from neutrophils of
immunocompromised patients (586-588) and the presence of neutrophilic infiltrates in CMV
associated retinitis (589), suggests neutrophils, as well as monocytes (590-592) are important in
HCMV dissemination . While the direct evaluation of vCXCL-1 in HCMV dissemination is
limited by the species specificity of CMVs, the function of vCXCL-1CCMV may correlate with its
HCMV homolog.
MCMV is a well-established animal model of CMV infection and has similar cellular
tropism and disease manifestations as HCMV (194). MCMV expresses a chemokine homolog,
MCK2, which has been shown to increase the inflammatory response in mice and enhance
dissemination of MCMV to the salivary gland (139, 140). Therefore, MCMV was chosen to
characterize the role of vCXCL-1CCMV in vivo. To test this in the mouse system, we generated a
recombinant MCMV expressing vCXCL-1CCMV and infected mice.

Results from our

experiments show that the aberrant expression of host or viral chemokine is detrimental to the
dissemination of the recombinants to the salivary gland (SG) during secondary viremia. The NK
cells and inflammatory monocytes play a role in an innate immune system-mediated blockade of
dissemination. Co-infection with a non-chemokine-expressing strain of MCMV restored the
dissemination of the recombinant to the SG by tipping the immune response to make conditions
more favorable for SG dissemination of the recombinants. Although our data shows that the
aberrant expression of vCXCL1CCMV is antagonizing viral dissemination, in reality CMV has
many checks and balances regulating the expression of the viral chemokine. It is therefore
possible that normal expression of this chemokine may aid the dissemination of CMV in vivo.
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Materials and Methods

Cells and Viruses
Murine NIH3T3 and M210B4 cells (ATCC) were propagated in DMEM supplemented with 10%
Fetalclone III (Hyclone), 1% penicillin/streptomycin (Hyclone), 1X NEAA, 1% sodium pyruvate
(100mM), and 0.5 % HEPES (1M). MEF 10.1 cells (ATCC) were propagated in DMEM
supplemented with FCIII to a final concentration of 10%, P/S and L-Gln to a final concentration
of 1%. The parental MCMV strain used in this study was MCMV RM4511 (593) which has a
1.7 kb puromycin-green fluorescent protein (GFP) cassette inserted into the ie2 region and a
double point mutation in the m131 gene resulting in a nonfunctional MCK2 protein (figure 2.1
A). This virus was obtained from Dr. Edward Mocarski, Emory University. For UV inactivation
of the virus, the stock virus was divided into 50µl drops in a petri dish and exposed to UV light
in a UV Crosslinker (Stratagene Stratalinker) at a setting of 1200 for 8 minutes. Complete
inactivation of the virus was tested in a plaque formation assay.

Mice
Initially, mice that over express human CXCR2 (hCXCR2) or have replace murine CXCR2
(mCXCR2) were used as there was concern that vCXCL-1CCMV might not stimulate the
mCXCR2 as seen with vCXCL-1Tol (142). The hCXCR2 transgenic BALB/c mice express
hCXCR2 under the control of the neutrophil-specific, human myeloid related protein-8 promoter
(142). In the co-infection experiments, mice that have the hCXCR2 gene replacing the murine
CXCR2 were used (594). These mice have normal expression levels of hCXCR2 and expression
on all the appropriate cell types. We have subsequently have shown that vCXCL-1CCMV can
function in normal mice (data not shown), which allowed us to use SCID and NSG mice with the
appropriate parental controls. 3-4 week old BALB/c, NOD-NSG (NSG) mice were purchased
from Jackson Laboratory (Bar Harbor, ME) and SCID/NCr were purchased from Taconic Labs.
All mice were housed under specific pathogen free conditions in the WLS LAF.

Plasmid Constructs
An EcoRI/PstI digested fragment containing the coding region for vCXCL-1CCMV or host
mCXCL1 (KC) was cloned into the EcoRI/PstI digested plasmid pcDNA3.1/Zeo immediately
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downstream of the HCMV immediate early promoter (HCMV IE). The 1.2kb HCMV IEchemokine fragment was PCR amplified adding the flanking restriction sites and a C-terminal 6His

tag

using

the

primers:

MluI

HCMV

IE

(5’-

CGACGCGTCGATGTACGGGCCAGATATACGCCTTGACATTGATTAT-3’) and SalI 6 His
(5’ACGCGTCGACTGGTGGTGGTGGTGGTGACCTCCTCC-3’).

The PCR fragment was

sequence verified. The HCMV IE-chemokine cassette was digested with MluI and SalI and
cloned into the plasmid L120.1 as illustrated in Figure 2. L120.1 has 5’ and 3’ sequences from
MCMV IE2 for homologous recombination and a gpt expression cassette used for selection of
recombinant viruses (C. Meiering, unpublished data).

Generation of Recombinant Viruses
NIH3T3 cells (60% confluent) were transfected with Drd-linearized L120.1+ vCXCL-1CCMV or
L120.1+mCXCL1 using Lipofectamine 2000 (Invitrogen). Three hours post-transfection, the
cells were infected with MCMV RM4511 at an MOI=3. Transfectants were harvested and
passaged twice under selection using growth media supplemented with mycophenolic acid (12.5
g/ml) and xanthine (100 g/ml). Recombinant virus was identified by the loss of gfp
fluorescence and subjected to three rounds of plaque purification using an overlay of 0.5% agar
in growth media. NIH3T3 cells were infected with virus stocks in T150 flasks at an MOI of 0.01.
Viral DNA was isolated by phenol-chloroform extraction and used for diagnostic PCR to verify
proper insertion of the chemokine cassette and loss of the GFP/puromycin insert. The primers
used were: RM4511 F (5’-CATTGACGTCAATGGTGGGAAAGTACATGGCG-3’), RM4511
gfp R (5’-CCCGACGCGCGTGAGGAAGAGTTCTTGCAG-3’), and HCMV IE R (5’GAACTCCATATATGGGCTATGAACTAATGACC).

In Vitro Growth Assay
M210B4 cells (4x105cells/well) were plated in triplicate in a 6-well dish and infected with
RM4511, RMvCXCL-1CCMV, or RMmCXCL1 for either a multi-step (MOI=0.5) or single-step
(MOI=5) growth analysis. Supernatants were collected at the indicated times post infection,
centrifuged (400 x g) to remove contaminating cells and sonicated prior to tittering. Standard
plaque assays on M210B4s were used to determine the virus titers.
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In Vitro Protein Expression
Aliquots from the single-step growth assay were removed and used to verify chemokine
expression. vCXCL-1CCMV and mCXCL1 were isolated from 100 g of total protein by
incubation with Ni-NTA agarose beads. The eluted protein samples were subjected to Western
blot analysis using the primary anti-6-His antibody (Qiagen) diluted 1:200 and secondary antimouse HRP antibody diluted 1:2000.

In Vivo Growth of Parental and Recombinant Viruses
106 PFUs of parental or recombinant viruses were inoculated in the footpad of hCXCR2
transgenic, Balb/c, or SCID mice. At different times post infection, mice were euthanized and
their footpads, spleens, liver, lungs, popliteal lymph node, and salivary glands were removed.
Organs were individually weighed, sonicated in growth medium and centrifuged at 400 x g to
pellet debris. Supernatants were stored at -80C until titered.

Plaque formation assay
Viral titers in the organs were determined by plaque formation assay as per lab protocol on
mouse embryonic fibroblast (MEF) 10.1 cells. Briefly MEF 10.1 cells were plated in a 6 well
dish. Organs were harvested and homogenized. The homogenate was diluted and added the
MEF 10.1 cells and incubated for 1 hr. After incubation the diluted virus was removed from the
plates and cells were overlayed with carboxy methyl cellulose media and incubated for 7 days.
At the end of the incubation period, CMC was removed and plates were stained and plaques
counted using a dissection microscope.

Depletion of Cellular Subsets
In vivo depletion of cellular subsets was performed by antibodies one day prior to MCMV
infection and then every three days until harvest. Neutrophils were depleted using 1A8 (antiLy6G) or RB6C (anti-Ly6G/C) antibody (1mg/ inoculation) (BioXcell, West Lebanon, NH).
Flow cytometry was used to confirm depletion of GR-1hi, Mac-1hi neutrophils (Pharmingen).
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Flow cytometry
The following fluorochrome-conjugated antibodies were used to analyze the cellular subsets:
anti-CD3 (17A2), anti-CD45.2 (104), anti-CD11c (N418), anti-Ly6G (1A8), anti-Ly6C (HK1.4)
(all from Biolegend); anti-CD49b (DX5) from eBiosciences; and anti-CD11b (M1/70) from BD
Pharmigen. Cells were analyzed on BD LSR II flow cytometer (BD Biosciences) and evaluated
using FlowJo Mac software, version 8.7.

Results

Construction of the chemokine expressing MCMVs
The strict species specificity of the CMVs precludes the use of CCMV directly in the mouse
model. Therefore, we created a recombinant MCMV expressing vCXCL-1CCMV (RMvCXCL1CCMV) to study the role of this viral chemokine in virus dissemination in vivo. mCXCL1 (KC) is
the murine equivalent of CXCL-1 (Gro-α) with a high affinity for CXCR2. Therefore, we also
generated MCMV expressing KC as a control to evaluate specific effects of the viral chemokine
on dissemination. MCMV RM4511 was the parental strain used for construction of these
recombinants. RM4511 lacks the expression of the functional MCMV viral CC chemokine,
MCK2. This will allow us to analyze the contribution of vCXCL-1CCMV and mCXCL1 in the
dissemination of MCMV in the absence of the endogenous MCMV encoded chemokine
(schematic diagram in figure 2.1 A).
The recombinant plasmid, L120.1, was constructed to contain either the vCXCL-1CCMV
or mCXCL1 coding sequence under the control of the HCMV IE promoter (figure 2.1B). This
promoter has been used to drive expression of other genes inserted in the MCMV genome and
was chosen to ensure adequate chemokine expression. We chose to insert the chemokine
cassette into the ie2 region as the ie2 has been shown to be dispensable for growth of MCMV in
vivo. The cassette displaces the puromycin-GFP segment present in RM4511. Loss of GFP
expression allowed visual selection of recombinant viruses.
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Figure 2.1 Schematic Representation of the wild type (WT) MCMV, parental MCMV
(RM4511), RMmCXCL1, and RMvCXCL1CCMV (A) The RM4511 recombinant MCMV
contains a double point mutation resulting in a missense mutation that converts amino acids
CC to GR in MCK2. This in effect creates an MCK2 negative strain. RM4511 also has a A
puromycin/green fluorescent protein expression cassette (puro-GFP) cassette in the ie2 locus
that is

replaced in

the chemokine expressing recombinants

(RMmCXCL1,

and

RMvCXCL1CCMV) was inserted of the MCMV genome in RM4511, replacing the Puro. The
mCXCL1 or vCXCL-1CCMV expression cassette containing a gpt selectable marker that was
used for selection (B) Schematic representation of the puro-GFP and chemokine expression
cassettes. The sizes of the diagnostic PCR products produced using the MCMV/GFP primers
(2.5kb) and MCMV F/HCMV IE primers (3.0 kb) are shown.
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Following transfection of NIH3T3 cells with Drd-linearized L120.1+vCXCL-1CCMV or
mCXCL1 and subsequent infection with RM4511, recombinant viruses were passaged twice in
medium containing mycophenolic acid and xanthine to select for recombinant virus expressing
gpt. The loss of GFP expression identified recombinant viruses and each virus was plaque
purified three times. PCR was used to confirm the recombinants and correct insertion of the
promoter chemokine cassette. No product was detected when the parental virus was used as a
template (supplemental figure S2.1).

In Vitro growth kinetics and chemokine expression of the recombinant MCMVs
The growth kinetics of RMvCXCL-1CCMV and RMmCXCL1 were evaluated to determine
whether insertion of the vCXCL-1CCMV or mCXCL1 cassette affected growth of the recombinant
viruses in cell culture. We performed both single (MOI=5) and multi (MOI=0.05) step growth
curves to identify any growth defects in replication or spread of the recombinant viruses relative
to the parental strain, RM4511. RMvCXCL-1CCMV and RMmCXCL1 replicated as well as
RM4511 in both assays figure 2.2A, indicating the absence of any deleterious effects of the
insertion on growth of virus in cell culture.
Before evaluating the role of RMvCXCL-1CCMV and RMmCXCL1 in vivo, temporal
expression of the chemokines in the supernatants of virally infected cell was confirmed (figure
2.2B). Immunoblotting of Ni-NTA-concentrated supernatants from each time point of the single
step growth curve detected RMvCXCL-1CCMV and RMmCXCL1 proteins.

Beginning on the

second day post infection and continuing for the duration of the experiment, both chemokines
were detected in the supernatants. This illustrates both host and viral chemokines are secreted in
detectable quantities beginning at day 2 post infection (p.i).

69

Figure 2.2 Recombinant viruses have equivalent growth rates and overexpress host and
viral chemokines in vitro. (A) NIH3T3 cells were infected in triplicate with RM4511,
RMmCXCL1 or RMvCXCL1CCMV at a MOI of 5 (single-step) or 0.05 (multi-step).
Supernatants were harvested daily for five days p.i. Plaque formation assays were performed
on M210B4 cells. (B) Western blot analysis was used to analyze the expression of mCXCL1
and vCXCL1CCMV. NIH3T3 cells were infected with RM4511, RMmCXCL1, or
RMvCXCL1CCMV at a MOI of 5. Supernatants were harvested at the indicated times post
infection. Recombinant proteins were enriched using Ni-NTA agarose beads from 100 mg of
total protein. The eluted protein samples were subjected to Western blot analysis using anti-6His antibody to detect the 6-His tagged chemokine.
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Dissemination of virus in vivo
To evaluate the contribution of vCXCL1 in the replication, dissemination of the recombinant
viruses in vivo, we infected mice with 1 x 106 PFU of RM4511, RMmCXCL1, and
RMvCXCL1CCMV in the foot pad and measured the viral titers in the organs by plaque formation
assay. The recombinants reached similar titers as the parental virus at the site of inoculation in
the footpad (FP), and in the organs of primary dissemination, the lymph node, lung, and the
spleen (figure 2.3). However, we could not detect the recombinant virus in the salivary gland
(SG) at day 7 and 14 p.i, when the parental virus reaches peak titers in the organ (figure 2.3). To
exclude the possibility that the dissemination of the recombinant virus to the salivary gland was
not delayed, viral load in the SG was also measured at day 21 p.i. No recombinant viruses were
detected even at this later time point (data not shown). The route of infection also did not alter
the dissemination outcome, as even when infected i.p with 1 x 106 PFU per mouse, no
recombinant viruses were detected in the SG (data not shown).
Next we investigated if the defective secondary dissemination of the recombinants to the
SG was a result of defective viremia. For this, mice were infected intra peritoneally (i.p.) with 1
x 106 PFU of each virus and an infectious centers assay was performed on isolated peripheral
blood leukocytes (PBLs) at day 4 p.i. As seen in figure 2.4 E left panel, viremia was observed
only for 4511 and not for the recombinants. Taken together these data suggest the absence of
recombinants in the SG is due to defective dissemination during secondary dissemination of the
virus.
Immune cell depletion rescues the dissemination of the recombinants
Both vCXCL-1CCMV and mCXCL1 bind and activate neutrophils via CXCR2 (143, 595), and it is
possible that the overexpression of these chemokines recruits and activates neutrophils,
triggering an inflammatory response capable of clearing the recombinant viruses (596). To
evaluate the contribution of the neutrophils in the clearance and/or dissemination, mice were
depleted of neutrophils using anti-Ly6G antibody before infection. Viral load in the SG was
measured at day 14 p.i. Neutrophil depletion did not restore the dissemination of the
recombinants to the SG (figure 2.4 A). Moreover in un-depleted mice, we did not see any
difference in the neutrophil frequency in the salivary gland of mice infected with either the
recombinants or RM4511 at day 14 p.i. (data not shown). These results show that neutrophils
are not responsible for increased clearance of the recombinants in the SG or the dissemination
defect observed in vivo.
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Figure 2.3 Overexpression of host or viral chemokine prevents MCMV dissemination to
the salivary gland. hCXCR2 transgenic mice were inoculated in the footpad with 106 PFUs
of either RMmCXCL1 (▼), RMvCXCL-1CCMV (▲), RM4511 (□). Organs were harvested at
indicated day p.i. and virus titers were determined via plaque assay. Each symbol represents
the mean virus titer of 5 mice (+/- standard error). This data is a representative of 2
experiments.
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Figure 2.4 Evaluation of MCMV dissemination to the SG in the absence of cellular
subsets. BALB/c mice depleted of neutrophils using anti-Ly6G antibody (A) or SCID mice
(B) were infected by FP inoculation (B). NSG mice (C), which lack NK cells in addition to T
and B lymphocytes, were infected i.p. and SG were harvested at day 14 p.i and viral titers
measured by plaque assay. Mice were treated with cyclophosphamide to cause systemic
immune ablation prior to infection with the viruses. Viral titer in the SG was measured at days
3, 7, 14 and 18 p.i. (D). Results are from 5-10 mice per infection and are representative of 2
or more experiments. Bars represent the mean virus titer (+/- standard deviation) (E) Viremia
on PBLs isolated from WT BALB/c mice on day 4 p.i,(left panel), NSG mice at day 14p.i.
(center panel), or cyclophosphamide-treated BALB/c mice at day4 p.i (right panel).. Data is
represented as Log10 % infected PBLs and the line represents mean from at least 3 mice for
each experiment.
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T cells have also been shown to play an important role in controlling CMV infection.
While CD8+ T cells effectively clear MCMV from many organs in the periphery (597), viral
clearance from the SG is dependent on CD4+ T cells (136, 598). To determine the role of the
adaptive immunity in clearing RMvCXCL-1CCMV and RMmCXCL1 from the SG, SCID mice
were infected with 1 x 106 PFU of recombinant or parental MCMV in the FP. SGs were
harvested at 14 day p.i. and viral load measured. No virus was recovered from SG of SCID mice
infected with recombinant viruses, while parental virus disseminated to the SG (figure 2.4 B).
This data suggests that the absence of RMvCXCL-1CCMV and RMmCXCL1 from the SG is not
due to an amplified adaptive immune response against the recombinants.
NK cells form an important arm of the innate immune response to MCMV infection (131,
211, 599). To address their role in our model, we utilized the NSG mouse model which is
severely immune deficient (600, 601). These mice not only lack T and B lymphocytes but have
a defective IL2 receptor that leads to absence of NK cells from these mice (600, 601). NSG mice
were infected i.p. with the different viruses, the SG was harvested at day 14 p.i. and viral load
was determined. Unlike the previous experiments, we were able to recover the recombinant
viruses from the SG of NSG mice, albeit much lesser than the parental virus (figure 2.4 C). Also,
as seen in figure 2.4 E middle panel, in NSG mice, we observed viremia for the recombinants as
well as the parental virus. Data from this experiment suggests that NK cells play a role in
preventing the dissemination of the recombinant virus to the SG.
To evaluate the full extent the innate immune system in preventing the dissemination of
the recombinants to the SG, mice were administered cyclophosphamide (cyclo) to deplete
immune cells (602-604). Cyclo is an antimitotic that depletes neutrophils within one week. Mice
become completely immune suppressed with continued cyclo treatment. At different times p.i.
viral load in the organs was determined. We did not observe any difference in the primary
dissemination between the recombinants and the parental virus in cyclo treated mice
(supplemental figure S2.2). However, the recombinant were recovered from the SG of cyclo
treated mice (figure 2.4 D), with detectable viremia measured at day 4 p.i (figure 2.4 E right
panel). Thus, the data from these experiments suggests that cells of the innate immune system of
the hematopoietic lineage are responsible for the lack of dissemination of the recombinant
viruses to the SG.
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Co-infection rescues the dissemination of recombinant virus in immune competent mice
The chemokine gene in the recombinants is under the control of the strong and constitutively
expressed HCMV MIEP promoter (605). This leads to an aberrant expression of the chemokine
from virally infected cells. This has an adverse effect on the dissemination of the recombinants to
the SG during secondary dissemination. Therefore, we hypothesized that in a setting of coinfection (parental + recombinant) that the dissemination defect would dominate. This would
lead to an inhibition or reduction in the dissemination of the parental virus to the SG. To test this
hypothesis, mice were infected in the same FP with a mixed inoculum (1:1 ratio
parental:recombinant). The SGs from these mice were harvested 14 days p.i. and the virus load
determined. To our surprise, and contradictory to our hypothesis, we were able to recover the
recombinant virus from the SG of mice infected with the mixed inoculum (figure 2.5 A and B).
This rescue in dissemination was not due to higher replication of the virus in the FP, spleen, or
lung post co-infection (supplemental figure S2.3). The rescue in dissemination was also not due
to higher virus at the site of infection as even twice as much RMmCXCL1 inoculum did not
rescue the dissemination of the recombinant to the SG (data not shown). This rescue of
dissemination was also observed when mice were infected i.p. (figure 2.5 C). However we did
not observe the rescue of dissemination of the recombinants when the infection with the two
viruses was spaced apart by 2 or 7 days (supplemental figure S2.4).
Our data shows that the rescue of the dissemination of the recombinants to the SG is
independent of MCMV endogenous CC chemokine (MCK2) as both the CC expressing RM4503
and non-expressing RM4511 rescue the dissemination to the SG. It also demonstrates that the
co-infection is temporally restricted and that the viruses interact early during infection. In
addition the data also shows that the interaction between the two viruses skews the immune
response such that it allows the dissemination of the recombinants to the SG. Thus with coinfection, we identified an immune competent mouse model where the recombinant virus can
successfully disseminate to the SG. This model can therefore be used to investigate how the
recombinants stimulate the immune system to prevent their dissemination to the SG.
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Figure 2.5 Co-infection with parental and recombinant viruses rescues the dissemination
of the recombinant to the SG. (A and B) Mice were infected in the foot pad with either
1x105 PFU of parental (RM4511 or RM4503) alone, recombinant (RMmCXCL1 or
RMvCxCL1CCMV) alone or a mixed inoculum containing 1:1 mix of 1x105 PFU of each of
parental and recombinant viruses. Viral titer was measured in the SG at day 14 post infection.
(C) Mice were infected i.p with either the parental virus alone, recombinant virus alone, or a
mixed inoculum containing 1:1 mix of 1x105 PFU each parental and recombinant. Virus titer
was measured in the SG at day 14 p.i. The symbols indicate titer from each individual mouse.
The * indicates viral titers in the SG from mice infected with a mixed inoculum. The
horizontal line is the median titer for each infection group.
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Co-infection at the site of infection is necessary for SG recombinant dissemination
To characterize how coinfection allows recombinant viruses to disseminate, we wanted to know
whether spatial localization rescues the dissemination of the recombinants. Mice were infected
with the two viruses in separate foot pads on the same day. This would eliminate the possibility
of the viruses interacting at the site of infection, but will still allow the viruses to interact at the
sites of primary dissemination. As seen in figure 2.6 A, we did not recover recombinant viruses
from the SG of these mice at 14 days p.i. The viruses grew to similar levels at the site of
infection and primary dissemination sites even after separate foot pad infections (supplemental
figure 2.3).
The requirement of the close proximity of the two viruses to mediate the rescue
phenotype suggests that the viruses may co-infect the same cell at the site of infection. To test
this possibility we infected mice with a mixed inoculum containing 100 PFU each of RM4511
and RMmCXCL1, effectively reducing the probability of co-infection by 10,000 fold. As seen
in figure 2.6 B, the infection with a low PFU inoculum reduces the frequency of dissemination
rescue. In order to directly address whether the viruses co-infect cells at the site of infection, we
performed infectious centers assay with plastic adherent leukocytes isolated from the FP at day 3
p.i. (schematically described in figure 2.6 C). During the amplification step, we were able to
detect GFP positive and negative plaques from ~ 49% of the purified GFP plaques (figure 2.6 C).
Purified GFP negative plaques yielded all GFP negative plaques during the amplification step in
all instances. Therefore, these results indicate that in this model system, the two viruses need to
be at the same site of infection, where they interact by co-infecting the same cell.
Live virus is required to rescue the dissemination of recombinant virus
We show above that the rescue of the dissemination of the recombinant to the SG in mice
infected with the mixed inoculum is due to the viruses co-infecting a cell at the site of infection.
One possible explanation is that the presence of the virus particles itself could stimulate an
immune response that overcomes the blockade of dissemination. We infected mice in the same
FP with a mixed inoculum containing a 1:1 mixture of viable RMmCXCL1 or RM4511 and UV
inactivated RM4511or RMmCXCL1 respectively. As seen in figure 2.7 A, UV inactivated
RMmCXCL1 did not affect the dissemination of RM4511 to the SG. However, UV inactivation
of RM4511 completely abolished the rescue of the dissemination of RMmCXCL1 to the SG
(figure 2.7 A). This proves that live replicating parental virus is necessary to mediate the rescue
of the recombinant to the SG.
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Figure 2.6 Co-infecting viruses interact with each other at the site of infection. (A) Mice
were infected in different foot pads with 1x105 PFU each of parental (RM4511) and the
recombinant (RMmCXCL1) virus. Viral titers in the SG were measured at day 14 p.i. (B)
Mice were infected in same FP with a mixed inoculum containing a 1:1 mix of 1x102 PFU
each of parental and the recombinant virus. Viral titers in the SG were measured at day 14 p.i.
The * indicates viral titers in the SG from mice infected with a mixed inoculum. The
horizontal line is the median titer from the experiment. Each symbol represents the titer from
an individual mouse. (C) Plastic adherent leukocytes were isolated from FP of mice infected
with a mixed inoculum of a 1:1 mix of 1x105 PFU each of parental and the recombinant virus
at day 3 p.i. GFP positive plaques were purified from an infectious centers assay. These
plaques underwent a round of amplification to ascertain the presence of GFP negative virus
within the purified plaques, represented as % co-infected plaques. Bars represent the average
from 9 mice + SD.
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Figure 2.7 Live parental virus required for the rescue the dissemination to the SG and
no recombination occurs during rescue. (A) Mice were infected in the FP with 1x105 PFU
of either parental (RM4511) alone, recombinant (RMmCXCL1) alone, or a mixed inoculum
containing 1:1 mix of 1x105 PFU of UV inactivated (UV ia) RMmCXCL1 and RM4511 and
live RM4511 and RMmCXCL1. Viral titer was measured in the SG at day 14 p.i. The symbols
indicate titer from each individual mouse. The * indicates viral titers in the SG from mice
infected with a mixed inoculum. The horizontal line is the median titer from the experiment.
(B) Viral DNA was isolated by phenol chloroform method and used to set up a diagnostic
PCR using mCXCL1 specific forward primer and 6His reverse primer to detect the presence
of the chemokine gene within the recombinants isolated form the SG of mice at day 14 p.i
infected with a mixed inoculum. –ve is the negative control for the PCR experiment.

79

One possibility that we needed to address is whether RMmCXCL1 undergoes
homologous or illegitimate DNA recombination with RM4511. This could lead to the loss of the
chemokine gene from the recombinant and explain the subsequent dissemination. To ascertain
the integrity of the chemokine gene in the rescued recombinants, GFP negative plaques were
purified from the SG of co-infected mice and DNA isolated. As seen in figure 2.7 B, these
isolated recombinants still carried the chemokine gene. There is also the possibility that
chemokine gene was mutated such that the chemokine is no longer secreted. However,
sequencing of the chemokine gene from the isolates did not show any mutations in the resulting
protein, and we were also able to detect the His-tagged chemokine in the culture supernatant of
the isolates (supplemental figure S2.5 A and B). We also performed RFLP analysis of these
isolates, and no evidence of overt recombination was found (supplemental figure S2.5 C).
Co-infection in vitro reduces KC production
Another possible explanation for the rescue of dissemination defect is that the parental virus
could affect the production of the chemokine from the recombinant during co-infection. To test
this possibility, we carried out an in vitro co-infection assay. Cells were infected with the
recombinant and parental virus alone at an MOI of 5, or with a mixed inoculum which provides
an MOI of 5 for both the viruses (MOI 10 total). Supernatants were harvested every 24 hrs. for 5
days and the amount of chemokine was measured. As seen in figure 2.8 A, the relative
expression of the chemokine is reduced during mixed infection compared to recombinant alone.
There was also a reduction in chemokine production when the cells were infected with the
recombinant alone at an MOI of 10 (data not shown). At the same time, there was no difference
in the viral titers at these time points for either of these infections (figure 2.8 B). This data
suggests that it is possible that, during in vivo co-infection, there may be less chemokine
produced without affecting the amount of virus produced. This reduction may be sufficient to
relieve the negative effects of the over expressed chemokine to allow for dissemination of the
recombinant.
Co-infection modulates the immune response to rescue dissemination
We have already shown that the adaptive immune system does not interfere with the
dissemination of the recombinants to the SG (figure 2.4 B). Focusing on the innate immune
system, as expected, we did see a slight increase in the number of neutrophils recruited to the site
of inoculation at day 3 p.i. in mice infected with the recombinants compared to parental (figure
2.9 A). However, as neutrophils do not contribute to the dissemination defect (figure 2.4 A),
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Figure 2.8 Co-infection in vitro reduces the recombinant MCMV chemokine levels
without affecting viral growth. (A) In vitro co-infection assay was performed on MEF 10.1
cells by infecting them at an MOI of 5 with RMmCXCL1, RM4511, or a 1:1 mixed inoculum
of RMmCXCL1 and RM4511 at a MOI of 5 for each of the viruses. The supernatant from the
infection was collected at the given time points. The 6xHis-tagged chemokine was enriched
using Ni-NTA agarose beads and analyzed on a silver stained SDS PAGE gel. Silver stained
image is representative of 2 experiments and the relative concentration is the average from
those experiments. (B) Viral titers were measured in the supernatant collected form the in
vitro co-infection assays. Mxd MOI 10 = (MOI5 4511 + MOI5 KC). The data is representative
from 3 experiments. Symbols represent the average titer +/- SD.
81

we did not pursue these cell types further. Experiments with the NOD-NSG mice suggest a role
of the NK cells in mediating the dissemination defect. Indeed, we observed more NK cells
recruited to the spleen and lung in mice infected with the recombinants compared to the parental
(figure 2.9 B). We also observed greater numbers of inflammatory monocytes, at the site of
infection in recombinant infected mice recombinants compared to the RM4511 infected mice
(figure 2.9 C).
We then used the immune-sufficient co-infection model, to evaluate the contribution of
these cell types in preventing the normal secondary dissemination of the recombinants. For this
mice were infected i.p with RM4511 alone, RMmCXCL1, or a mixed inoculum of RM4511 +
RMmCXCL1. We observed a reduction in the NK cells recruited to spleen and lung in mice
infected with the mixed inoculum, compared to RMmCXCL1 alone infected mice (figure 2.10
A). At the same time we also observed a reduction in the number of inflammatory monocytes in
the lungs of mixed inoculum infected mice compared to RMmCXCL1 alone infected mice
(figure 2.10 B). The data from these experiments suggests that infection with the recombinant
viruses leads to a higher infiltration of NK cells and inflammatory monocytes compared to the
parental virus to the site of infection. These cell types might interfere with the normal secondary
dissemination of the recombinants. Co-infection reduces the number of recruited NK cells and
shifts the scale in favor of patrolling monocytes that help the recombinant disseminate to the SG
along with the parental virus.
Discussion
In our previous study we characterized the CCMV chemokine homolog, vCXCL-1CCMV, and
demonstrated that it is a functional chemokine, activating and recruiting human neutrophils
similar to the HCMV chemokine vCXCL-1Tol (143). Due to the species specificity of CMV, the
in vivo function of vCXCL-1CCMV is unknown. We have gained significant knowledge about
various aspects of HCMV dissemination using the MCMV model (574, 585). MCMV has similar
tropism to HCMV (574, 585), and both the viruses demonstrate a cell-associated viremia in cells
of the myelomonocytic lineage such as neutrophils, monocytes, and their precursors (430, 574,
585, 586, 606, 607). Although the mechanism and relative contribution of each of these cell type
to viral dissemination in vivo has been studied in some detail, the role of host and viral
chemokines on this dissemination remains to be discovered (141, 430, 574, 585).
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Figure 2.9 Cellular infiltrate is altered at the sites of infection after parental and
recombinant virus infection.

Mice were infected in the foot pad with RM4511,

RMmCXCL1 or RMvCXCL1. Flow cytometry was used to analyze number and types of
cellular infiltrate into the different locations. (A) The number of neutrophils infiltrating the
FP at day 3 p.i. (B) Mice infected i.p. with RM4511, RMmCXCL1, and RMvCXCL1. The
number of NK cells (B) and patrolling and inflammatory monocytes (C) recruited into the
spleen and the lung at day 4 p.i. was measured. Bars represent the average of the data from at
least 5-6 mice per experiment +/- SEM. One Way ANOVA was used to compare the data. ***
= P < 0.001, ** = P < 0.01, * = P < 0.05
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Figure 2.10 Co-infection alters the cellular infiltrate at the sites of infection to favor
dissemination. Mice were infected i.p. with RM4511, RMmCXCL1 or a mixed inoculum of
1:1 mix of 1x106 PFU RM4511:RMmCXCl1. Flow cytometry was used to analyze NK cells
(A), patrolling and inflammatory monocytes (B) within the spleen and the lung recruited into
the spleen and the lung at day 4 p.i. Bars represent the average of the data from at least 5-6
mice per experiment +/- SEM. One Way ANOVA was used to compare the data. *** = P <
0.001, ** = P < 0.01, * = P < 0.05
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The MCMV CC chemokine, MCK2, contributes to the dissemination of MCMV to the salivary
gland while spread to other organs is MCK2-independent (140). In this study, we used MCMV
RM4511, which does not express functional MCK2, to generate recombinant MCMV expressing
viral and host CXC chemokines to evaluate the impact of vCXCL-1CCMV on viral dissemination
The primary dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was similar to
RM4511 (figure 2.3). However, the recombinant viruses were not recovered from the SG (figure
2.3). The absence of the recombinants from the SG could not be explained due to impaired viral
growth at other sites of infection, as we did not see any difference in the viral growth of the
recombinant compared to the parental virus at the site of inoculation in the foot pad, or the
primary dissemination organs: the popliteal lymph node, spleen, and the lung (figure 2.3). It is
possible that our recombinants are unable to replicate in the SG and carry a mutation in the sgg1
gene, which has been shown for other MCMV recombinants with a salivary gland growth defect
(608, 609). However, this is not likely for several reasons. First, the independently generated
recombinants show a similar dissemination phenotype (data not shown). Moreover, when the
recombinants reach the SG, as is the case of NSG mice, cyclo treatment or co-infected mice, they
are able to replicate in the SG (figure 2.4 C and D). However, we did observe defective viremia
for the recombinants (figure 2.4 E). Therefore, the recombinants are sufficiently capable of SG
replication, but show a dissemination defect.
It is possible that overexpression of the chemokine leads to an over active immune
response against the recombinants, which results in their increased clearance from the SG. Viral
clearance from the SG is CD4+ T cell mediated (136, 598).

However, the absence of

recombinants from the SG of SCID mice, lacking B and T lymphocytes, argues against this
possibility (figure 2.4 B). However, we recovered the recombinants from the salivary gland in
NSG mice and after systemic immune ablation with cyclo treatment, implicating some aspects of
the innate immune system are responsible for the SG dissemination defect (figure 2.4 C and D).
Interestingly, restored viremia for the recombinants in both the cases paralleled SG
dissemination (figure 2.4 E). Thus, although the recombinants are not susceptible to adaptive
immune mediated clearance in the SG, they show an innate immune-mediated defect in
dissemination to the SG.
While working with the co-infection model (i.e., parental + recombinant virus), we made
the serendipitous discovery that the recombinants were able to disseminate to the SG even in
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immune-competent mice (figure 2.5). This rescue of dissemination required the two viruses to
infect simultaneously and at the same site, as separating the infection of the two viruses spatially
or temporally does not support the rescue of dissemination of the recombinants to the SG (figure
2.6 A and supplemental figure S2.4). This localization of the infection is required for the two
viruses to infect the same cell, most likely a monocyte/macrophage population at the site of
infection (figure 2.6 C). Our experiments also show that live replicating virus was required to
rescue the dissemination of the recombinants to the SG, not just viral particle interference with
recombinant dissemination (figure 2.7 A). This gives rise to the possibility that, the recombinant
might undergo recombination, mutation or the deletion of the chemokine gene while replicating
inside the parentally infected cell. We show that the recombinants that disseminate to the
salivary gland still carry a fully intact chemokine gene (figure 2.7 B and supplemental figure
S2.5). There is the additional possibility that during co-infection, the recombinants might grow to
higher titers, which would help seed the SG better. This does not seem likely as, we did not
observe an increased viral growth in the organs of primary dissemination during co-infection
(supplemental figure 2.3). On the other hand it is also conceivable that the parental virus reduces
the replication and or production of the chemokine from the recombinant during co-infection.
Our in vitro co-infection assay showed that co-infection did not affect the viral growth, however
we did observe a modest reduction in the chemokine levels produced (figure 2.8). Therefore, the
reduced chemokine level seen during mixed infection is not due to lesser virus produced, but
probably due to intracellular resource competition (610-616) or some direct parental alteration
within the infected cell leading to reduced chemokine expression. Even though we observed no
effect on virus growth in the primary dissemination organs during co-infection (supplemental
figure S2.3), we were unable to show a concomitant reduction in the chemokine levels in vivo
due to experimental limitations of chemokine detection. We speculate that similar to the in vitro
set up, intracellular resource competition or gene expression suppression within the infected cells
could also lead to reduced chemokine levels in vivo (610-616). From these experiments, it is
clear that immune suppression/ablation is not an absolute requirement to restore the
dissemination of the recombinants to the SG, and lends support to the idea that overproduction of
the chemokine by the recombinants is the culprit. The over produced chemokines may be
recruiting or activating cells of innate immune system that are detrimental for the dissemination
of the recombinants to the SG. This data also brings up the interesting observation that the
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immune system mediated blockade of the dissemination of the recombinants to the SG is not
very stringent and a little reduction in chemokine levels seems to be sufficient to tip the scales in
favor of proper dissemination.
Neutrophil depletion did not restore dissemination to the salivary gland (figure 2.4 A).
Therefore another innate cell type that expresses CXCR2 and is not depleted with the anti-Ly6G
antibody could be playing a role in preventing the dissemination of the recombinants. For
example, dendritic cells, a subset of monocytes, and NK cells can be induced to express CXCR2
and CXCR1 (617-620) and may be involved in this process. Although an exhaustive analysis of
vCXCL1CCMV receptor usage is lacking, mCXCL1 receptor usage is well-characterized (621),
and as both have the same phenotype in our experiments, this does not seem to be exclusively a
vCXCL1CCMV phenomenon. We used the co-infection model to evaluate the role the innate
immune cell types in dissemination blockade of the recombinants. NK cells play a major role in
the antiviral response against MCMV (131, 211, 599). BALB/c mice which are unable to induce
NK cell activation via the m157-Ly49H axis are susceptible to MCMV infection and show much
higher viral titers in peripheral organs (622, 623). In our experiments we observed higher
number of NK cells recruited to the site of infection when mice were infected with the
recombinants (figure 2.9 B), which might be compensating for proper activation of the NK cells
and prevent the dissemination of the recombinants. Evidence in support of this premise comes
from the following observations all of which have restored SG dissemination (i) Co-infection is
associated with a reduction of NK cells recruited to spleen and lung (figure 2.10 A), (ii) There
was a significant reduction in the NK cells in mice treated with cyclo (supplemental figure 2.6),
and (iii) NSG mice, which lack NK cells. The reduction or absence of NK cells correlates with a
reduced inflammation at the site of infection or around the foci of during primary organ
infection, which could potentially be beneficial for virus growth and escape from the organ.
This model is also useful to evaluate the role of inflammatory monocytes in the
dissemination of MCMV, given the experimental limitations of selectively depleting either
inflammatory or patrolling monocytes. While patrolling monocytes have been shown to play a
role in viral dissemination (430), inflammatory monocytes extravasate into the tissue during
inflammation and differentiate into M1 macrophages that contribute to the antiviral response
(434, 624). In addition, the infected macrophages can support productive infection of MCMV
(198, 625-627). Interestingly, this rescue of dissemination was independent of MCK2 (figure 2.5
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A). The dissemination of MCMV to the SG is aided with MCK2 expression; viral dissemination
to the other organs is independent of MCK2. This most likely is because the first round of early
infiltrating patrolling monocytes that carry the virus are recruited independent of MCK2
expression (430). Indeed we can detect virus in the popliteal lymph node of mice infected in the
foot pad as soon as 30 min post infection (unpublished data). Mechanisms contributing to this
early exit of the virus from the site of inoculation are currently under investigation. In mice
infected with the recombinant, we observed higher number of inflammatory monocytes in the
lungs and spleens compared to mice infected with the parental virus (figure 2.9 C). Co-infection
reduced the number of inflammatory monocytes in the lung, while not affecting the number of
patrolling monocytes (figure 2.10 B). This data supports our hypothesis that the monocytes at
the site of infection or around the foci of infection might be the wrong type (i.e., inflammatory
rather than patrolling). Although this might not affect viral growth at the site of infection, it
would adversely affect the dissemination of the virus during viremia. Preliminary experiments
with adoptively transferring leukocytes isolated at day 3 p.i. from the FP of mice infected with
parental, recombinant, or a mixed inoculum show that, while we could recover the virus from the
SG of mice receiving cells from mice infected with parental or a mixed inoculum, no virus was
recovered from the SG of mice receiving cells infected with the recombinant (supplemental
figure S2.7).
Therefore we propose a model where the virus is carried out of the FP to the organs of
primary dissemination initially in the absence of viral gene expression by patrolling monocytes.
During infection with the recombinant alone, the over expression of the chemokine in the organs
of primary dissemination (LN, SP, LU) causes an increased recruitment of NK cells to the site
and an enhanced inflammatory state. This supports the differentiation of inflammatory
monocytes to M1 macrophages at the site, which do not contribute to the dissemination of the
virus to the SG. The increased number of inflammatory monocytes around the foci of infection
may also interfere with ability of patrolling monocytes to gain access to virus infected cells.
During co-infection, there is reduction in chemokine levels without affecting viral titers. The
reduced chemokine leads to a reduction in the number of NK cell at the site of infection,
reduction in the inflammatory environment granting patrolling monocyte access to the foci of
infection, which then allows for the dissemination of recombinants to the salivary gland. This
model has been summarized in figure 2.11.
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Figure 2.11 Model of dissemination defect and rescue of dissemination of the
recombinants during co-infection. (A) During single infection, the overproduction of the
chemokine at the site of infection in the primary organs of dissemination recruits
inflammatory cells (NK and IM) to the site and interferes with normal virus dissemination
during secondary viremia. (B) During co-infection, the reduction in the chemokine levels at
the site of infection in the primary organs of dissemination reduces the number of
inflammatory cells (NK and IM) to the site and allows PMs to gain access to the virus. The
infected PMs then are able to disseminate the virus to the SG during secondary viremia.
Abbreviations used: IM = Inflammatory monocyte, PM = Patrolling monocyte, NK =
Natural killer cells, FP = Foot pad, SP = Spleen, LN = Popliteal lymph node, Lu = Lung and
Sg = Salivary gland,

= Chemokine,

= RMmCXCL1/RMvCXCL1CCMV,
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= RM4511

The recombinants that we have generated are attenuated, in the sense that they do not
disseminate to the SG. Therefore, they cannot be shed and transmitted horizontally through
mouse biting. However, as shown with the co-infection model, the parental and the recombinant
virus collaborate to allow the otherwise dissemination defective virus to reach the SG. This
aspect of our study raises an important concern about using attenuated strains for CMV
vaccination purposes (507). The infection of humans with multiple strains of HCMV is very
common (628-636). Therefore, it is possible that in the presence of a previously existing
infection, or a newly acquired HCMV infection, the vaccine strain can regain some of its
infectious potential depending on the type of attenuation. This finding thus warrants the careful
testing of attenuated viral vaccine strains in the context of co-infections during the development
phase.
MCMV has several genes regulating the spread and replication of the virus in the salivary
gland highlights the importance of this organ to MCMV biology, as it is both a site of viral
persistence and of transmission from host to host (199, 598, 607). For example, sgg1 gene is
important for MCMV replication in the SG (608, 609), and the MCMV G protein-coupled
receptor homolog, M33, is also needed for efficient salivary gland replication based on
mutagenesis studies (145, 473-475, 477). The virally encoded chemokine, MCK2, enhances
MCMV dissemination to the salivary (139-141). It also suggests MCMV may require unique
mechanisms to facilitate dissemination to and growth in the SG. Although our results may seem
to contradict our original hypothesis (i.e., that the expression of HCMV CXC chemokines helps
in its dissemination), we have to consider the caveat that our recombinants over express the
chemokines. In reality, the expression of the vCXCL1 gene in HCMV is tightly regulated and it
is expressed with late expression kinetics (407, 417), and not constitutively, as in the case of our
recombinants. Studies have shown that CXC chemokines are capable of making the monocytes
adhere to and halt on the endothelium (637-639), which could allow them to be infected more
efficiently. Not only can the monocytes be infected by CMV, but the infection increases their life
span (640), allows them to re-circulate (569) and promotes their differentiation into a
macrophage (590-592). This differentiation then allows for productive infection of the virus in
these cell types (641-643). Because monocytes play an important role in HCMV dissemination in
vivo (568, 569, 640), it is conceivable that, HCMV has evolved to express vCXCL at the stage
when the virus is budding from the infected cell. The halted monocyte is at the right place at the
right time to pick up the budding virus and once the infected the monocyte re-circulates carrying
the virus to a distal site spreading infection within the host.
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SUPPLEMENTAL FIGURES
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Supplemental figure S2.1 Confirmation of recombination and correct insertion of the
expression cassette. Three PCR reactions were performed using viral DNA as template. A)
Amplification of either the mCXCL1 or vCXCL-1CCMV gene using HCMV IE and 6 His
primers. This generates a ~325 bp product (mCXCL1) and a ~425bp (vCXCL-1CCMV). B)
Verification of the loss of the puromycin-GFP expression cassette using a primer flanking
the 5’ MCMV IE2 homologous region and a primer within the puromycin-GFP cassette
(MCMV GFP). This generates a 2.3kb product. C) Verification of the correct insertion site
of the mCXCL1 or vCXCL-1CCMV expression cassette using a primer flanking the 5’
MCMV IE2 homologous region and a primer within the expression cassette (HCMV IE).
This generates a 3kb PCR product.
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Supplemental figure S2.2 Primary dissemination of virus in cyclophosphamide treated
mice. Mice were treated with cyclophosphamide to deplete the immune cells prior to
infection with the viruses. Un-treated mice were use as control. Organs (popliteal lymph
node, spleen and lung) were harvested at days 3, 7, 14, 18 post infection, homogenized and
viral titer measured by performing a plaque formation assay as described in materials and
methods. Bars represent average virus titer from at least 5 mice per time point + SD.
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Supplemental figure S2.3 No difference in the titer of recombinant virus when coinfected with the parental virus either in the same or different foot pad. Mice were
infected in the same foot pad with a mixed inoculum consisting of a 1:1 mix 1x105 PFU
each of RM4511 and RMmCXCL1 (Mixed) or in the different foot pad with 1x105 PFU
each of RM4511 and RMmCXCL1. Organs (Foot pad, Popliteal lymph node, Spleen and
Lung were harvested at days 3 and 5 p.i, homogenized and viral titer measured by plaque
formation assay. Bars represent average virus titer from 5 mice per group + SD. The
horizontal lien represents the limit of detection in the experiment.
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Supplemental figure S2.4 The dissemination of the recombinant is not rescued when
the infection with the two viruses is temporally separated. Mice were infected with
1x106 PFU of RM4511 and RMmCXCL1 by spacing the infections 2 or 7 days apart. The
salivary glands from these mice were harvested at 14 days post the second infection,
homogenized and viral titer measured by performing plaque formation assay as described in
materials and methods. Symbols represent viral titer form each individual mouse, line is the
median titer from the experiment. RMmCXCL1->RM4511 = first infection RMmCXCL1
and second infection with RM4511, RM45111->RMmCXCL1 = first infection RM4511
and second infection with RMmCXCL1.
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Supplemental figure S2.5 Recombinant virus isolated from the salivary gland after coinfection with parental virus does not undergo recombination or mutation of the
chemokine gene. RMmCXCL1 plaques were isolated from the SG of co-infected mice at
day 14 p.i and grown in large scale cultures. (A) Viral DNA was isolated by phenol
chloroform method and used for sequencing using HCMV IE and 6His primers described in
materials and methods. Protein sequence was generated from the resulting DNA sequence
and aligned using Web based ClustalW (1, 2). Green is the signal peptide sequence, Red is
the CXC motif, Blue is the His tag, * = 100% identity of the amino acid at the position
among the sequences analyzed (B) Results from western blot using anti-His antibody to
detect the presence of the chemokine in the supernatant from large scale virus cultures (C)
RFLP analysis was performed on viral DNA isolated form the RMmCXCL1 virus used for
inoculation (RMmCXCL1 parental) and the isolates from the SG using BstZ17I, HpaI and
HindIII restriction endonuclease.
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Supplemental figure S2.6 NK cells are reduced upon cyclophosphamide treatment of
mice. Mice were treated with cyclophosphamide to deplete immune cells prior to i.p
infection with the viruses. The spleen and lung were harvested at day 4 p.i, leukocytes
prepared and stained for analysis by flow cytometry. The graph shows the number of NK
cells in the spleen and lung of infected untreated and cyclo treated mice. Bars represent
average NK cell numbers from 5 mice per treatment group + SEM.
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Supplemental figure S2.7 Dissemination of virus after adoptive transfer of infected
leukocytes. Mice were infected with 1x105 PFU of RM4511/RMmCXCL1 or a mixed
inoculum consisting of a 1:1 mix 1x105 PFU each of RM4511 and RMmCXCL1.
Leukocytes were isolated from the foot pad at day 3 p.i and adoptively transferred to mice
via tail vein injection. The salivary glands form these mice were harvested at day 14 post
transfer, homogenized and viral titer measured by plaque formation assay. Bars represent
average virus titer from 3 mice per group +/- SEM.
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CHAPTER 3: NOVEL HEPARAN SULFATE-BINDING PEPTIDES FOR BLOCKING
HERPESVIRUS ENTRY
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This chapter is a publication by the same title published in PLOS One in 2015 authored by
Pranay Dogra, Emily B. Martin, Angela Williams, Raphael L. Richardson, James S. Foster,
Nicole Hackenback, Stephen J. Kennel, Tim E. Sparer, and Jonathan S. Wall

Dogra P, Martin EB, Williams A, Richardson RL, Foster JS, et al. (2015) Novel Heparan
Sulfate-Binding Peptides for Blocking Herpesvirus Entry. PLoS ONE 10(5): e0126239. doi:
10.1371/journal.pone.0126239
My use of “we” in this chapter refers to my coauthors and myself. My primary contributions to
this paper include (1) researching the topic, (2) performing lab work, (3) data analysis and, (4)
writing the paper.

1. Abstract

Human cytomegalovirus (HCMV) infection can lead to congenital hearing loss and mental
retardation.

Upon immune suppression, reactivation of latent HCMV or primary infection

increases morbidity in cancer, transplantation, and late stage AIDS patients. Current treatments
include nucleoside analogues, which have significant toxicities limiting their usefulness. In this
study we screened a panel of synthetic heparin-binding peptides for their ability to prevent CMV
infection in vitro. A peptide designated, p5+14 exhibited ~ 90% reduction in murine CMV
(MCMV) infection. Because negatively charged, cell-surface heparan sulfate proteoglycans
(HSPGs), serve as the attachment receptor during the adsorption phase of the CMV infection
cycle, we hypothesized that p5+14 effectively competes for CMV adsorption to the cell surface
resulting in the reduction in infection. Positively charged Lys residues were required for peptide
binding to cell-surface HSPGs and reducing viral infection.

We show that this inhibition was

not due to a direct neutralizing effect on the virus itself and that the peptide blocked adsorption
of the virus. The peptide also inhibited infection of other herpesviruses: HCMV and herpes
simplex virus 1 and 2 in vitro, demonstrating it has broad-spectrum antiviral activity. Therefore,
this peptide may offer an adjunct therapy for the treatment of herpes viral infections and other
viruses that use HSPGs for entry.
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2. Introduction

Human cytomegalovirus (HCMV) is a beta-herpesvirus with nearly 90% prevalence in the adult
human population in developing countries (644).

Initial viral infection is generally

asymptomatic in immune competent individuals. However, severe CMV disease occurs in
individuals with a deficient immune system (e.g., transplant patients suppressed to avoid graft
rejection, late stage AIDS patients, and the developing fetus). In immune deficient adults,
HCMV can cause pneumonitis, multi-organ disease, and death (644-646). Retinitis and blindness
are also common in HCMV-infected, late-stage AIDS patients in the absence of highly active
antiretroviral therapies (646). In utero infection can cause neurological sequela in infants,
including sensorineuronal hearing loss (SNHL) and mental retardation (644, 647).
Attempts to develop a vaccine for CMV infection are ongoing but have met with limited
success (507, 511). Current regimens to treat HCMV infection (i.e., ganciclovir, foscarnet, and
cidofovir) target viral DNA synthesis (648) but can have detrimental side effects (649).
Furthermore the increased use of these drugs has led to HCMV drug-resistance to these therapies
(650-653). Due to these limitations, it is clinically important to develop new therapeutics against
HCMV that are selective, less toxic, and circumvent resistance.

One avenue for drug

development is to target other aspects of the HCMV life cycle besides genome replication.
One of these potential targets is virus attachment to the cell. HCMV uses heparan sulfate
(HS) for entry into cells and to initiate viral replication (654, 655). Virtually all cells express HS
glycosaminoglycans as long un-branched chains associated with protein cores in the form of cell
surface heparan sulfate proteoglycans (HSPGs) (656). Heparan sulfate and heparin are both
linear glycosaminoglycans (GAGs) composed of alternating glucosamine and uronic acids that
can be N-acetylated and N-sulfated (656-658).

Although both HS and heparin are highly

sulfated, HS has fewer modifications, making heparin more electronegative than HS GAGs (657,
658). This is an important distinction as heparin is often used as a surrogate for HS GAGs in
spite of these differences.
HSPGs act as docking sites for growth factors (657, 659), parasites such as the malarial
sporozoite (660), pathologic amyloid-related proteins (661), and many human and non-human
pathogenic viruses including HCMV (654) and herpes simplex virus (HSV) (662). The HCMV
envelope glycoproteins glycoprotein B (gB) and the glycoprotein M/N (gM/gN) heterodimer
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complex are involved in virus adsorption via interaction with HSPG expressed on the cell surface
(654). The ability of HS to act as a binding site for numerous distinct viruses can be attributed to
its diverse structure and variable negative-charge density (656, 663, 664). Despite the critical
role that HS has in HCMV infection, therapeutics targeting HS to treat CMV infections are
lacking. This is likely due to its ubiquitous expression on mammalian cells and its important role
in facilitating the biological activity of growth factors.
Recently, a panel of heparin reactive peptides has been shown to preferentially bind the
HSPG GAGs associated with pathologic deposits containing amyloid fibrils, in vitro and in vivo
(665, 666). Of these peptides, a synthetic, 31 amino-acid, polybasic peptide with a +8 net
positive charge, designated p5, was shown to bind amyloid in visceral organs, including the liver,
spleen, heart, and kidneys (667). Notably, this peptide does not bind to HS-related GAGs
expressed in healthy (i.e., amyloid-free) organs and tissues. Specific reactivity with amyloidassociated HSPGs and not healthy tissues is likely due to the fact that the amyloid-associated
tissues are hypersulfated and electrochemically similar to heparin (668, 669). Based on these
properties, we hypothesized that these peptides could block CMV entry.
In this study we screened a panel of synthetic, heparan sulfate reactive, p5-related
peptides to identify novel inhibitors of CMV HS-mediated adsorption and subsequent infection.
We explored the mechanism of action of the peptide and whether it could prevent other viruses
that use HS for entry.

3. Materials and Methods

Peptide Synthesis and Purification
Peptides were purchased from Keck Laboratories as semi-pure preparations. Routine purification
was performed by HPLC (1100 series; Agilent) using elution from a reverse-phase C3 matrix in
a linear gradient of 0–50% acetonitrile in water with 0.05% trifluoroacetic acid. Peptide peaks
were eluted from the column using a flow rate of 1 mL/min; 1 mL fractions were collected, peak
fractions were pooled, and the mass was determined by mass spectrometry (MS) using a single
quadropole MS (Applied Biosystems). If multiple peaks were observed, peptides were further
purified by RP-HPLC and the mass of each confirmed by MS. In all cases, the purified peptides
used in these studies appeared as single peaks during HPLC purification and as single bands
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following electrophoresis by using SDS-polyacrylamide gel electrophoresis. The purified
peptides were lyophilized as 5 mg aliquots and re-suspended in phosphate-buffered saline (150
mM NaCl, pH7.2; PBS) before use. The re-suspended peptides were stored at 4°C until use.

Cells and virus
Low passage-number cells (< 20) were used for all the experiments. Mouse embryonic fibroblast
10.1 (MEF 10.1 (670)) were cultured in DMEM (Lonza, Rockland, ME) supplemented with
Fetal Clone III serum (FCIII) to a final concentration of 10% (Hyclone, Logan, UT), Pen/Strep
(P/S) to a final concentration of 100 U/ml and L-glutamine (L-Gln) to a final concentration of 2
mM. Human foreskin fibroblast cells (HFF; obtained from ATCC) were cultured in DMEM
(Lonza, Rockland, ME) supplemented with Fetal Bovine Serum (FBS) to a final concentration of
10% (Hyclone, Logan, UT), L-Gln to a final concentration of 2 mM, and sodium pyruvate to a
final concentration of 1 mM. Human Aortic Endothelial Cells (HAEC) were cultured in EGM-2
Bullet Kit (Lonza, Rockland, ME) supplemented with FBS to a final concentration of 6%.
Human retinal pigment epithelia (ARPE-19) cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM):F12 medium (Lonza, Rockland, ME) supplemented with FBS to a final
concentration of 10%. Human normal lung fibroblast (MRC-5) cells cultured in Minimal
Essential Medium (MEM) (Lonza, Rockland, ME) supplemented FBS to a final concentration of
10% and L-Gln to a final concentration of 2 mM. These lines were a kind gift from Dr. Mike
McVoy, VCU. African green monkey kidney epithelial (VERO; ATCC) cells were cultured in
DMEM media supplemented with FBS to a final concentration of 10%, sodium pyruvate to a
final concentration of 1 mM, HEPES buffer to a final concentration of 10 mM and P/S to a final
concentration of 100 U/ml.
MCMV RM4503 (140), was cultured in vitro in MEF 10.1 cells. The virus stock was
titered using plaque assay (described below) and stored at -80°C. Bacterial artificial chromosome
generated HCMV TB40/E-mCherry (470, 671) and TB40/E-pp150-GFP (672, 673) were
cultured in vitro on HFF cells. The virus stock was titered using a plaque assay and stored at 80°C. Low passage number HCMV (passaged 2-3 times) was used for all experiments. Herpes
Simplex Virus (HSV-1 KOS and HSV-2 186 Syn+) were cultured in vitro on VERO cells. The
virus stock was titered using a plaque assay and stored at -80°C.
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Plaque reduction assay
Peptides were screened for their ability to reduce viral infection using a plaque reduction assay.
Cells were cultured in 12-well (VERO) or 24-well culture plates (MEF 10.1 and HFF). When
cells reached ~80 % confluence the media was removed and washed once with PBS before
addition of peptide. As a control, cells were incubated with PBS alone. After a 30 min
incubation with peptide in PBS, virus (~100 PFU/well for MCMV and ~30-40 PFU/well for
HCMV and HSV) was added and incubated for another 90 min (HSV and HCMV) or 60 min
(MCMV). Following virus incubation the peptide/virus mixture was removed and replaced with
0.75% carboxymethyl cellulose (Sigma Aldrich, St. Louis, MO) (CMC) + complete media
(DMEM + P/S + L-Gln) for MCMV and HSV experiments or 0.5% agarose (Lonza, Rockland,
ME) in complete media for HCMV experiments. The plates were incubated at 37° C in 5% CO2
for 4 days and when plaques began to develop, plates were stained with Coomassie stain
(AMRESCO, Solon, Ohio). Due to the inability of HCMV to form distinct plaques on HAEC
and ARPE-19 cells, infection in these cell types was measured by counting mCherry positive
foci 14 days post infection. Plaques were counted manually using a dissection microscope. Data
was analyzed using Prism 5.0 (GraphPad Software, La Jolla, CA). Data were expressed as
percent infection (100 x (number of plaques after treatment/ the number of plaques in the PBStreated wells)).

Flow cytometric analysis of attached virus
HFF cells were grown in a 24 well dish and allowed to reach ~80% confluency. The cells were
cooled to 4°C to prevent virus internalization before addition of peptide (100µM) and incubated
for ½ h. Following the incubation, HCMV TB40/E pp150-GFP was added (MOI 10) at 4°C and
incubated for 1h. Following the incubation, cells were removed from the wells using nonenzymatic cell stripper solution (Corning), fixed (with paraformaldehyde) and the data acquired
using a BD FACS Calibur flowcytometer (BD Biosciences). The data was analyzed using
FlowJo software (TreeStar).

Heparin blockade of peptide-mediated plaque reduction
Peptide p5+14 (100 µM) was pre-incubated with heparin sodium salt (Acros Organics, NJ) at
different concentrations for 1 h at 37°C. This heparin/peptide mix was added to the cells and
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incubated for 30 min at 37°C. Following the incubation, supernatant was aspirated and cells
washed once with PBS to remove unbound/excess heparin or peptide. The cells were
subsequently infected with ~100 PFU/well of MCMV. To test whether heparin treatment of cells
interferes with virus infection, MEF 10.1 cells in a 24 well dish were pre-incubated with
different concentrations of heparin for 1 hour and washed as described above. Following this
pre-incubation, infection was initiated as described above. Finally to test the effect of heparin
treatment on the infectivity of virus, MCMV was incubated with different concentrations of
heparin for 1h before infecting cells. For all treatments, virus was removed 1h post infection and
cells were overlaid with CMC. Plates were incubated for 4 days before staining and counting the
plaques.

Enzymatic treatment of cells
Heparinase I, Heparinase II, Heparinase III, and Chondroitinase ABC were purchased from
Sigma Aldrich (St. Louis, MO). MEF 10.1 cells in culture were treated with heparinase in
heparinase buffer (20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 4 mM CaCl2, and 0.01% bovine
serum albumin (BSA)) at a concentration of 1U/ml or chondroitinase re-suspended in
chondroitinase buffer (50 mM Tris, pH 8.0, 60 mM sodium acetate and 0.02% BSA) at a
concentration of 1 U/ml for 1 h at 37°C. As a control, cells were treated with enzyme buffer
alone. Following incubation, the enzyme solution was removed and cells were washed with PBS
to remove excess enzyme. Subsequently the cells were treated with peptide and infected with
virus. Data was collected and analyzed as described above.

Visualization of bound peptide
Coverslips with fixed MEF cells were prepared, washed in PBS, and blocked with 1% BSA/PBS
for 5 min. Following a PBS wash, the nuclei were stained using Hoechst (Life Technologies
Molecular Probes, Grand Island, NY) 1:100 in H2O for 30 min at 37°C. Cells were then blocked
using a casein block solution (Scytek) for 5 min, AVIDIN/Biotin blocks (VECTOR) for 20 min
each at room temperature (RT) followed by a 5 min PBS wash. Biotinylated p5+14 or CGGYp5G (control) at 1.6 µg/mL in PBS was added and incubated overnight at 4° C. Following a PBS
wash Alexa Fluor 594-conjugated streptavidin (Molecular Probes) was added at a 1:200 dilution
in PBS for 1h at RT. Cells were then permeabilized with 0.2% Triton X-100 (Sigma) in PBS for
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10 min at RT and washed with a solution of 1% BSA in PBS for 30 min. The cells were then
stained with Alexa Fluor 488-conjugated phalloidin (Molecular Probes) at a 1:100 dilution of
stock in 1% BSA/PBS, for 45 min at RT to visualize actin filaments. Slides were cover-slipped
using a fluorescent mounting medium (Dako) to minimize photobleaching.

Measuring bound peptide
MEF 10.1 Cells were grown in 24-well cell culture plates as described above. Each well was
probed with 100 μL of biotinylated peptides at 1 μg/mL in cold DMEM/F12 with 0.1% BSA and
incubated for one hour at 4°C. Following the incubation, cells were washed twice with ice cold
PBS and fixed with 1.25% glutaraldehyde. Fixed samples were washed twice and stored in PBS
for 24 hours. The samples were then blocked with 1% BSA in PBS and probed with 100 μL of
Europium-conjugated streptavidin (Perkin-Elmer, Waltham, MA) in PBS/0.1% BSA for 30 min
at RT. The plate was washed three times with PBS and enhancement solution added. The
fluorescence counts of the control peptide (i.e., background), P5+14 treated cells, and P5+14
treated cells with added enzymes were measured using time resolved fluorescence on the Wallac
Victor 3 (Perkin-Elmer) plate reader. Background counts were subtracted from all treatments.
The percent reduction in bound peptide was calculated as 100%-(enzyme treated fluorescence
counts/no enzyme treated counts x 100).

Statistical analysis
The data presented are pooled results from three or more experiments performed independently
(i.e., repeats), with at least three replicates in each experiment. Error bars represent the standard
deviation (SD). Statistical significance was calculated using one tailed student’s t test or 1 way
ANOVA followed by Tukey's Multiple Comparison Test in GraphPad Prism following the
recommendations of Vaux et al (674, 675). Significance was determined for each separate run
for each of the repeats. A p value < 0.05 was considered statistically significant, * = p<0.05, ** =
p<0.01, *** = p<0.001, NS = non-significant reduction in infection. In the case of experiments
with only three samples, statistical significance should be interpreted with caution. The small
sample size could be susceptible to type II error.
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4. Results

Screening of peptides
Seven synthetic peptides based on the structure of peptide p5 were screened for their ability to
reduce MCMV infection in vitro (Table 3.1). In the initial screening assays all peptides were
tested at a single concentration (500 µg/ml) using a plaque-reduction assay, in which mouse
embryonic fibroblasts were incubated with the peptides for 30 min prior to the addition of virus.
The polybasic peptides exhibited a range of viral inhibition up to >90% inhibition for peptide
p5+14 (Fig. 3.1A).

In contrast, the poly anionic, uncharged, and hydrophobic p5 variant

peptides, CGGY-p5E, CGGY-p5G, and CGGY-p5L, respectively, did not reduce MCMV
infection (Fig. 5.1A).

The presence of an N-terminal Cys residue, which was originally

generated to facilitate incorporation of the radionuclide

99m

Tc in peptide CGGYp5, did not alter

the efficacy of GGGY N-terminal variant (p5) (Fig. 3.1A). However, the CGGYp5 was prone to
self-aggregation (data not shown) and was therefore not further considered in this study.
Following the initial screen, peptide p5+14 was selected for further analysis because it
induced the greatest reduction in infection. Serial dilution of p5+14 peptide resulted in
significant reduction in infection at concentrations > 5 µg/mL (Fig. 3.1B) with an IC50 of 5.2
µM.

Structural aspects and insights into the mechanism of action
ITASSER software (676, 677) predicted the secondary structure of peptide p5+14 to be α-helical
with the majority of the Lys residues aligned along one face of the peptide due to the heptad
repeat in the protein sequence (678) (Fig. 3.2A). To test our hypothesis that peptide p5+14
prevents MCMV infection by competing effectively for negatively charged cell surface HSPG,
biotinylated p5+14 was incubated with fibroblasts in culture. Biotinylated peptide CGGY-p5G,
which replaces Lys with Gly throughout the peptide, served as a negative control. The p5+14
bound mouse fibroblasts in culture as evidenced by the red (Alexa 540) fluorescence stain
associated with the cells (Fig. 3.2B left). In contrast, the electro-neutral peptide CGGY-p5G did
not bind (Fig. 3.2B right), suggesting that the binding of the peptide to fibroblasts was dependent
upon the presence of basic (Lys) residues.
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Table 3.1 Primary sequence of peptides

Peptide

CGGY-p5
CGGY-p5E
CGGY-p5L
CGGY-p5G
p5
p5R
p5+14

G2

Sequence

CGGYS KAQKA QAKQA
AQKAQ AKQAK Q
CGGYS EAQEA QAEQA
AQEAQ AEQAE Q
CGGYS LAQLA QALQA
AQLAQ ALQAL Q
CGGYS GAQGA QAGQA
AQGAQ AGQAG Q
GGGYS KAQKA QAKQA
AQKAQ AKQAK Q
GGGYS RAQRA QARQA
AQRAQ ARQAR Q
GGGYS KAQKA QAKQA
AQKAQ AKQAK QAQKA
KQAKQ
MPRRR RIRRR QK

108

Net
Charge
KQAQK

+8

Plaque Reduction
(Average from
Fig.1)
~61 %

EQAQE

-8

0

LQAQL

0

0

GQAQG

0

0

KQAQK

+8

~53 %

RQAQR

+8

~75 %

KQAQK
QKAQA

+12

~90 %

+8

Figure 3.1 Heparin-reactive peptides reduce MCMV infection in vitro. (A) Peptides (500
µg/ml) with different net charges and lengths were incubated with cells 30 min prior to
addition of MCMV (~100 PFU/well). Bars represent the average of the percent reduction in
infection compared to PBS-treated control from three independent experiments with at least
three replicates in each + SD. (B) p5+14 and CGGY-p5G (control peptide) were serially
diluted and assayed in a plaque reduction assay as described in materials and methods.
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Figure 3.2 p5+14 binding to cells is charge dependent. (A) Predicted α-helix structure of
peptide p5+14 based on ITASSER modeling. (B) Biotinylated peptide p5+14 (left panel) or
CGGY-p5G (right panel) was added to MEF 10.1 cells followed by addition of Alexa Fluor
594-conjugated streptavidin (red). Nuclei are stained blue with Hoechst and F-actin stained
green with Alexa Fluor 488-conjugated phalloidin.
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Peptide-mediated reduction of MCMV infection through cell surface HS binding
If p5+14 binds to negatively charged HS moieties on the cell surface, pre-incubation of the
peptide with heparin, which has similar charge and structural properties to HS, should interfere
with peptide-mediated reduction of infection. To test this, we incubated p5+14 with various
concentrations of heparin. Pre-incubation of peptide with heparin before addition to the cells
reduced its ability to inhibit MCMV infection in a dose-dependent manner (Fig. 3.3A). It should
be noted that the ~50% reduction in infection with peptide and no heparin (i.e., 0ug/ml heparin
concentration in Fig. 3.3A) is different than the ~90% reduction in Fig. 3.1. We ruled out
degradation of the peptide during the pre-incubation step as an explanation for this discrepancy
(data not shown). This disparity could however be due to the additional wash step after
incubation of peptide + heparin. This additional wash could remove cell-surface bound peptide
decreasing peptide interference with infection. This step is necessary to avoid any free heparin
neutralizing the virus so it could not be eliminated from the protocol. In contrast, pre-incubation
of the cells with negatively charged heparin prior to virus addition did not alter MCMV infection
(Fig. 3.3B). However, when heparin was pre-incubated with MCMV (without peptide), infection
was reduced > 80% at all heparin concentrations ≥ 2 µg/mL (Fig. 3.3C). This data supports our
hypothesis that p5 is binding the negatively charged GAGs on the cell surface which can be
counteracted by incubation with the negatively charged heparin (679).
Because p5+14 can bind both HS and CS GAGs, the reduction in infection could be
mediated by direct competition for virus adsorption sites via HS on the cell surface, stearic
hindrance mediated by peptide bound to CS on the cell surface, or both. To distinguish between
these possibilities, cells were treated with heparinase or chondroitinase enzymes to cleave the
different GAGs from the cell surface. Treatment of cells with heparinase caused a ~40%
reduction in the amount of bound peptide, whereas chondroitinase treatment resulted in a ~11%
reduction (Fig. 3.4A). Treatment of cells with heparinase (1U/ml) led to a ~60% reduction in
MCMV infectivity as expected, which was enhanced further by the addition of p5+14 leading to
an ~80% reduction (Fig. 3.4B). There was no significant difference between peptide alone and
peptide in conjunction with heparinase treatment. In contrast, treatment of cells with
chondroitinase (1U/ml) did not reduce MCMV infectivity nor did it have any effect on the
activity of the peptide (Fig. 3.4C).

Pre-treatment of MCMV itself with heparinase or

chondroitinase prior to addition to MEFs did not alter its infectivity (data not shown). These
results indicate that p5+14 blocks MCMV infectivity via heparan sulfate and not steric hindrance
after binding to chondroitin sulfate.
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Figure 3.3 Soluble heparin interferes with peptide inhibition of virus infection. The
effect of heparin on the activity of peptide and MCMV viral infectivity in vitro when (A)
pre-incubated with the peptide (100 µM), (B) incubated with the cells before adding virus,
and (C) pre-incubated with virus alone in a plaque reduction assay as described in materials
and methods. Bars represent the average of the percent reduction in infection compared to
PBS-treated control from three independent experiments with at least three replicates in each
+ SD. Statistical significance is indicated as: * = p<0.05, ** = p<0.01, *** = p<0.001.
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Figure 3.4 Peptide interacts with cell surface heparan sulfate but not chondroitin
sulfate to mediate anti-viral activities. (A) MEF 10.1 cells were treated with heparinase I,
II, III or chondroitinase ABC and the amount of bound peptide was assessed as described in
materials and methods. (B) Cells were treated with heparinase I (1U/ml) or (C)
chondroitinase ABC (1U/ml) and peptide p5+14 was added.

The amount of plaque

reduction of MCMV infection in each treatment was measured in a plaque reduction assay as
described in materials and methods. Bars represent the average of the percent reduction in
infection compared to PBS-treated control from three independent experiments with at least
three replicates in each + SD. Statistical significance is indicated as: * = p<0.05, ** =
p<0.01, *** = p<0.001, NS = non-significant difference in the reduction of infection.
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Peptide competes for virus adsorption to the cell surface
In the infectivity assays described above, peptide and virus were co-incubated with the cells. In
this experimental setup, the peptide could bind to the virus, to cells, or both and reduce infection.
Therefore to ensure that the peptide was not directly inactivating the virus, MCMV was coincubated with 100µM (~20x the IC50) peptide at 37°C for 1 h, diluted to an ineffective peptide
concentration (1 µM) and infection of fibroblasts measured. There was no reduction in MCMV
infection under these conditions, whereas addition of peptide and virus simultaneously to the
cells showed significant reduction in infection (Fig. 3.5A).
To determine at which stage of the MCMV entry cycle the peptide interferes, four
different peptide treatment protocols were tested: 1) 30 min prior to infection (pre-adsorption) 2)
simultaneously with virus (during adsorption) 3) after letting the virus adsorb to the cells at 4°C
for 1h (post adsorption, then shifted to 37°C to induce membrane fusion) or 4) after allowing the
virus to fuse with the cellular membrane at 37°C for 1h (post fusion) (Fig. 3.5B). Addition of the
p5+14 peptide before or in conjunction with virus addition to the cells resulted in >80%
reduction in infection. However, when peptide was added after the adsorption or fusion phase of
viral entry, no significant reduction in plaque formation was observed (Fig. 3.5B).
To specifically show that p5+14 prevents adsorption of HCMV to cells, HCMV
expressing a tegument protein-green fluorescent fusion protein, pp150-GFP, was incubated with
HFF cells at 4°C in the presence or absence of the different peptides. The fluorescence of cellassociated virus was measured via flow cytometry (Fig. 3.5C). Incubation of the cells with
p5+14 reduced the amount of fluorescent virus attached to the cell surface, whereas there was no
reduction in fluorescence when cells were incubated with peptide CGGY-p5G compared to PBS
treated cells.

Comparison of p5+14 to other inhibitory peptides
The efficacy of p5+14 to reduce infection was compared to the recently reported inhibitor
peptide, G2, which was also inhibits infection of herpes viruses (HSV and MCMV) (680) (Table
1). Both peptides effectively inhibited MCMV infection at 100 µM, but p5+14 leads to a >80%
reduction in infection at 10 µM at which concentration peptide G2 was ineffective (Fig. 3.6).
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Figure 3.5 Peptide p5+14 blocks adsorption of MCMV. (A) MCMV was pre-incubated
with p5+14 peptide (100 µM) before diluting the virus/peptide to an ineffective peptide
concentration (1 µM) and assayed in the plaque reduction assay as described in materials and
methods. As a control, virus and peptide (100 µM) were added to cells simultaneously. (B)
Cells were incubated with p5+14 peptide either prior to virus adsorption, during virus
adsorption, after virus adsorption (at 4°C) but prior to fusion, or after fusion (at 37°C).
Plaque reduction was measured in a plaque reduction assay as described in materials and
methods. Bars represent the average of the percent reduction in infection compared to PBStreated control from three independent experiments with at least three replicates in each +
SD. Statistical significance is indicated as: * = p<0.05, ** = p<0.01, *** = p<0.001, NS =
non-significant difference in the reduction of infection compared to PBS treated control
wells. (C) Adsorption of HCMV TB40/E-pp150-GFP (MOI 10) fusion protein expressing
HCMV was measured via flow cytometry in the presence of p5+14 (green), control peptide
CGGY-p5G (orange) and PBS (blue). Red line represents uninfected cells. Inset is a scatter
plot of the mean fluorescence intensity (MFI) for GFP with the line representing average of
3 replicates +/- SD for the different treatments.
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Figure 3.6 Comparison of the efficacy of p5+14 and peptide G2 to reduce MCMV
infection in vitro. Peptides G2 and p5+14 were added at different concentrations (100, 10, 1
µM) in a plaque reduction assay as described in materials and methods. Bars represent the
average of the percent reduction in infection compared to PBS-treated control from three
independent experiments with at least three replicates in each + SD. Statistical significance
is indicated as: * = p<0.05, ** = p<0.01, *** = p<0.001, NS = non-significant difference in
the reduction of infection compared to PBS treated control wells.
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p5+14 inhibition of other herpesvirus infection
Because most herpesviruses use HS for their initial attachment to cells and can infect different
cell types, we evaluated the efficacy of the peptide to block infection of other human
herpesviruses infecting different cells types. Addition of peptide p5+14 at a concentration of 100
µM 30 min prior HCMV infection resulted in a reduction of ~70% on HFF, ~50% on HAEC,
~90% on ARPE-19 and ~ 60% on MRC-5 cells (Fig. 3.7). An ~80% reduction in infection was
observed with herpes simplex virus (HSV) 1. However, reduction of HSV 2 infection was less
remarkable (~40% reduction).

5. Discussion
Cytomegalovirus infection is a significant clinical problem in infants and immunodeficient
populations. There are two major problems with current anti-CMV treatments. First, current
anti-CMV therapies have significant organ toxicity. Secondly, resistance to current therapies is
increasing. In this study we examined a panel of synthetic peptides that bind hypersulfated
GAGs for their ability to inhibit herpesvirus infection, using MCMV as a model system. Of the
seven peptides evaluated in this study, peptide p5+14 demonstrated effective inhibition of
MCMV infection and reduced infection of both HCMV and HSV (HSV-1 and 2) in vitro (Figs.
3.1A and 3.7). This suggests a broader applicability of GAG-binding synthetic peptides for
inhibiting virus-cell interactions. We established that the peptide effectively competed for
adsorption of CMV to susceptible cells, thereby reducing infection. We also demonstrated that
the peptide does not have a direct neutralizing effect on the virus itself.
The p5-related peptides are synthetic polybasic reagents with a predicted α-helical
secondary structure. The heptad amino acid repeat -KAQKAQA- positions the Lys residues
along one face of the helix. This structural feature was engineered and intended to facilitate an
interaction with linear sulfated GAG molecules, notably heparin (678, 681). Due to their ability
to preferentially bind hypersulfated GAGs these peptides have been used to effectively target and
image tissue amyloid deposits (666, 668), which contain hypersulfated HS and possibly CS
proteoglycans (682). Remarkably, when radiolabeled the p5 and p5+14 peptides were injected in
disease-free mice, peptide did not bind to GAGs expressed in healthy organs or tissues (666).
This lead us to hypothesize that the linear positive charge on peptide p5+14 facilitates binding to
negatively charged PGs on the cell surface, which mediates antiviral activity. This is supported
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Figure 3.7 Peptide p5+14 inhibits HCMV and HSV infections in vitro. Peptide p5+14
(100 µM) was added in a plaque reduction assay as described in materials and methods using
HCMV (TB40/E) on different cell types (HFF, HAEC, and ARPE-19) and HSV-1 or HSV-2
on VERO cells. Bars represent the average of the percent reduction in infection compared to
PBS-treated control from three independent experiments with at least three replicates in each
+ SD. Statistical significance is indicated as: * = p<0.05, ** = p<0.01, *** = p<0.001.
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by the fact that peptides with the same net positive charge exhibit differential anti-viral effects
that are consistent with the peptide affinity for the GAGs and subsequently amyloid. Thus,
peptide p5R (+8 charge), which has a higher affinity for heparin (678) and amyloid (683) as
compared to peptide p5 (+8 charge), blocks viral infection 2-fold better (Fig. 3.1A). These data
suggest that the secondary structure of the peptides, as well as the overall net charge, affects
binding to specific GAGs on the cell surface and their subsequent anti-viral activity. Based on
the known restricted reactivity of peptides p5 (666) and p5+14 in vivo, our data using p5+14
suggests that CMV may preferentially bind hypersulfated GAGs, such as 6-O-sulfated GAGs
(679) on the cell surface of cultured fibroblasts. This may differ from the ubiquitously expressed
GAGs found in tissue HSPG and CSPG proteins in vivo. This is similar to the proposed
mechanism for HSV that uses multiple different interactions for entry including 3-O sulfated
GAGs, which differ between cells grown in vitro and in vivo (684).
An alternative mode of action for these peptides may involve internalization of the
peptide along with the GAG ligands that the virus uses for entry. For example, peptides that are
rich in Arg or Lys are known to bind HS on the cell surface resulting in internalization of the
peptide/HS complex (685, 686). Because of this mechanism, these peptides are being considered
for drug delivery or diagnostic/therapeutic nanoparticles (687-689). It remains to be evaluated
whether peptide p5+14 binding to the HSPG ligands results in internalization of the peptideligand complex, resulting in less HS for virus to bind and enter. These studies are underway. If
this is the case, it would provide an alternative explanation for HS binding peptides’ inhibition of
CMV infection and suggest that p5+14 could also be used as a reagent for delivery of
intracellularly active payloads.
Tiwari et al. (680) and Borst et al.’s (679) recent work identified HS-reactive anti-viral
peptides G2 and CYVIP from a phage library screen and human hemofiltrate, respectively. In
concordance with our findings, the positive charge of these peptides was critical for their antiviral activity. Notably, our peptide p5+14 was more effective at lower concentrations in
inhibiting MCMV infection of mouse fibroblasts in vitro when compared with peptide G2 (Fig.
3.6). Although these peptides have similar modes of action, there are significant differences in
their size and charge distribution. The length and spatial arrangement of charged amino acids
affect binding to heparin (678), HS-laden amyloid (690), and cell surface HS (685). Although
we used the L form of the peptide G2 in the current study, recently the D form of the G2 peptide
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was shown to be 4 times as efficacious as the L form in vitro (691). This form has the additional
advantage of being proteolytically stable. Thus the authors propose that D form could be
important for in vivo treatments because it would be more stable in serum. A systematic
evaluation of the physical, electrochemical, and structural characteristics that contribute to antiviral activity of all these peptides will aid in the design of next generation antivirals.
In this study we show that peptide p5+14 exhibited significant anti-viral activity against
HCMV, HSV-1 and 2 (Fig. 3.7). It is interesting that the antiviral effects were more robust on
the HSV-1 than on HSV-2. Even though we propose a similar mode of action against each virus
(i.e., blocking of viral adsorption to cell surface HS) the difference in peptide p5+14 efficacies is
intriguing. Differences in the viral gB glycoproteins could lead to preferential use of specific
GAGs to adsorb to the cell surface (692) that lead to differences in the efficacy of the peptide
against the two HSV serotypes. Indeed, the fine structure and distribution of HS GAGs can be
different on different cell types. This can explain differences in the efficiency of peptide
blockade on different strains and cell types (693, 694). It is possible, indeed likely, that the
p5+14 peptide and similar reagents exhibit preferential binding to GAGs that could lead to
differences in cell-surface binding and antiviral efficacy. Notably, circular dichroism
measurements showed that peptide p5 preferentially binds heparin and adopts an α-helical
configuration compared to HS, CS, dermatan sulfate, and hyaluronic acid (681).
Using SPECT imaging and micro-autoradiography, we have previously shown that the
“ligand” bound by peptides p5 (666) and p5+14 (unpublished data) has a restricted distribution in
vivo. The peptides do not bind cellular GAGs or those in the extra-cellular matrix of healthy
tissues (666). This observation, taken together with the fact that these peptides compete with
herpesviruses for binding to cells in culture suggests that viruses may preferentially bind to a
subset of HS in vivo that is characterized by a high sulfation pattern, (i.e., electrochemically
more reminiscent of heparin). This pattern has been observed with HSV (663, 692). This
remains to be established in vivo.
CMV and other herpes viruses establish latency within the host, which is dependent upon
virus entry and infection of host cells. Preventing viral entry using competitive peptides could
potentially reduce the ability of virus to establish latency. Even though HS on the cell surface is
an attractive target for developing antivirals, reports targeting this pathway during viral
infections in vivo are scarce (680). This is likely due to the fact that HS is ubiquitous and
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involved in numerous critical cell-signaling pathways. Thus, peptides such as p5+14 that
specifically targeted heparin-like HS may provide selective viral competition in vivo without
detrimentally affecting biological processes through a more common HS.
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Conclusions

The Human Cytomegalovirus (HCMV) genome carries several genes that have immune
modulatory properties (138, 411). An example is the UL146 gene which encodes for a functional
viral CXC chemokine (vCXCL-1), which exhibits significant variability between the clinical
isolates and has been demonstrated to be associated with clinical outcome of HCMV infection
(405, 416). Gerna et. al showed viral transmission from HCMV infected endothelial cells to
peripheral blood neutrophils (PBNs) in vitro after as little as 1 hour of co-culture (560, 695).
Even though HCMV infection of PBN is abortive, vCXCL-1’s recruitment of PBN could be
beneficial for HCMV, as it may use them as a means of transportation (695). HCMV
transmission requires contact between the endothelial cells and PBNs, during which transitory
microfusion events allow the PBNs to pick up the virus and disseminate HCMV through the
bloodstream (695). This study characterized the vCXCL-1 protein from different clinical isolates
in vitro (chapter 1) and evaluated the contribution of vCXCL-1 in the pathogenesis of CMV
infection in vivo (chapter 2). In addition, we also tested the efficacy of heparan sulfate binding
peptides as potential antivirals (chapter 3).
Because the hypervariability observed in the UL146 gene from the different clinical
isolates occurs within receptor binding motifs, such as ELR and N-loop (416), we hypothesized
that, variability in vCXCL-1 leads to differential activation of neutrophils, which leads to
the observed difference in HCMV pathogenesis. This hypothesis was addressed in chapter 1
by synthesizing vCXCL-1 proteins using a baculovirus protein expression system. All the
vCXCL-1s bound to CXCR2 with different binding affinities, whereas only three of them bound
to CXCR1. All vCXCL-1s were capable of inducing intracellular calcium mobilization in human
peripheral blood neutrophils (PBNs). The chemotaxis of PBNs was dependent on the affinity of
vCXCL-1 for CXCR2, and vCXCL-1s also differentially upregulate CD11b and CD11c on the
surface of PBNs. β2-integrins are important in the adhesion and extravasation of PBNs across the
endothelium and this might lead to difference in the infectivity of these cell types during CMV
infection. In addition the induction of secondary chemokine CCL22 (macrophage-derived
chemokine (MDC)), which can attract other leukocytes including monocytes, dendritic cells, and
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the Th2 cells (552) was also dependent on the affinity of the CXCL-1 for CXCR-2. Monocytes
and dendritic cells support productive infection of the virus upon activation (430, 561, 696) and a
Th2 responses also can help HCMV pathogenesis by diminishing CTL responses (553, 554).
Taken together, in this study we identified the similarities and differences in the functional
activity of vCXCL-1 from different HCMV isolates and suggest how the variability can affect
neutrophil function and CMV pathogenesis.
In chapter 2 we evaluated of the role of vCXCL-1 in vivo using the murine model of
CMV infection. We generated recombinant murine CMV (MCMV) expressing the vCXCL1CCMV from chimpanzee CMV. We tested the hypothesis that vCXCL-1CCMV
(vCXCL1CCMV) is a functional CXC chemokine that contributes to viral dissemination,
similar to MCMV CC chemokine. The primary dissemination of recombinant MCMV expressing
vCXCL-1CCMV, and mCXCL-1KC was similar to RM4511 (parental MCMV not expressing
any chemokine). However, neither of the recombinants was recovered from the SG at any time
point. The absence of the recombinants from the SG of SCID mice suggested that the virus was
not cleared in the organ by the adaptive immune system. Neutrophil depletion in mice was
unable to rescue the dissemination of the recombinants to the SG. This suggested that neutrophils
too are not involved in blocking the dissemination of the recombinants to the SG. The
dissemination of the recombinants to the SG was restored upon cyclophosphamide induced
immuneablation and in NSG mice, which lack T, B lymphocytes and NK cells. These results
suggest that the over expression of the chemokine induced cells of the innate immune system
which curtail the dissemination of the recombinants to the SG. We also observed restoration of
the dissemination of the recombinants to SG in an immune competent co-infection system
(RM4511 + recombinant). The two viruses co-infecting the cell at the site of infection is critical
for restoration of the dissemination to the SG. In an in vitro system of co-infection we observed
reduced the chemokine levels, without affecting the virus titer compared to single infection. The
co-infection also reduced the number of NK cells and inflammatory monocytes at the site of
infection, compared to a recombinant alone infection. Therefore, from this study we concluded
that vCXCL-1 is a functional chemokine in vivo. However, overexpression of the chemokine is
detrimental to the dissemination of MCMV because recruitment of more inflammatory
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monocytes and NK cells to the site of infection. In case of co-infection, there occurs a resource
competition that reduces the chemokine levels and allows SG dissemination.
Like other herpes viruses, once infected with CMV, the host is infected for life. Latent
virus reactivates and can cause serious complications in immune-compromised individuals.
Antivirals are the only recourse in this situation, but their use is limited due to toxic side effects.
Moreover HCMV strains are becoming resistant with prolonged treatment with these drugs (697700). CMV binds to negatively charged heparan sulfate on the cell surface during the attachment
step of viral entry into the cell, making it a potential target for anti-CMV drug development (654,
701). We targeted this step of the CMV infection lifecycle to develop novel therapeutics. These
drugs would attack a different step in the viral life cycle than the currently used drugs. In
chapter 3 we tested the hypothesis that heparan sulfate binding peptides will block CMV
infection of the cells, by preventing the attachment and subsequent entry of the virus into the
cells. Peptides of different lengths and net charge were generated. Of them, the cationic peptides
reduced MCMV infection in vitro by ~ 90%. The peptides bound to the cells in a charge
dependent manner. Pre-incubation of the peptides with soluble heparin reduced the activity of the
peptide and viral infectivity of the cells suggesting that the peptide and the virus interact with a
negatively charged moiety on the cell surface. Treating the cells with GAG cleaving enzymes,
demonstrated the peptide preferably binds HS and mediates reduction in infection via blocking
the attachment of virus to the cells, which in HS dependent. The peptide did not to neutralize the
virus itself and was more efficacious than similar antiviral peptide G2 (680). Finally the peptide
was shown to be effective against HCMV and herpes simplex 1 and 2 virus on a wide variety of
cells. Thus we characterized a novel antiviral peptide, which is effective against herpesviruses
that use HS to attach to cells and has a mechanism of action different than the existing antiviral
drugs. This peptide could therefore be used to treat HCMV disease in the conjunction with
current therapies and in the treatment of drug resistant strains of HCMV.
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Future Directions

Chapter 1:
In this chapter we characterized some of the functional differences in the vCXCL-1 chemokines
from different clinical isolates. Future work along the following lines will help to better
understand vCXCL-1 and its role in HCMV pathogenesis.

1. Even when bound to the same receptor, subtle differences in the chemokine can lead to
different signaling and cellular responses (702). Therefore, investigating the signal
transduction pathways induced by the different VCXCL-1 variants will help clarify the
polymorphisms at the molecular level.
2. Our experiments show that all vCXCL1s can bind to CXCR2 and some can also bind
CXCR1. It is also known that these receptors induce a different downstream signaling
cascade leading to difference in the leukocyte response (703). Therefore it would be
interesting to investigate the contribution of the each of these receptors individually in
functional assays (calcium flux, chemotaxis, adhesion molecule upregulation, CCL22
induction etc.). This can be done by using receptor blocking antibodies while performing
these assays.
3. In our previous studies we had observed significant variability in and around the ELR
motif and the N-loop regions of the vCXCL1s (416). Both of these regions have been
shown to be involved in the chemokine-receptor interactions (259, 265, 270, 337, 369,
373, 374). Therefore, we should perform domain swap studies to understand the key
elements in vCXCL1s that are responsible for the functional differences of the vCXCL1
from the different isolates.
4. Variability in the sequence of protein isoforms could translate into structural differences,
which could trigger different downstream signaling cascades from the receptor (457, 485)
or ligand binding affinities e.g. for Hemoglobin isoforms. Therefore, it would be
worthwhile to carry out structure homology modelling of the vCXCL1s from different
isolates, using other previously crystalized chemokines and receptors as templates. These
can then be used to carry out molecular docking (protein-protein) studies to visualize how
the different vCXCL1s interact with the chemokine receptors. This might help us
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understand why and how these different vCXCL1s elicit different downstream signaling
responses.
5. Previous studies have shown that treating fibroblasts with CXCL8 (IL-8) leads to
increased viral replication (704, 705). It would therefore be interesting to investigate
whether treating fibroblasts with the different vCXCL1s would also increase viral titers.
This might be another mechanism by which viral chemokines contribute to the
pathogenesis of CMV.
6. We have shown that the viral chemokines upregulate the expression of adhesion
molecules on neutrophils and propose that this aids in virus transfer to the neutrophils.
However, it is also possible that vCXCL1s upregulate adhesion molecules (e.g. selectins,
and integrins) on endothelial cells. This too might allow for better interaction of
leukocytes with the infected endothelial cells also allowing for better transfer of the virus
to the leukocytes form the infected cells.
7. Neutrophils can transmigrate through a monolayer of endothelial cells and pick up virus
from the infected cells while doing so (560). It will be valuable in understanding how the
variability in the vCXCL1s effects the transmigration and the ability of neutrophils to
pick up the virus from infected endothelial cells by carrying out endothelial
transmigration assays in the presence of vCXCL1.
8. As an alternate to the experiment mentioned above, we could also perform co-culture
experiments with infected endothelial cells and neutrophils (560, 695). During these
experiments we can treat the cell types in isolation or together with the different viral
chemokines and evaluate the transfer to virus to the neutrophils from the infected
endothelial cells.

Chapter 2:
In this chapter we evaluated the in vivo functionality of vCXCL1 from CCMV (vCXCL1CCMV). The following experiments would help to better define the role of vCXCL1 in vivo
and explain the results obtained from the co-infection model.

1. Generate recombinant MCMVs expressing vCXCL1s from HCMV clinical isolates
(416). These recombinants could be used to investigate the role viral CXCL1 from
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HCMV in CMV pathogenesis and dissemination. In addition, this model will also allow
us to investigate how the variability in the sequence of the chemokine affects CMV
dissemination and pathogenesis in vivo.
2. The vCXCL1 gene is expressed with late expression kinetics (407, 417).

It has been

shown that the amount and timing of the chemokine can lead to an aberrant immune
response (706, 707). Our model may not be mimicking the real life scenario, as the
recombinants overexpress the chemokine constitutively. Therefore, we should generate
MCMV recombinants that express the chemokine with late gene kinetics (i.e., the mck2
promoter. This will provide us with a model more closely matching HCMV for
chemokine expression and usage in vivo.
3. Viral titers and persistence, both of which are controlled by the immune system,
determine the ability of MCMV to establish latency and subsequent reactivation at the
site of infection (430). Because the recombinant viruses alter the immune response, it
will also be important to assess how the expression of vCXCL1 affects the establishment
of latency and the ability of MCMV to reactivate.
4. The BALB/c mice are susceptible to MCMV infection because they cannot induce an
effective NK response (622). From our experiments it seems that when infected with the
recombinants, they recruiting more NK cells to the site of infection. Using the NSG
mouse model we have shown that NK cells mediate the dissemination blockade of the
recombinants to the salivary gland (SG). However there are several other components of
the immune system are defective/lacking in this mouse model including dendritic cells,
macrophages, T and B lymphocytes etc. (600, 601). Therefore, I would also suggest
carrying out in vivo dissemination experiments in WT BALB/c mice following NK cell
depletion (708, 709) to demonstrate the role of these cells types in an otherwise immune
sufficient mouse.
5. It is also possible that the overproduction of the chemokine leads to chemokine receptor
desensitization (706, 707, 710-712). This may lead to poor recruitment to the site of
infection or impaired re-circulation of cells, which might contribute to the blockade of
dissemination of the recombinant to the SG. To test this possibility we should sort the
cells from the sites of infection from mice infected with either the parental or the
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recombinants. These isolated cells would then be tested in in vitro functional assays for
responsiveness to chemokine stimuli.
6. Infection of the host with multiple strains of HCMV is a very common phenomenon
(628-636), which happens even in the face of pre-existing immunity to CMV (519). The
co-infection model can be used to investigate the host pathogen-pathogen interaction
further. For example we have shown that recombinants generate an abnormal immune
response, and the co-infection skews the immune response to favor the dissemination of
the recombinant. In the future we can carry out experiments with other combinations of
recombinants and parental virus to evaluate how mixed infection or sequential infection
affects the development of T and B cell responses to CMV infection.

Chapter 3:
In this chapter we tested heparan sulfate (HS) binding peptides as potential anti virals. However
there are a few questions still remaining that need to be addressed to evaluate the full potential of
these peptides as therapeutics.

1. We propose that our peptide interacts with cell surface HS and that this binding is not
indiscriminate (un-published data from Jon Wall). It is necessary to define the HS
subtype being targeted by the peptide is the same one that is also used by the virus to
attach to the cell during infection. This can be done by either performing peptide-HS
pulldown assays using biotinylated peptide, or by using HS arrays available at the
University of Georgia, Complex Carbohydrate Research Center. This data will help in
revealing the specificity of the peptides for HS subtypes, which will help us to improve
the peptide even further and to avoid any side effects associated with non-specific
binding. In addition, this knowledge will be of great interest to CMV biologists, as it
might help in understanding CMV’s cell tropism in vivo.
2. In the future, we should also carry out a systematic analysis to identify the sequence and
structural features of the peptide that contribute to its function. This will help in the
development and optimization of the peptides. For example, from our experiments it
seems that peptides with Arg function better than peptides with Lys, even if they have the
same charge. Future experiments to test the validity of this observation can be carried out
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by using Arg and Lys containing peptides of different lengths. In addition, we show that
the greater the positive charge on a peptide the better it functions. Experiments could
also be performed to identify the optimum charge:length ratio that would offer the best
protection against infection. Structural features of the peptide may also contribute to the
function of the peptides. The peptide we tested forms an α-helix. However some other
peptides that we tested initially and the ones published elsewhere do not. Because the
structure might contribute to the turnover and ability of the peptide to bind to the cell
surface, it would be interesting to investigate the relative contribution of the secondary
structure of the peptide to the overall function of the peptide.
3. Cationic peptides have the tendency to be internalized after being bound to cell surface
HS. Therefore, they have been used to transport small molecules into the cells (687). It
has also been shown in other studies that the internalized peptide can interfere with viral
replication (713-715). It would therefore be interesting to test if our peptides also get
internalized. In addition to being a new use for these peptides (i.e., small molecule
transporter), if the peptides interfere with virus replication after entering the cell, it will
increase the usability of these peptides to treat other viral infections too.
4. Although we did not observe any cytotoxicity for the peptide in vitro, in order to develop
the peptides for in vivo use, we need also need to perform toxicity assays in animals. In
addition we also need to address the issue of bioavailability and stability of the peptides
in vivo. Peptides with modifications to increase their stability and bioavailability e.g.
acylation and PEGylation (716) need to be tested in vitro before proceeding to in vivo
testing. One of the factors that might reduce the stability of the peptide is the proteolytic
environment in vivo. To address this issue we have developed proteolytically stable
peptides. These peptides are made up of D amino acids rather than L amino acids. The
use of the D amino acids makes these peptides resistant to proteolytic cleavage
(manuscript in preparation) (691). In addition, it has also been proposed that this lack of
cellular proteolytic processing of peptides with D amino acids, they are less likely to
induce an immune response (717-719).
5. Because CMV can infect different cell types in various organs, for a peptide to be used
successfully as a therapeutic in vivo, we need to know the bio distribution of the peptide.
This can be done using radiolabeled peptide with SPECT/CT scans in Dr. Wall’s lab. At
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the same time we can also assess the bioavailability of the peptide in different organs and
tissue.
6. Finally after carefully evaluating the peptides for toxicity, stability, and distribution we
should proceed to in vivo experiments. We need to evaluate the utility of peptides for in
vivo use by comparing the route of administration (i.e., intravenous, local, oral etc.). We
can also test the efficacy of the peptide in a mouse model of re-activation vs. primary
infection.

These experiments will help us to determine the best route where these

peptides will be most effective.
7. We show that the peptide functions by blocking viral attachment to the cells. This
mechanism is different from the currently used nucleoside analog antivirals (e.g.
ganciclovir, valganciclovir, foscarnet etc., that inhibit viral DNA polymerase (521-523)).
This suggests the interesting possibility that the peptides could still function against drug
resistant HCMV strains, which should be tested in future experiments. In addition, the
currently used drugs are also associated with toxic side effects (521-523). Therefore, we
should also experiment with treating cells with peptide and the anti-CMV drugs
simultaneously with the goal of reducing the IC50 of the anti-CMV drug being tested. A
reduction in the IC50 of drug could translate into less toxicity when used in vivo.
8. We show that the peptides do not target the virus directly and hypothesize that there is
lesser possibility that the virus develops resistance against these peptides. To test the
robustness of these peptides as antivirals, we can carry out experimental evolution
studies. During these experiments we would infect cells with the virus in the presence of
the peptides. Then isolate the virus that infects even in the presence of the peptide. This
infection-isolation cycle will be repeated several times with increasing concentration of
the peptides. The escape variants could then be sequences to examine what changes lead
to their resistance to the peptide. If our observation is true that the peptide does not exert
any direct selective pressure on the virus, the virus should not be able to develop
resistance to the peptide by switching to use a different HS subtype during infection.
9. In other experiments we observed that SG isolated MCMV was less susceptible to
peptide mediated reduction of infection compared to the tissue culture grown virus. This
susceptibility however could be restored upon one round of passaging the virus in
fibroblasts in vitro. This observation in addition to the observations that i) SG isolated
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virus is less capable of infecting macrophages (430, 625) and ii) HCMV shed in the urine
is not neutralized by anti CMV antibodies and susceptibility could be restored by one
round or passaging the virus in fibroblasts (720) suggest that virus grown in vivo is
different in its attachment and/or entry process. This might be because the cell type from
which the virus is derived affects the subsequent infectivity of CMV (721, 722). The
peptides could be used to elucidate the mechanistic difference in the infection process
between the viruses from the two sources. This in turn can lead to the identification of
targets/features that can be exploited to develop newer therapeutics in future.
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APPENDIX 1: MATHEMATICAL MODELLING OF MCMV DISSEMINATION IN VIVO

Abstract

Human cytomegalovirus (CMV) infects with seroprevalence reaching 100% in some countries. It
causes life threatening disease in immune compromised patients and congenital defects if
infection occurs in utero. Mouse CMV (MCMV) is used as model to understand the spread of
virus in the host. Following foot pad infection of mice with MCMV, the viral load is followed
over time in organs including foot pad (FP), spleen (SP), popliteal lymph nodes (LN), and
salivary glands (SG). Our experiments show a decrease of virus in the FP, accumulation then
decline of the virus in LN and SP, and delayed appearance of virus in SG. In the presented here,
we developed mathematical models to understand viral dynamics during the first 2 weeks of
MCMV infection of mice. From our final model, we conclude that, the virus diffuses out of the
FP without any growth at site of inoculation, both the LN and the SP contribute equally to the
seeding of virus to the SG and the net growth rate for virus was positive only in the SG as in
other organs the death rate (natural/immune system mediated) cancelled out the growth rate.
However, data from recent experiments challenges this model and necessitates a reevaluation of
our model.

Introduction

Human Cytomegalovirus (HCMV) infects people throughout the world with adult
seroprevalence approaching 100% in many countries (723). It causes severe disease in
immunocompromised patients including individuals with AIDS, organ transplant patients, cancer
(30) and newborns (31). Infection in these patients can lead to clinical disease including
mononucleosis-like syndrome, interstitial pneumonia, gastroenteritis, retinitis, or transplant
rejection. HCMV is the leading viral cause of congenital birth defects following infection in
utero. Worldwide between 0.5 to 2% of newborns are infected. The majority of newborns are
asymptomatic at birth but some exhibit outward signs of infection including microcephaly,
jaundice, and hepatosplenomegaly (35, 36). About 10% of the asymptomatic newborns develop
neurological dysfunction, most prominently sensorineural hearing loss (SNHL) (20, 37, 38). In
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immunocompetent individuals HCMV infection is generally asymptomatic. However, clinical
studies implicate HCMV’s contribution to cardiovascular (39-42) and inflammatory bowel
diseases (43-45). HCMV pathogenesis is diverse but with an inflammatory component to each.
In order to develop a CMV vaccine or effective treatments, an understanding of CMV
pathogenesis and viral dissemination are required. Due to the strict species specificity of HCMV,
murine CMV (MCMV) is the preferred model to study CMV infection. The dissemination of
MCMV within the mouse is cell associated. The cells of hematopoietic origin including
monocytes, neutrophils, and late monocyte progenitors have been implicated in this process
(141, 429, 430, 434). However, the exact role that these different cell types play in viral
dissemination is not clearly defined. It has been shown that the MCMV CC chemokine, MCK2
plays a role in the dissemination of the virus in vivo and also contributes to virus-cell tropism
(139-141, 429, 435). In the footpad model of MCMV infection, the virus disseminates within the
host with biphasic kinetics. In the first phase (primary dissemination) the virus disseminates from
the site of infection, the foot pad (FP) to the popliteal lymph node (LN), spleen (SP), lung (LU)
and liver (days 3-5). During the second phase (secondary dissemination) the virus can be isolated
in the salivary gland (SG) (days 7-18). MCMV spreads in the mouse population by saliva
transferred to an uninfected mouse during biting. Hence the ability of the virus to disseminate to
the salivary gland is used as readout for the characterization and successful dissemination of
MCMV in vivo.
Mathematical modelling studies to understand the aspects of pathogen dissemination and
or colonization in vivo e.g. for HIV, salmonella etc., have helped in defining several pathogen
associated attributes such as preferred route of entry, anatomical localization, replication,
migration, and death rates in vivo (724-726). We do not full understand the contribution of the
intermediate organs, cell types, chemokines etc. in the dissemination of MCMV to the SG.
Recent studies looking at the dissemination of MCMV in vivo have identified the cell types
infected and viral reservoirs in vivo (141, 429, 430, 599, 727); however, currently there is no
quantitative model for the in vivo dissemination of MCMV. A well-defined model of MCMV
dissemination in vivo could help identify key events during MCMV infection life cycle that
would be more suitable for therapeutic intervention e.g. replication or migration. In this study we
developed a mathematical model to determine the rate of spread of MCMV after foot pad
infection of mice. From our study we concluded that the virus diffuses out of the FP and does not
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undergo any replication there. However viral replication was required in the SG to explain the
high titers observed. Our model also suggests that both the SP and the LN might contribute
equally to seeding the SG with disseminated MCMV.

Materials and methods
Cells and Viruses
MEF 10.1 cells (ATCC) were propagated in DMEM supplemented with FCIII to a final
concentration of 10%, P/S and L-Gln to a final concentration of 1%. MCMV RM4511 strain was
used to infect mice. This virus has a 1.7 kb puromycin-green fluorescent protein (GFP) cassette
inserted into the IE2 region and a double point mutation in the m131 gene resulting in a
nonfunctional MCK2 protein (593).
University.

This was obtained from Dr. Ed Mocarski, Emory

Mice
hCXCR2 transgenic BALB/c mice expressing hCXCR2 under the control of the neutrophilspecific, human myeloid related protein-8 promoter were used for the experiments. For infection
the mice were infected with 1x106 PFU of RM4511 in the foot pad. All mice were housed under
specific pathogen free conditions in WLS LAF.
Plaque formation assay
Viral titers in the organs were determined by plaque formation assay as per lab protocol on
mouse embryonic fibroblast (MEF) 10.1 cells. Briefly MEF 10.1 cells were plated in a 6 well
dish. Organs were harvested at selected time points post infection (p.i) and homogenized. The
homogenate was diluted and added the MEF 10.1 cells and incubated for 1 hr. After incubation
the diluted virus was removed from the plates and cells were overlaid with carboxy methyl
cellulose media and incubated for 7 days. At the end of the incubation period, CMC was
removed, plates were stained and plaques counted using a dissection microscope.
Mathematical model and statistical analysis
Wolfram Mathematica, the mathematical computational software was used to generate the
models and to carry out statistical analysis. Bootstrap was done to determine the bias of the
parameters and the correlation matrix for the parameters. Confidence interval estimates were
obtained from 1000 resampling events during bootstrapping. The quality of the fits was assessed
with a χ2 goodness of fit test.
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Results and discussion
Dissemination of RM4511 in vivo
The dissemination of RM4511 in vivo following a foot pad infection was determined by
measuring viral load in the FP, LN, SP and the SG on days 3, 5, 7, and 14 post infections by
performing plaque formation assay as described in materials and methods (Figure A1.1). For our
analysis we used total virus as it provides a better estimate of the viral load in each organ. Virus
per gram of tissue on the other hand gives ambiguous results for smaller organs like LN which
are very small in size and can have higher values.
Mathematical modelling for of spread of MCMV after foot pad infection
Based on the experimental data for MCMV dissemination after foot pad infection (Figure A1.1),
we developed a simple model, defined by a set of ordinary differential equations (ODEs) that
describe the replication, clearance and migration of the virus from the FP to the LN, SP and
subsequently to the SG. The initial “full model” assumes that the virus replicates in all the organs
and there is viral death in all the organs. It also assumes that MCMV dissemination in vivo is
unidirectional (Figure A1.2). Subsequently, we reduced the number of parameters in the full
model to generate sub models and fitted the curves to the data (Figure A1.3). From this analysis
we identified that any model that does not consider viral replication in the SG could not explain
the observed data sub model 1.1 and figure A1.3 B. Following this reductionist approach, we
reached the final “minimal model” defined by the sub models 1.4a and 1.4b, figure A1.3C and
graphically depicted in figure A1.4 A and B. The parameter values for these models were
estimated by fitting the models to the in vivo dissemination data, and the confidence interval
determined by bootstrapping with 1000 resampling events (Table A1.1).
In conclusion, the minimal model that could explain the spread kinetics suggests that (i)
the virus migrates from FP to LN and SP without death or replication in the FP (ii) the virus halflife T1/2 = 23hrs in the LN and T1/2 = 2.3hrs in SP suggesting an immune system mediated
clearance of virus in these organs (iii) the virus migrates to SG from either LN or SP; however a
definite answer cannot be provided with available data (iv) they delayed appearance of virus in
SG is due to extremely low migration rates of virus into SG, and (v) increased viral titer in SG is
due to viral replication at the rate of 0.9/day, which is very close to that predicted for MCMV .
Alternate models were also tested that could explain the MCMV spread kinetics. These
include models where it is assumed that (i) multiple organs serve as reservoirs for virus before it
reaches SG, (ii) there time dependent migration of virus from LN to SG or S to SG: using a piece
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Figure A1.1 Dissemination of RM4511 in mouse following foot pad
infection. Mice were infected in the foot pad with RM4511 as described
in materials. Organs were harvested at days 3, 5, 7 and 14 p.i, and viral
titer in each organ was determined by plaque formation assay. Dots
represent viral titer for individual mouse, and the lines connect the
average values. FP = Foot pad, LN = Popliteal lymph node, S = Spleen
and SG = Salivary gland.
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Figure A1.2 The full model. The full model assumes that MCMV replication and death in
all organs. It also assumes that the dissemination of MCMV is unidirectional indicated by
the direction of the arrows. The following parameters are used to define the model above:
VX (t), where X can be Foot Pad (FP), Lymph Node (LN), Spleen (S), Salivary Gland (SG)
= Number of viruses in organ X.
mXY, where X,Y could be FP, LN, S, SG = Migration rate from organ X to organ Y.
dX, where X could be FP, LN, S, SG = Death rate in organ X.
rX, where X could be FP, LN, S, SG = Replication rate in each organ.
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Figure A1.3. Various sub models. (A) Various sub models with salient features of
each model (B) Plot for best fit for Sub Model 1.1, dots represent experimental data
points (C) Representative plot for best fit for Sub Models 1.3, 1.4.a, 1.4.b, dots
represent experimental data points. Sub Model 1.1 was discarded as it could not
explain the increase of virus in SG. Sub Models 1.3, 1.4.a, 1.4.b could explain the
data equally well.
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Figure A1.4 The final minimal models. (A) No death in FP, Death in LN and S, replication only
in SG and migration of virus from only from LN to SG (B) No death in FP, Death in LN and S,
replication only in SG and migration of virus only from S to SG (parameter abbreviations same as those
in figure A1.2)
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Table A1.1 Parameter values from model fitting and Confidence Interval (CI)
from bootstrapping (parameter abbreviations same as in figure A1.2.)
(rX – dX) : Net viral growth rate in organ (X = FP, LN, S, SG)

Parameter

Sub Model 1.4.a

VFP(t) pfu

Fitted
Values
3.4 x 105

mFPLN day-1

CI

Sub Model 1.4.b

(7.0 x 104,1.5 x 106)

Fitted
Values
3.4 x 105

(7.0 x 104, 1.5 x 106)

2.9 x 10-3

(4.5 x 10-4, 2.6 x 10-2)

2.9 x 10-3

(5.0 x 10-4, 2.1 x 10-2)

mFPS day-1

1.45

(1.1, 1.8)

1.45

(1.1, 1.8)

mLNSG day-1

2.4 x 10-4

(2.0 x 10-5, 1.3 x 10-3)
2.4 x 10-6

(1.8 x 10-7, 3.5 x 10-5)

mSSG day-1

CI

(rS – dS) day-1

-7.1

(-16.7, -2.7)

-7.1

(-17.5, -2.9)

(rLN – dLN) day-1

-0.7

(-1.2, -0.3)

-0.7

(-1.2, -0.4)

(rSG – dSG) day-1

0.9

(0.8, 1.0)

0.9

(0.8, 1.0)
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wise function to represent mLNSG(t) and mSSG(t), and (iii) the viral load dependent migration of
virus from LN to SG and S to SG: using piece wise function to represent m LNSG(VLN(t)) and
mSSG(VS(t)). Further experimentation is required allow for better understanding how MCMV
disseminates, to exclude the alternate models.

Future Directions

It has been shown that the early events following viral infection such as, induction of cytokines
and chemokines or cell types recruited, are critical in determining the fate and outcome of the
infection (728-730). Even for CMV, the cells recruited to the site of infection early on after
infection play a role in dissemination (430). Therefore, it would be interesting to expand our
existing model to include the early time points after infection. However due to lack of data, we
could not model the MCMV spread kinetics at early time points after infection during our initial
analysis. To address this issue, we performed experiments measuring the dissemination of
MCMV at very early time points (30 min, 60 min, 2hrs, 1 day and 2 day p.i). The results from
these experiments make us question some of the conclusions drawn from our previous model. In
particular, in these recent experiments we noted that the virus disappears from the foot pad and
becomes un-detectable by day 1 p.i, and then re-appears at day 2 p.i. (figure A1.5). This suggests
that the virus might be replicating at the site of inoculation in the foot pad. It is still possible that
MCMV diffuses out of the foot pad into the LN early on during infection and the virus
undergoes the “latent phase” of the infection/replication cycle, and then reappears at day 2 p.i.
Therefore, in light of these recent observations, it is required that in future we update our existing
model to more accurately represent the in vivo growth/dissemination kinetics of MCMV.
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Figure A1.5 Dissemination of RM4511 in mouse at early time
points following foot pad infection. Mice were infected in the foot
pad with RM4511 as described in materials. Organs were harvested at
30, 60, 120 min p.i, and on days 1 and 2 p.i, and viral titer in each
organ was determined by plaque formation assay. Dots represent viral
titer for individual mouse, and the lines connect the average values.
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APPENDIX 2: THE ROLE OF mir-155 IN CMV PATHOGENESIS

Abstract
Human CMV (HCMV) is widespread β-herpes virus that is prevalent in upwards of 90% of the
population in developing countries and 30-60% of women of childbearing age in developed
nations. Primary infection in healthy adults is controlled by the cells of the adaptive system after
which it establishes latency. Suppression of the immune system can lead to re-activation as seen
in transplantation patients. In this study we investigated the role of micro RNA-155 (miR-155)
in immune response to MCMV infection. miR-155 knock out (miR-155 KO) mice generate a
weaker CD4+T cell response as expected. However, there was lower virus titer in the salivary
gland (SG) of the knock out mice. Upon further investigation we discovered a higher percentage
of macrophages in the SG of miR-155 KO. We also observed higher numbers of IFN-β
transcripts and reduced levels of IL-10 transcripts in the SG of miR-155 KO mice. Therefore we
suggest a mechanism where an increase in activated macrophages coupled with lower IL-10
levels contribute to the control of MCMV infection in the SG.

This highlights a role of

macrophages in an organ where control of infection was believed to be exclusively under the
control of CD4+ T cells.
Introduction
Human Cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus. It is estimated that its
prevalence is between 90-100% in developing nations (723). Even in the USA HCMV infects
30-60% of women of child bearing age (731). HCMV is the leading cause of birth defects and
congenital infection causes neurodevelopmental defects (38, 574). In immune compromised
individuals like AIDS and transplant patients, CMV infection can lead to serious complications,
which can be fatal in some cases (574). In healthy adults however, HCMV infection is usually
asymptomatic, with mononucleosis-like symptoms (574). After clearance of the primary
infection, HCMV establishes lifelong latency in an immune competent individual (574). Cells of
both the innate and adaptive immune system contribute to controlling CMV infection. Animal
models have contributed significantly to our understanding of the contribution of the immune
system components in the control of CMV infection (127-130). Studies using the mouse model
of HCMV infection have demonstrated that NK cells, neutrophils, and CD8+ T cells play a
critical role in the control of infection in the primary organs of dissemination i.e. spleen, lung,
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and liver (131-133). However, MCMV growth in the salivary gland is controlled only by CD4+
T cells (134-136). In humans, ~10% of the total CD4+ and CD8+ T cells are HCMV specific
and prevent virus reactivation (519).

Indeed, in immune suppressed individuals HCMV

reactivation in observed (574). Therefore it is important to understand the mechanisms that
control the immune response to viral infections.
Micro RNAs (miRNA) are 19-24 nucleotides non-coding RNAs that bind to the 3’ UTR of
their target genes and suppress or up-regulate the expression of the gene (732-738). They
regulate the expression of their target genes 1.2 to 4 folds fine tuning the response of a cell (734,
736, 738) and play a critical role in immune cell homeostasis and function (734-737, 739-741).
miR155, miR21, miR146a etc. are regulated in response to inflammatory cues, disease states,
and stages of cell differentiation (734-737, 741-743). They directly or indirectly regulate the
expression of genes of the inflammatory response pathways (734-737). Fredman et.al
demonstrated that different miRNAs expressed between acute and chronic/delayed inflammation.
causes impaired homeostasis (744). Studies in mice suggest that miR-155 influences
inflammatory disease by both promoting the expansion of proinflammatory Th1 and Th17 cells
and amplifying inflammatory gene expression in macrophages and T cells (745, 746). Studies
evaluating the role of miR-155 in HSV infection show that mice lacking mir-155 show high
virus titers and are more susceptible to encephalitis due to impaired CD4+ and CD8+ T cells
response (747-749). Previous studies have shown that several miRNAs are expressed in the
mouse salivary gland in steady state (750). A presentation at the AAI meeting 2012 implicated a
role for mir-155 in CMV infection. In this study Sun et.al showed that that knocking out miR155 from mice lead to an impaired NK and CD8+ T cell response (751).
In this study we investigated the role of mir-155 during MCMV infection in mice. The
primary target cells for virus replication in salivary glands are the sub mandibular salivary gland
acinar cells (SMSG-acinar cells). To our surprise, contrary to previous studies where knocking
out miR-155 leads to higher virus titers, we observed lower titers of MCMV in the salivary gland
(SG) of mir-155 knock out mice (miR-155 KO). This difference could be traced to an increased
infiltration of macrophages in the SG of miR-155 KO mice. We also observed higher levels of
IFN-β and lower levels of IL-10 transcripts in the SG of miR-155 KO mice compared to WT
mice. Therefore, even though the number of CD4+ T cells recruited to the SG of miR-155 is
less, this study shows reduced MCMV titers in the SG of miR-155 KO mice that could be due to
the recruitment of highly activated macrophages to the SG. These macrophages create an
environment unsuitable for virus growth in the SG. This study sheds new light on the role of
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macrophages for controlling MCMV infection in the SG, an organ in which virus growth was
thought to be exclusively controlled by CD4+ T cells.
Materials and Methods
Mouse Infection
Breeder pairs miRNA-155 knock out mice on B6 background and WT B6 mice were purchased
from Jackson Laboratories (Bar Harbor, ME). Subsequent mouse colonies were housed in WLS
LAF. The mice used in this study were a generous gift of Dr. Barry T. Rouse. For the
experiments, mice were infected i.p with 1x106 PFU MCMV K181 per mouse.
QPCR
Total mRNA and miRNA was isolated from salivary gland using mirVana miRNA Isolation Kit
(Ambion). For RNA, cDNA was made with 500 ng RNA using oligo (dT) primer and ImPromII™ Reverse Transcription System (Promega). For miRNA, cDNA was made with 5ng of
miRNA using the TaqMan microRNA reverse transcription kit (Applied Biosystems) and
primers for miR -155 and small nucleolar RNA 202 (SnoRNA202). QPCR was set up using the
cDNA samples from above. Primer for SYBR Green PCR (IFN-β, IFN-ϒ, IL-10, MCP-1, KC
and beta actin) and TaqMan probes (for miR-155 and SnoRNA202) were purchased from
Applied Biosystems and were used to quantify microRNAs and mRNAs using a 7500 Fast RealTime PCR System (Applied Biosystems). The expression levels of the target genes were
normalized to β-actin for mRNA and SnoRNA202 for miRNA with the ΔCT method, and
relative quantification between control and infected mice was performed using the (2-ΔΔCT)
*1000 formula.
Plaque formation assay
Viral titers in the organs were determined by plaque formation assay as per lab protocol on
mouse embryonic fibroblast (MEF) 10.1 cells. Briefly MEF 10.1 cells were plated in a 6 well
dish. Organs were harvested and homogenized. The homogenate was diluted and added the
MEF 10.1 cells and incubated for 1 hr. After incubation the diluted virus was removed from the
plates and cells were overlayed with carboxy methyl cellulose media and incubated for 7 days.
At the end of the incubation period, CMC was removed and plates were stained and plaques
counted using a dissection microscope.
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Flow Cytometry
Single cell suspensions were prepared from SG days 10 post infection (p.i.) and surface staining
was performed. To enumerate the number of IFN-γ and IL-17 producing CD4+ T cells, cells were
stimulated with PMA at 100ng/ml and Ionomycin at 1ug/ml for 6 hrs. at 37˚C in 5% CO2.
Brefeldin A (5 mg/ml) was added for the duration of the culture period to facilitate intracellular
cytokine accumulation. After incubation, cell-surface staining was performed, followed by
intracellular cytokine staining using a Cytofix/Cytoperm kit (BD Pharmingen) to enumerate the
number of IFN-– and TNF-–producing CD8 T cells as previously described (22). Finally, the
cells were washed three times and resuspended in 1% paraformaldehyde. The stained samples
were acquired with BD LSR II (BD Biosciences) and the data were analyzed using the FlowJo
software.
Statistical analysis
The statistical significance between two groups was determined using unpaired two-tailed
Student t test. For our analysis *** = p < 0.001, ** = p < 0.01, and * = p < 0.05 were
considered significant. All statistical analysis was done using, GraphPad Prism software.
Results and Discussion
miR-155 expression in the SG of B6 mice
To measure the expression level of miR-155 following infection with MCMV, salivary glands
were collected at day 10 p.i. and miRNA levels were quantified by QPCR. As seen in figure
A2.1, miR-155 is upregulated ~12 fold p.i compared to the uninfected control group. Because
miR-155 is upregulated in response to infection and a sign of activated and functional CD4+ T
cells, change in expression levels of this miRNA might affect viral titers in the organ.
Effect of miR-155 on virus growth
To investigate the role of miR-155 on virus growth in vivo, we infected miR-155 KO and WT B6
mice with MCMV following intraperitoneal (i.p.) infection. The lungs and salivary glands were
isolated at day 10 p.i. and viral titers were measured by viral plaque assay. No virus was detected
in the lungs of both WT and miR-155KO mice at this time point (data not shown). However, we
observed 10 fold lower viral titers in the SG of miR-155 KO mice at day 10 p.i compared to WT
mice on the same day (figure A2.2). This observation is contrary to previously published reports
where knocking out miR-155 leads to higher virus titers following HSV infection.
Immune cell infiltration in response to MCMV infection in SG of miR-155 KO mice
We evaluated the infiltration of immune cells in the SG of infected WT and miR-155 KO mice
by flow cytometry. As expected, KO mice demonstrate a severely diminished infiltration of the
cells of the adaptive immune system in the SG at day 10 p.i. (Figure A2.3B). We did not
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Expression of miR-155 in Salivary Gland
Day 10 post infection

Figure A2.1 Change in miR-155 level in salivary gland post infection. WT
B6 mice were infected i.p. with 1 x106 PFU of MCMV K181. Salivary glands
were isolated at day 10 post infection. miRNA was isolated and quantified as
described in materials and methods. Data represents fold change in the
expression of miR-155 over uninfected control WT B6 mouse. Bars represent
the average fold change + standard deviation from 3 mice in each group. All
mRNA samples were run in triplicates. * = P value <0.05
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Salivary Gland Titer Day 10
Post Infection

Figure A2.2 Decreased virus in the SG of KO mice. WT B6 and miR-155
knockout (KO) mice were infected i.p. with 1 x106 PFU of MCMV K181.
Salivary glands were isolated at day 10 p.i., homogenized and viral titer was
determined by plaque formation assay described in materials and methods. Bars
represent average from 12 mice in each group + SEM. *** = P value < 0.001.
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observe any difference in the number of infiltrating neutrophils in the SG, but observed a
reduction in the infiltration of NK cells in miR-155 KO mice. However, at the same time, we
observed a higher frequency of macrophages in the SG. (Figure A2.3A). Due to a poor CD4+ T
cell response that controls virus growth in SG in miR-155 KO mice, it was expected that the
virus growth will be enhanced in the SG. However as seen in figure A2.2, we observed lower
virus titers. This could be explained by the increase in macrophages in the SG.
Effector function of infiltrating cells in response to infection in miR-155 KO mice
In order to understand how the weaker CD4+ T cell response results in lower virus titers and the
contribution of infiltrating macrophages in this phenomenon, we measured the transcript levels
of several effector molecules in the SG of WT and miR-155 KO mice. Using QPCR we
observed reduced levels of CXC chemokine KC, IFN-ϒ and IL-10 in miR-155 KO mice (Figure
A2.4). However no difference was observed for MCP-1. We did observe an increase in the
transcript levels of IFN-β in the SG of miR-155 KO mice. Previous studies had shown that CD4+
T cells are the primary source of IL-10 in the SG (598, 752), which could explain the reduced
levels of IL-10 in the SG of miR-155 KO mice. It has also been shown that blocking IL-10
signaling reduces viral titers in the SG (134). IFN-β is synthesized by several cell types including
macrophages (753, 754). It is possible that the increased level of IFN-β is a consequence of an
increased macrophage presence in the SG of miR-155 KO mice.
Conclusion and Future Directions
Taken together, we speculate that two mechanisms are at work here which are responsible for the
reduced viral titers in the miR-155 knock out mice, 1) reduction in the level of IL-10 as a result
of diminished CD4+ T cell infiltration, which supports viral clearance and 2) highly activated
macrophages in the SG are producing greater amounts of IFN-β, which creates an environment
not suitable for virus growth. Future experiments are required to evaluate the activation and
function of the macrophages recruited into the SG of miR-155 KO mice. Additionally,
experiments with depletion of macrophages (using clodronate) in miR-155 KO mice could also
be performed to confirm the role of these cell types in the observed phenotype.
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Cell infiltrate in Salivary Gland at Day 10
Post Infection

Figure A2.3 Alteration in the cellular infiltrate in the SG in could be
responsible for difference in SG viral titers. WT B6 and miR-155 knockout
(KO) mice were infected i.p. with 1 x106 PFU of MCMV K181. Salivary glands
were isolated at day 10 p.i.

Cells were stained for flow cytometry and

analyzed. Bars represent the average from 3 mice in each group + SEM. * = P
value < 0.05, ** = P value <0.01, *** = P value < 0.001
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RNA Levels of Effector Molecules
in Salivary Gland at Day 10 Post Infection

Figure A2.4 miR155KO mice have increased IFNβ and decreased IL10,
KC, MCP-1, and IFNϒ mRNA. WT B6 and miR-155 knockout (KO) mice
were infected i.p. with 1 x106 PFUof MCMV K181. SG were isolated at day 10
p.i. and mRNA was assayed via qPCR. Bars represent the average from 3 mice
in each group + SEM. * = P value < 0.05.
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APPENDIX 3: THEROLE OF PD-L1 EXPRESSING NEUTROPHILS IN CMV
PATHOGENESIS

Abstract
Human CMV (HCMV) is widespread β-herpes virus that is prevalent in upwards of 90% of the
population in developing countries and 30-60% of women of childbearing age in developed
nations. Primary infection in healthy adults is controlled by the cells of the adaptive immune
system after which it establishes latency. Suppression of the immune system can lead to reactivation as seen in transplantation patients. The UL146 gene of CMV encodes a potent CXC
chemokine, vCXCL1 which induces migration and calcium flux in peripheral blood neutrophils
(PBNs). It has been suggested that vCXCL1 attracts neutrophils that help CMV disseminate
within the host. In this study we show that neutrophils recruited to the site of CMV infection
express PD-L1, which could suppress CD4+ and CD8+ T cell immune responses. This might be
an additional immune evasive strategy used by the virus to buy some extra time to replicate at an
initial site and then disseminate successfully to another site.

Introduction
Human Cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus. Reports have estimated its
prevalence being between 90-100% in developing nations (723). Even in the USA HCMV
infection is prevalent in between 30-60% of women of child bearing age (731). It is the leading
cause of child birth defects and congenital infection with HCMV causes neurodevelopmental
defects (38, 574). In immune compromised individuals like AIDS and transplantation patients,
CMV infection can lead to serious complications, which can be fatal in some cases (574). In
healthy adults however, HCMV infection is usually asymptomatic with mononucleosis-like
symptoms in some cases (574). After clearance of the primary infection, HCMV establishes
lifelong latency in an immune competent individual (574). Cells of both the innate and adaptive
immune system contribute to controlling CMV infection. Animal models have contributed
significantly in understanding the contribution of the immune system components in the control
of CMV infection (127-130). Studies using the mouse model of CMV infection have
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demonstrated that NK cells, neutrophils and CD8+ T cells play a critical role in the control of
infection in the primary organs of dissemination (i.e., spleen, lung, and liver (131-133)).
However, MCMV growth in the salivary gland (SG) is controlled only by CD4+ T cells (134136). In humans, ~10% of the total CD4+ and CD8+ T cells are HCMV specific and prevent
the virus from reactivation (519). Indeed, in immune suppressed individuals e.g., transplant
patients, HCMV reactivation is observed (574). Therefore it is important to understand the
mechanisms that control the immune response to viral infections.
In the setting of a chronic infection, signaling through PD-1 expressed on the surface of T
cells leads to a suppression of the functionality of these cells and exhaustion of these cells.
Blocking of signaling through this receptor can lead to reversal of exhaustion and restoration of
the effector function of these cells (755-759). Interestingly, in a recent study it was shown that
neutrophils recruited to the site of HIV infection express PD-L1, the ligand for PD-1 and
suppress the response of T cells against virus; this allows the virus to persist in the host (760). In
this study we investigated the expression of PD-L1 on neutrophils recruited to the site of CMV
infection in the footpad. PD-L1 expressing neutrophils might suppress the T cell response against
CMV, creating a more favorable environment for the virus to replicate and establish latency.
Because the CMV genome encodes for a functional CXC chemokine with the ability to induce
migration of neutrophils, we propose that the viral chemokine-mediated recruitment of PDL-1
expressing neutrophils to the site of infection might be an additional immune evasion mechanism
employed by the virus.

Materials and Methods

Mice an Infection
WT BALB/c mice were bred in WLS animal facility and were used at the age of 6-8 weeks for
all the experiments. Mice were infected in the foot pad with 1x106 PFU of MCMV RMmCXCL1
per mouse.

Flow Cytometry
Single cell suspensions were prepared from the foot pads mice at day 3 post infection. Feet were
minced and digesting with in collagenase D. After this, cell-surface staining was performed to
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stain for neutrophils expressing PDL-1 (CD45+ Cd11b+ Ly6G+ PD-L1+). Finally, the cells were
washed three times and resuspended in 1% paraformaldehyde. The stained samples were
acquired with a BD LSR II (BD Biosciences), and the data were analyzed using the FlowJo
software.
Results and Discussion
Neutrophils recruited to site of CMV infection express PD-L1
Neutrophils are the first cell types recruited to the site of infection and form an important part of
the host anti-viral defense (761). As seen in figure A3.1 the neutrophils recruited to the site
express PD-L1. We did not observe any difference in the level of PD-L1 expression on the
neutrophils between mice infected with RM4511 and RMmCXCL1, a recombinant MCVM that
expresses the host chemokine mCXCL1. It is possible that CMV has evolved to carry UL146
gene to recruit PD-L1 expressing neutrophils to the site of infection, which leads to a suppressed
immune response. This might provide the virus enough time to replicate at the site of infection
before being controlled by the adaptive immune system. It has also been shown that CMV
specific CD4+ and CD8+ T cells express PD-1, and blocking the (PD-1)-(PD-L1) signaling axis
leads to better control of viral infections post transplantation (762). It is therefore conceivable
that the neutrophils at the site of infection are the source of PD-L1 and help the virus evade Tcell mediated control. Further experimentation is required to fully evaluate the contribution of
this observation in the CMV pathogenesis including its role in replication, latency, reactivation,
and superinfection.
Future Directions
In order to investigate the role of PD-L1 expressing neutrophils in CMV immune evasion, future
experiments need to be done to show the ability of PD-L1 expressing neutrophils to suppress
CMV specific T cell function in vitro and whether the depletion of neutrophils leads to a better
CMV specific T cell response in vivo. In their study, Bowers et al. show that the infection of
neutrophils by HIV was sufficient to upregulate PD-L1 on their surface (760). Because CMV can
infect neutrophils, we should also evaluate whether CMV infection of neutrophils can upregulate
PD-L1 on their surface. It addition, it would also be interesting to evaluate whether the different
viral chemokines can induce a differential expression of PDL-1 on the surface of neutrophils.
Experiments should also be carried out with isolated human PBNs to show the relevance of this
mechanism in the setting of HCMV infection of humans.
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PD-L1
Figure A3.1 PD-L1 is expressed on neutrophils at day 3 post infection. Mice
were infected in the footpad with either RM4511 (green) or RMmCXCL1 (blue).
Cells of the footpad were stained for PD-L1 expression on neutrophils and
analyzed by flow cytometry. The histogram represents the expression of PDL-1 on
neutrophils or the unstained control (red). Data is representative of 3 mice for each
infection group.
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APPENDIX 4: THE ROLE OF VIRAL IL-10 IN CMV PATHOGENESIS

Abstract

Human cytomegalovirus (HCMV) infects with seroprevalence reaching 100% in some countries.
It causes life threatening disease in immune compromised patients and congenital defects if
infection occurs in utero. The HCMV genome encodes for potent immunemodulatory proteins
such as the human interleukin (IL-10) homolog, cmvIL-10 that aids in viral dissemination and
survival within the host. The cmvIL-10 is structurally different from human IL-10 (hIL-10) and
has been suggested to have functional differences from its human counterpart. Due to CMV’s
host specificity, murine CMV (MCMV) has been used as model for in vivo studies. MCMV
lacks a homolog of cmvIL-10 and it has no effect on mouse cells. The biological basis of this
non-functionality is unknown, thus a mouse model to investigate the role of cmvIL-10 in vivo
does not exist. The present study was undertaken to develop a recombinant MCMV expressing a
mouse-adapted cmvIL-10 (MAcmvIL-10), which would be functional in mice and may
subsequently lead to the development of a mouse model to test this viral cytokine.

Introduction

Human cytomegalovirus (CMV) infects people throughout the world with adult seroprevalence
approaching 100% in many countries (723). CMV infections cause life-threatening diseases in
immunocompromised individuals and congenital birth defects if infection occurs in utero. In
healthy individuals it has been associated with vascular disease (39-42, 51-53). The CMV
genome encodes interleukins (e.g., cmvIL-10) and chemokines (e.g., vCXCL-1) (401, 407).
Cytokines are small proteins responsible for regulation of cell proliferation, differentiation,
production of other cytokines, leukocyte trafficking, inflammation etc. Interleukins are a class of
cytokines secreted by leucocytes, having effects on other leukocytes. Interleukin 10 (IL-10) is
the major anti-inflammatory and immunosuppressive cytokine with effects on a wide range of
immune cells including T cells, B cells, NK cells, monocytes, and macrophages (763). cmvIL10 sequence shares only 25 to 27% identity with hIL-10 at amino acid level (401). This suggests
that cmvIL-10 may not only function similarly to hIL-10, but it could also have different or
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additional properties. Based on this knowledge, we hypothesize that these viral factors have a
global effect on host immune response and is involved in viral dissemination and survival.
The goal of this study is to assess the in vivo role of cmv-IL10 in virus dissemination and
persistence. In vivo studies with cmvIL10 have been impeded because it is ineffective on mouse
cells (156). In order to identify the molecular mechanisms of the lack of cmvIL-10 functionality
on mouse cells, we synthesized hIL-10 and cmvIL-10 using the Pichia expression system. These
cytokines will be used in in vitro functional assays in the future.

In addition, using

bioinformatics we identified key amino acids in cmvIL-10 for subsequent mutation and
generation of a mouse adapted cmvIL-10 (MAcmvIL-10) that would function on mouse cells.
Recombinant Mouse CMV (MCMV) expressing MAcmvIL-10 will be used to carry out in vivo
studies to assess whether this viral cytokine functions to manipulate the host immune response
and the survivability of the virus.

Materials and methods

Genes
The genes for hIL-10 and cmvIL-10 were codon optimized for protein production in yeast and
artificially synthesized (Gene Script, NJ). The proteins were FLAG tagged at the N-terminus to
facilitate identification and purification of the induced protein.

Cloning and selection
The hIL-10 and cmvIL-10 genes were cloned in to pPICZ A Expression Vector (Life
Technologies, NY) under the control of the methanol inducible S. cerevisiae AOX promoter.
Transformation of Pichia pastoris (strain X-33) was achieved by electroporation. Successful
transformants were selected by plating on Yeast Extract Peptone Dextrose (YEPD) agar plates
with 100µg/ml zeocin.

Clones with multiple integrations of the expression cassette were

selected on 1mg/ml zeocin plates.

Protein induction and purification
Selected clones were grown as 2.5 ml mini- induction cultures and supplemented with methanol
for 4 days to induce protein production. For large scale protein production, clones expressing
high levels of hIL-10 and cmvIL-10 were gown to high density in 1L cultures overnight. The
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cells from the overnight cultures were transferred to 250ml induction medium and supplemented
with methanol for 4 days to induce protein production. Medium from the large-scale induction
experiment was dialyzed in a 3kDa cutoff dialysis membrane against FPLC buffer. The pH and
conductivity of the dialyzed medium was adjusted to match the FPLC buffer. The processed
medium was run over a Q (anion exchange) column at pH6.5 with a NaCl gradient of 0 – 1 M to
purify the protein. The fractions from the Q column-FPLC run containing the protein were
pooled and run over a Sepharose DEAE column at pH9.0 and a NaCl gradient of 0 – 0.5 M.
Screening for protein production
Western blotting using the anti-FLAG antibody was performed on supernatants to screen for
protein expressing clones. The fractions obtained from the FPLC of the large scale induction
cultures were also silver stained and blotted to determine the fraction(s) containing the protein.
Results
Production of host and viral chemokine in yeast
To determine the reason for the lack of functionality of cmvIL-10 in mice, we produced and
purified cmvIL-10 and hIL-10 from the yeast, Pichia pastoris expression system (Figure A4.1).
These proteins will be tested on mouse cells for receptor binding and downstream signaling
defects that may render the cmvIL-10 functionless on mouse cells.
Structure based sequence alignment
It is possible that cmvIL-10 is unable to bind the mouse IL-10 receptor which leads to its lack of
functionality on mouse cells. Structural studies of cmvIL-10 bound to sIL-10R1 identified
several residues that are involved in the receptor ligand interaction (485, 764). Building upon
these structural studies we carried out an in silico analysis of the amino acid sequences of hIL10, mouseIL-10 (mIL-10) and cmvIL-10 to identify residues within the receptor binding domains
(485, 764), which are depicted by the circles in figure A4.2. The amount of the buried surface
area for these cytokine residues in the receptor binding pocket is denoted by the different
numbers of circles with 1 > 5 Å2, 2> 10 Å2< 35 Å2, 3 >35 Å2 < 60 Å2, 4 >60 Å2 < 85 Å2, and 5 >
85 Å2. As observed in figure A4.2, mIL-10 and cmvIL-10 share only 30% identity in the
receptor binding domain I and only 27% identify in the binding domain II. Changing the
residues of cmvIl-10 to match the residues at the same position in mIL-10, would result in 100%
identity of the interacting residues in the receptor binding domains.
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Figure A4.1 Detection of the expressed cytokine. The gene for hIL-10 and cmvIL-10 was
codon optimized and cloned into yeast and the expression of the cytokine was induced by
adding methanol as described in materials and methods. Cytokine expression was detected
by western blotting using anti-FLAG antibody. M is the molecular weight marker. H1 is
the yeast clone expressing hIL-10, C1 is the yeast clone expressing cmvIL-10, and X33
negative control.
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This would be designated as mouse adapted cmvIL-10 (MAcmvIL-10) (figure A4.2). Because
the residues in the receptor binding domain of MAcmvIL-10 match that of mIL-10, we
hypothesize that MAcmvIL-10 will bind and signal via the mouse IL-10R and gain functionality
in the mouse model. This hypothesis needs to be tested with future experiments.
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Binding domain I

Binding domain II

Figure A4.2 Structure based sequence alignment of hIL-10, cmvIL-10, mIL-10 and
MAcmvIL-10. The cmvIL-10 or hIL-10 residues that are buried into surface into sIL10R1 are marked with circles. The amount of buried surface area for the cytokine residues
is denoted by different numbers of circles with 1 > 5 Å2, 2> 10 Å2< 35 Å2, 3 >35 Å2 < 60
Å2 4 >60 Å2 < 85 Å2, and 5 > 85 Å2. Figure adapted from Jones et al, 2002, PNAS

213

APPENDIX 5:

SPRINGER LICENSE
TERMS AND CONDITIONS
Jun 16, 2015

This is a License Agreement between Pranay Dogra ("You") and Springer ("Springer")
provided by Copyright Clearance Center ("CCC"). The license consists of your order
details, the terms and conditions provided by Springer, and the payment terms and
conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number
3650940660989
License date
Jun 16, 2015
Licensed content
Springer
publisher
Licensed content
Springer eBook
publication
Licensed content title
What We Have Learned from Animal Models of HCMV
Licensed content author Pranay Dogra
Licensed content date
Jan 1, 2014
Type of Use
Thesis/Dissertation
Portion
Full text
Number of copies
6
Author of this Springer
Yes and you are a contributor of the new work
article
Order reference number None
Title of your thesis /
CMV CHEMOKINES, CO-INFECTION DISSEMINATION
dissertation
PLOT AND PEPTIDES THAT CAN STOP IT ALL
Expected completion
Aug 2015
date
Estimated size(pages)
200
Total
0.00 USD

214

APPENDIX 6:

215

VITA

Pranay Dogra was born on March 17th, 1986 in India. He attended Hislop College, University of
Nagpur, India where he received his Bachelors of Science degree with triple majors in Botany,
Chemistry and Biotechnology in 2007 and his Masters in Biotechnology from the Nagpur
University, India in 2009. He started his doctoral program at the University of Tennessee
Knoxville in August 2010 in the lab of Dr. Tim Sparer. His work included investigating the role
of CMV encoded chemokines in the pathogenesis of virus and to develop antiviral peptides in
collaboration with Dr. John Wall at the University of Tennessee Health Science Center. He
completed his studies and graduated with a Doctor of Philosophy in Microbiology in August
2015.

216

